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Abstract
The protease resistant protein (PrP) plays an essential role in transmissible spongiform
encephalopathies, a group of fatal neurodegenerative diseases in mammals which
include sporadic CJD and variant CJD in humans. While polymorphisms in the PrP open
reading frame affect an individual's susceptibility to sCJD and vCJD, other factors must
also act in detemiining susceptibility. One possible candidate is the level of PrP gene
expression, as transgenic mice that over or under express PrP have shorter or longer TSE
incubation periods. Therefore, this study aimed to characterise regulatory regions of the
PRNP gene, which encodes the human PrP protein, to determine if polymorphisms in
these regions affect an individual's susceptibility to sCJD or vCJD.
Based on analysis of PrP gene regulatory regions in other species 4.8 Kb of human
genomic sequence containing 1.5Kb of upstream sequence the first exon and 3.1Kb of
intron was cloned from a human genomic lambda library into a CAT reporter gene.
Transient transfections in human neuroblastoma cells of this construct and of nested
deletions of this construct identified two regulatory regions, one between -43 and -9
bases upstream of the transcription initiation site and one within the intron between
+292 and +622 basepairs.
Having identified regulatory regions in neuroblastoma cells the effect of the two
regulatory regions on expression in vivo was examined by making three constructs
where expression of a LacZ reporter gene was driven by the 4.8Kb human fragment, the
upstream and exon sequence or the exon and intron sequence. A construct which
contained 3.4Kb of equivalent murine sequence was used as a control. Although all four
constructs were successfully injected into fertilised eggs giving rise to transgenic
embryos and adults, no LacZ expression was detected suggesting that additional
sequences may be required for full expression ofPRNP.
The upstream and intronic regions were sequenced in sCJD, vCJD and control
individuals to determine if any polymorphisms or mutations exist in the regulatory
in
regions which cause or affect susceptibility to either form of CJD. Three polymorphisms
were identified, a C to G transversion at position -101 relative to the start of exon one
was found at an allele frequency of 13% in control individuals, a G to C transversion at
+310 found at a frequency of 6% in controls and a T to C transition at position +385
found at a frequency of 5% in controls. Analysis of the frequency of these
polymorphisms in CJD patients and controls showed that the -101G and +310C alleles
each independently increase an individual's risk of developing sporadic CJD. The effect
of the -101G allele was strongest in PrP ORF codon 129 methionine homozygotes even
when the linkage between -101G and codon 129 methionine was accounted for. The
+385C allele increased susceptibility to vCJD but this was not significant.
These results suggest that variation in the levels of expression of PrP in humans affect
susceptibility to sCJD. Further work is needed to confirm these associations and to
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1 Chapter One: Introduction
1.1 Transmissible spongiform encephalopathies
1.1.1 Overview
Transmissible Spongiform Encephalopathies (TSEs) are a group of fatal
neurodegenerative diseases ofmammals (Table 1-1). Clinically TSEs are characterised
by ataxia, myoclonus and dementia. Affected individuals typically show neuronal cell
death, astrocyte gliosis and spongiform degeneration in the grey matter of the brain. The
most characteristic feature of these diseases is the deposition ofPrP (Proteinase resistant
protein) in the brain. The deposition can occur either in diffuse deposits, or in large
plaques of amyloid, depending on the particular TSE. The extent and anatomical
location of each of the characteristic pathological features of TSEs can vary between
different forms of TSE, and between individuals with the same form of TSE.
Analysing PrP protein from infected animals shows the presence of a form ofPrP that
is proteinase K resistant. This form ofPrP is PrPSc (the "Sc" referring to scrapie, a sheep
TSE where PrPSc was first identified) while normal PrP is referred to as PrPc ("c"
meaning cellular). TSEs also have very long incubation periods ranging from months
in experimental rodent models to over 40 years in one form of human TSE. The
aetiology of TSEs is varied, they can be acquired through medical procedures or eating
infected animals, occur genetically through mutations in the PrP Open Reading Frame
(ORF) or they can develop spontaneously with no identifiable cause. The most
remarkable feature of TSEs is their transmissibility, for regardless of their aetiology,
TSEs can be experimentally transmitted to other animals (Brown et al., 1994) by
injecting brain homogenate of an infected animal into the brain of the experimental
animal. Such transmission studies have also shown that TSEs exist as strains (Bruce,
1993) which upon passage (infection) in mice have a distinct phenotype, consisting of
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a characteristic incubation period and patterns of brain lesions that are retained on
subsequent passages.
PrPSc has a different secondary structure from PrPc with an increase in the amount of (5-
sheet structure (Caughey et al., 1991) (Pan et ah, 1993). The N-terminal region remains
sensitive to proteinase K resulting in the three bands running at 27-30kDa on a PAGE
gel after limited proteinase K digestion. The amount of glycosylation on PrPSc is used
to discriminate between strains of TSE (Collinge et ah, 1996) (Hill et ah, 1997). One
study has found four different patterns of glycosylation in different types of CJD, but
this method of strain identification has been questioned as other groups have only found
two patterns (Parchi et ah, 1997) or found that the pattern varies in different regions of
the brain (Somerville, 1999) and changes on transmission between species (Somerville
et ah, 1997).
Although TSEs are infectious diseases and exist as strains thus resembling a virus (TSEs
were originally referred to as slow viruses due to their long incubation periods) there is
a large body of evidence which suggests that a novel infectious agent is involved. This
is the prion theory, which argues that the infectious agent is solely comprised of PrPSc
and that the conversion of PrPc to PrPSc is catalysed by PrPSc itself. Two lines of
evidence supporting this theory are that firstly the mutated PrP proteins produced in
genetic forms of disease can give rise to an infectious disease and secondly infectivity
co-purifies with PrPSc. Treating infectious material with UV-light, DNase and RNase
has no effect on infectivity implying no involvement of a nucleic acid, yet proteinase or
urea treatment destroys infectivity implying that protein plays an important role in
disease (Prusiner et ah, 1981) (Millson et ah, 1976).
Transmission studies ofmany different TSEs have shown it is more difficult to transmit
disease between species (e.g. TSE infected mouse to hamster) than within species (e.g.
mouse to mouse), with a lower proportion of animals developing disease and with longer
incubation periods. However once the second species has been infected subsequent
passages (infection) within that species (e.g. hamster to hamster) results in a higher
proportion of animals developing disease with shorter incubation periods than the cross-
2
species transmission. This reduced efficiency of infection between species is termed the
species barrier.
Table 1-1 Distribution and aetiology of Transmissible Spongiform
Encephalopathies.
Disease Species Aetiology Reference
CJD Fluman Sporadic, Acquired or Familial (Sternbach et ah, 1997)
GSS Human Familial (Ghetti et ah, 1994)
FFI Human Familial (Rossi et ah, 1998)
Kuru Human Acquired (Gajdusek and Zigas, 1959)
vCJD Human Acquired (Will et ah, 1996)
Scrapie Sheep Unknown, possibly maternal (Brown and Bradley, 1998)
BSE Cattle Acquired (Wells et ah, 1987)
CWD Deer Unknown (Sigurdson et ah, 1999)
TME Mink Unknown/Oral? (McKenzie et ah, 1996)
FSE Cats Oral (Cadore, 1996)
Other SE Zoo mammals Oral (Kirkwood and
Cunningham, 1994)
1.1.2 Human TSEs
Four TSEs have been identified in humans, Creutzfeldt-Jakob Disease (CJD)
Gerstmann-Straussler-Scheinker syndrome (GSS), Fatal Familial Insomnia (FFI) and
kuru. All GSS and FFI cases and about 10% ofCJD cases are familial (fCJD), linked to
dominant acting mutations in the PrP ORF. A small proportion of CJD cases are
iatrogenic (iCJD) i.e. caused by medical procedures which used equipment or products
inadvertently contaminated by, or derived from CJD patients. The majority (90%) of
CJD cases have no known cause, with no mutation in the PrP ORF and no association
with occupation, medical procedures or area of residence (vanDuijn et ah, 1998), these
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cases are therefore referred to as sporadic CJD (sCJD). Kuru is a TSE spread by
cannibalism in one tribe in New Guinea. A new form ofCJD was identified in 1996 that
has different clinical and pathological signs to other forms ofCJD. Variant CJD (vCJD)
as it has been termed is believed to be causally related to bovine spongiform
encephalopathy (BSE) a TSE of cattle.
1.1.3 Human Familial TSEs
Familial TSEs are linked to mutations in the PrP ORE that act in an apparently
autosomal dominant manner (see Figure 1-1). Each mutation causes one of three
diseases, fCJD, GSS or Fatal Familial Insomnia (FFI). These mutations can be point
mutations that change the identity of an amino acid or insertions of two to nine copies
of the 24bp region which encodes the octapeptide repeat found in the N-terminal of the
PrP protein. Although diseases caused by mutations in the PrP gene are classed as GSS,
CJD or FFI there can be some overlap in clinical signs depending on the particular
mutation involved (Parchi et ah, 1996).
Familial CJD accounts for about 10% of total CJD cases. The average age of onset of
clinical signs is 60 years of age with a median duration of disease of 4 months (Belay,
1999). The most common clinical sign is a rapidly progressing dementia accompanied
by pyramidal and extra-pyramidal signs leading to spasticity, rigidity, tremors and
myoclonus sometimes leading to akinetic mutism and cortical blindness. (Parchi et al.,
1996). Most fCJD patients exhibit periodic tri-phase sharp waves electroencephalograph
(EEG) patterns (Parchi et ah, 1999). About 10% of cases have amyloid plaques in the
brain containing PrPSc although the rest show diffuse PrPSc deposits. Mutations which
have been associated with CJD are point mutations in codons 178, 180, 188, 200, 202,
203, 208, 210, 211, 212 or 232 of the PrP ORF or insertions of two or six copies of the
octapeptide repeats at the N-terminal end of the protein (Figure 1-1) (Belay, 1999)
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GSS appears to be exclusively genetic, always being associated with dominant acting
mutations at codons 102, 105, 117, 187, 198 or 287 or a stop codon mutation at codon
145 or insertions of 5,6,7,8 or 9 copies of the octapeptide repeats in the PrP open
reading frame more (Belay, 1999) (Owen et al., 1990). Clinical features include
dementia and extrapyramidal signs. The most consistent pathological finding is PrP
amyloid plaques deposited in the brain (Bugiani et ah, 2000) and the average course of
GSS is five years. This contrasts with familial CJD where PrP plaques are found in only
10% of cases and the duration of disease is generally takes less than a year. There can
be an overlap in pathology between GSS and CJD especially in GSS kindreds with
insertional mutations (Parchi et ah, 1996) there can also be variation in pathology
between individuals with different GSS mutations (Piccardo et ah, 1998).
Fatal Familial Insomnia (FFI) is the rarest familial TSE and only 24 affected kindreds
have been found (Parchi et ah, 1996) (Belay, 1999). Symptoms include reduction in
sleep time, dementia and ataxia while the pathological effect is atrophy of the thalamus
and olivary regions with marked neuronal loss. There is mild gliosis while spongiform
degeneration or amyloid plaques are rare. However, as PrPSc can be detected in FFI it is
classed as a TSE. FFI is caused by a point mutation in the PrP gene at codon 178, which
changes an aspartic acid to asparagine. However, the disease is influenced by the
common polymorphism at codon 129 that encodes valine or methionine. FFI only occurs
if the codon 178 aspartic acid to asparagine mutation occurs on an allele which is
methionine at codon 129, if codon 129 is valine familial CJD occurs. As the symptoms
and pathology ofFFI and CJD are quite distinct, the interaction between the asparagine
at 178 and either valine or methionine at 129 must affect the structure of the protein
sufficiently to alter the type of disease. However an FFI kindred from Australia (McLean
et al., 1997) where the mutated allele was 178N 129M showed heterogeneity in clinical
and pathological symptoms between FFI and CJD. The allele/phenotype relationship
may therefore be more complicated and other factors may be involved. In both 178CJD
and 178FFI kindreds the duration of disease is shorter and age of onset lower in
homozygotes (MM in FFI and VV in CJD) than heterozygotes (Goldfarb and al., 1992).
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Six cases have been reported of patients with a neurological disease similar to fatal
familial insomnia but where there is no mutation of the PrP ORF. These may be cases
of fatal sporadic insomnia (Nixon et al., 1996) (Parchi et ah, 1999) analogous to
sporadic CJD.
The clinical and pathological features of familial TSEs varies from mutation to
mutation, from kindred to kindred and there can be considerable variation even within
kindreds. For example, the average age-of-onset in kindreds with the F198S GSS varies
from 34 to 71 years. While the penetrance (proportion of individuals carrying amutation
who develop disease) ofD178N CJD is 100% while that ofE200K CJD is estimated at
56% averaging over all affected kindreds. (Goldfarb et ah, 1991) However, there is
considerable variation between E200K kindreds as the disease is fully penetrant by the
age of 80 in Libyan Jewish kindreds (Chapman et ah, 1994) but not in a Chilean
kindred. These two kindreds not only have the same mutation, but are thought to be
related to each other as haplotype analysis of highly polymorphic markers around the
PRNP gene show that both kindreds carry the same E200K mutation (Lee et ah, 1999).
The course of familial disease can be affected by factors other than the PrP coding
sequence. A GSS kindred has been reported with the P102L mutation where affected
individuals could be divided into two groups, one ofwhom suffered from dementia and
a relatively short illness lasting just a year which is not "typical " ofGSS course while
the other group had ataxia over a longer period (five years), but had no cognitive
impairment which is typical ofGSS. There was no correlation between the two clinical
courses and the codon 129 polymorphism (Barbanti et ah, 1996), implying that there
may be other genetic or environmental factors affecting the course of the disease.
A number of individuals with neurological disease have mutations in the ORF but have
not been classified as GSS or CJD. This is due either to lack of any family history
((Finckh et ah, 2000) mutations Q160X and T188K) or a lack ofmaterial to carry out
pathological analysis in a suspected CJD patient ((Windl et ah, 1999) T188R). The
T183A mutation (Nitrini et ah, 1997) has distinct clinical and pathological features
which differ from most CJD cases, it rarely has the abnormal EEG pattern which is
found in most sporadic and familial CJD patients and has a long course of disease of 50
7
months compared with the average of 8 months for sCJD. It cannot therefore be
classified as GSS or CJD with any confidence. It has been argued that the CJD/GSS
division is somewhat arbitrary and that each mutation should be classified as a sub-type
of a single disease (Collinge et ah, 1992).
1.1.4 Sporadic CJD
The commonest TSE in humans is sCJD. This neurodegenerative occurs at a rate of
approximately one case per million people per year in every country and ethnic group
examined. The average age of onset of clinical signs is 60 years of age with a median
duration of disease of 6 months (Belay, 1999). The most common clinical sign is a
rapidly progressive dementia accompanied by pyramidal and extra-pyramidal signs
leading to spasticity, rigidity, tremors and myoclonus sometimes leading to akinetic
mutism and cortical blindness. Most sCJD patients exhibit periodic tri-phase sharp
waves electroencephalograph (EEG) patterns. About 10% of cases have amyloid plaques
in the brain containing PrPSc although the rest show a variety of PrPSc deposition
patterns.
Although there are no mutations of the PrP ORF in sCJD patients, two polymorphisms
in the PrP ORF affect susceptibility to the disease. The most important polymorphism
clinically is at codon 129 which can encode Methionine or Valine (129MV) (Owen et
al., 1990). Although the 129MV polymorphism does not cause disease it exerts an
influence on the susceptibility ofCaucasians to sCJD (Collinge et ah, 1991; Palmer et
ah, 1991) (Deslys et ah, 1998; Zimmermann et ah, 1999). In Caucasians 39% of the
population are methionine homozygotes, 50% heterozygotes and 11% Valine
homozygotes. Whereas analysis of over 1500 European sCJD cases shows that 71% of
cases are methionine homozygotes, 13% of cases heterozygous and 16% valine
homozygotes (Alperovitch et ah, 1999). The reason for the increased susceptibility of
codon 129 homozygotes but reduced susceptibility of heterozygotes is proposed to be
that interactions between similar PrP proteins enable the development of disease; this
will be discussed further in section 1.3.6
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A second polymorphism at codon 219 where glutamine is replaced by lysine (E219K)
(Kitamoto and Tateishi, 1994) also affects susceptibility to sCJD. This polymorphism
is found at a frequency of 6% in the Japanese population but has not been found in
Caucasians (Petraroli and Pocchiari, 1996). A study of 85 Japanese sCJD patients has
found that all were glutamine homozygotes; this lack of lysine alleles in sCJD patients
is statistically significant (Shibuya et ah, 1998). Therefore, codon 219 heterozygotes
(12% of the Japanese population) have a reduced susceptibility to sCJD. The codon 129
methionine/valine polymorphism is also present in Japanese populations but the
frequency of valine is much lower at 4% (34% in Caucasians) analysis of Japanese sCJD
patients shows no difference in susceptibility between codon 129 methionine
homozygotes and heterozygotes (Doh-ura et al., 1991).
There are several other polymorphisms of the PrP gene which have no apparent effect
on any form of CJD. Two are coding region polymorphisms which affect the coding
region A polymorphism (N171S) has been found in a Brazilian family and been
tentatively linked to atypical schizophrenia, although none of the affected individuals
suffered from any symptoms of TSEs (Samaia et al., 1997) and not all carriers suffered
from the disease. This mutation has also been reported in healthy individuals (Fink et
al., 1994). Another polymorphism occurs where one of the five imperfect octapeptide
repeats in the N-terminal region of the protein has been deleted although this mutation
appears to have occurred several times independently as different repeats have been
deleted (Salvatore et al., 1994) (Palmer et al., 1993). This rare polymorphism has not
been associated with disease. There are also several synonymous substitutions of the
open reading frame and a single nucleotide polymorphism at the 3' end of the human
intron.
Analysis of sCJD patients in Europe and Japan has shown that different PrP ORF
polymorphisms have different affects on sCJD susceptibility. The incidence of sCJD is
the same in Japan as in Europe so perhaps different genetic factors affect susceptibility
in different populations. This suggests that sCJD is a complex disease affected by
several genetic loci. The examination of genetic factors to date has focused on the PrP




CJD has been transmitted by medical procedures where hormones such as growth
hormone and gonadotropin derived from the pituitary glands of CJD cadavers were
injected into individuals with hormonal deficiencies. Tissues such as dura mater and
corneas taken from CJD cadavers for grafting have also transmitted CJD to the
recipients. Iatrogenic CJD (iCJD) has also been transmitted by medical equipment such
as intra-cerebral electrodes, which cannot be sterilised adequately after use on the brains
ofCJD patients (Bernoulli et al., 1977) (Will and Matthews, 1982).
As the date of infection in iCJD cases can be determined, the incubation periods of iCJD
can be calculated, this cannot be done in sporadic CJD as the cause of disease is
unknown. The largest and best-characterised group of iatrogenic CJD patients are French
individuals who developed CJD due to Growth hormone treatment in the 1980s
(dAignaux et ah, 1998). Growth hormone collected from cadavers was pooled into
batches and presumably at least one cadaver used in the preparation of some batches was
a pre-clinical CJD case. Analysis of 1361 individuals treated between 1982 and 1985
with growth hormone batches now known to be contaminated has shown that 55
individuals (4%) developed CJD. The mean incubation period has been estimated at 9
to 10 years. The 129MV polymorphism had an effect on the incubation period and
susceptibility to iCJD that was different to that seen in sCJD. Heterozygotes were less
susceptible (comparing the codon 129 genotype frequency of iCJD patients with that of
the normal French population) and had longer incubation periods than homozygotes.
There was no difference in incubation period between methionine and valine
homozygotes. Valine homozygotes were actually slightly more susceptible to iatrogenic
CJD than methionine homozygotes, which contrasts with sCJD where methionine
homozygotes are more likely to develop sCJD. Analysis of iatrogenic CJD in Britain
showed that 35 of 1880 (1.9%) growth hormone treated individuals developed CJD.
Twenty of these patients have been sequenced at codon 129 of whom 11 (55%) were
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valine homozygotes and only one was a methionine homozygote (Brown et al., 2000).
The excess of valine homozyogtes among growth hormone iCJD patients may mean that
valine homozygotes are more susceptible to either the route of infection or the inoculum.
Perhaps a valine homozygote CJD patient was one of the infected donors and therefore
valine homozygotes are more susceptible, although as several batches of growth
hormone were contaminated it is unlikely that every batch just contained valine
homozygote CJD patients. The small proportion of individuals treated with
contaminated GH who developed CJD (4% in France 1.9% in Britain) must mean that
factors other than codon 129MV status determines an individual's susceptibility to iCJD,
these factors could include variation in PrP expression levels or patterns which could
affect the rate of replication of the agent after infection.
1.1.6 Variant CJD
A new variant ofCJD (vCJD) was identified in 1996 (Will et al., 1996). Up to the start
of January 2001 there have been 88 confirmed or suspected cases in the UK, two in
France and one in the Republic of Ireland (Table 1-2). The clinical and pathological
symptoms are slightly different from classical CJD (the collective term used to describe
sCJD, fCJD and iCJD). Most strikingly the age of onset is much lower (median age 28)
with some patients being in their teens whereas very few (Belay, 1999) classical CJD
cases under the age of 42 have been reported. The duration of the disease is also longer
(median 13 months) than classical CJD (median 6 months) while the initial clinical
symptoms are behavioural changes and ataxia compared with the dementia and
myoclonus seen in classic CJD. Periodic sharp waves in electroencephalographs (EEG)
found in most classical CJD cases are absent in vCJD. Pathologically vCJD is
characterised by distinctive "florid" plaques in the brain containing PrP only rarely seen
in classical CJD. Much evidence has accumulated that vCJD is caused by exposure to
BSE (Bovine Spongiform Encephalopathy) infected material. The incubation periods
and lesion profiles (the amount of vacuolar pathology in particular regions of the brain)
of a panel of inbred mouse lines infected with BSE cattle brains or vCJD brains are
indistinguishable from each other but different from those of scrapie or sCJD (Bruce et
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al., 1997)(Figure 1-2). Epidemiological evidence also points to a link as almost all vCJD
cases have occurred in Britain after the peak of the BSE epidemic.
All vCJD patients to date have been homozygous for the methionine polymorphism at
codon 129 (Ironside, 1998) (Zeidler et al., 1997) a genotype shared with 40% of the
Caucasian population. This genotype also increases the risk of developing sCJD. The
absence of any heterozygous or valine homozygote vCJD patients may indicate that
human methionine homozygotes are much more susceptible to vCJD. This may be due
to the fact that, along with almost all species examined so far (Schatzl et al., 1995)
(Schatzl et al., 1997), cattle are also methionine homozygotes at codon 129, which could
increase the efficiency of interactions between bovine PrPSc and human PrP.
Alternatively, all genotypes might be equally susceptible to BSE, but methionine
homozygotes may have the shortest incubation period and valine homozygous and
heterozygote individuals are still incubating the disease. Although the study of French
Growth Hormone iCJD patients suggests that codon 129 genotype can affect both
susceptibility and incubation period which could mean that VV and MV individuals will
be less susceptible and have increased incubation periods. At present there is no way of
determining which of these scenarios will occur.
Table 1-2 Number of vCJD cases in the UK 1995-1st January 2001.
Source CJD surveillance unit. There have also been two cases in France and one case
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Figure 1-2 Lesion profiles of BSE,vCJD scrapie and sCJD. Brain homogenate
from infected individuals were injected into RIII mice and and upon development
of disease the vacuolation in various brain regions was examined and the amount
of vacuolation scored from 1 to 5. Brain regions examined were l=dorsal medulla,
2=cerebellar cortex, 3=superior colliculus, 4=hypothalmus, 5=thalmus,
6=hippocampus, 7=septum, 8=retrosplenial and adjacent motor cortex,
9=cingulate and adjacent motor cortex.Adapted from Bruce et al. 1997.
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It is difficult to predict the number of individuals who will eventually develop vCJD
from the numbers who have so far developed the disease to date (Table 1-2), as many
of the parameters which will determine the size of the epidemic (e.g. amount of
infectivity that entered the food chain, average incubation period, genetic variations in
susceptibility and/or incubation period) are unknown. The individuals who have
developed vCJD may represent the people with the shortest incubation periods who were
infected at the beginning of the BSE epidemic, (in which case the epidemic will be very
large) or they may be uniquely susceptible individuals who were infected at the height
of the BSE epidemic, in which case the epidemic will be small. Computermodelling of
the eventual scale of the epidemic has focused on two parameters, the average
incubation period and the number of people who could be infected by one infected
animal. Using data on vCJD deaths to the end of 1999 (Ghani et al., 2000) one model
predicts that the total number of cases will be less than 6000, assuming that the mean
incubation period is less than 60 years and that each infected bovine carcass infects two
people on average. However, this model assumed that only methionine homozygotes
would develop disease therefore assumed that 60% of the population is resistant to
vCJD. If susceptibility or incubation period is affected by additional loci outside of the
PrP open reading frame then the eventual scale of the epidemic could be larger than
these predictions.
1.1.7 Kuru
Kuru is a TSE which has been described in the Fore tribe ofNew Guinea. It is thought
to have first occurred at the beginning of the 20th, century but only came to the attention
ofWestern doctors when it reached epidemic proportions in the 1950s (Gajdusek, 1996).
Clinically it is characterised by extra-pyramidal signs, strabismus, dysphagia, mutism
and inappropriate laughter. The pathology is characterised by many amyloid plaques
composed of PrP in addition to diffuse deposits ofPrP gliosis and vacuolation (Lantos
et al., 1997) (Hainfellner et al., 1997). It is thought to have been transmitted by the
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practice of cannibalistic funeral feasts ofmembers of the community who had died of
Kuru. The origin of the initial case which started the epidemic is unknown but may have
been a fCJD or sCJD case. The disease was the largest cause of death of Fore women
and was common in prepubescent children of both sexes. The route of infection is
uncertain, the oral route is a distinct possibility with the distorted sex ratio due to the
practice ofwomen eating the brains (presumably with a high titre of infectivity) while
men ate the flesh of the deceased. However kuru transmits poorly to primates via the
oral route, this fact and the unusual sex and age distribution has led to the proposition
of an alternative route of infectivity through cuts in the hands or mucous membranes.
This may have occurred more often in women and children, as women prepared the
bodies for funeral feasts and children were cared for exclusively by women possibly
becoming infected at the same time. The ending of cannibalism from the 1960s onward
led to a reduction in the number of cases ofKuru, but the disease has an exceptionally
long incubation period as a few individuals have developed Kuru 40 years after the
cessation of cannibalism.
Analysis of the M129V genotype of 91 kuru victims (Cervenakova et al., 1998) shows
a strong correlation between genotype and age of onset. Younger patients (<15 years)
tend to be pre-dominantly homozygous with more Methionine homozygotes then Valine
homozygotes yet in older patients (>30 years) the situation is reversed with more
heterozygotes than homozygotes. This difference may reflect longer incubation periods
in heterozyogtes resulting in heterozygotes infected in childhood not developing disease
until adulthood. This elongation of heterozygote incubation periods is similar to that
seen in iatrogenic CJD. The frequency ofmethionine and valine alleles at codon 129 in
the pre-Kuru Fore population is unknown so the effect of the codon 129 polymorphism
on susceptibility to Kuru cannot be determined.
1.1.8 Scrapie
The most common TSE is scrapie, a fatal disease of sheep and goats. Scrapie was first
mentioned in 1755 (Brown and Bradley, 1998) and the disease is endemic in all
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countries with sheep with the exception ofNew Zealand and Australia. The pathology
is characterised by vacuolation of the neuronal perikarya and grey matter neuropil,
neuronal loss and astrocytosis (Wood et ah, 1997). The clinical signs include pruritis,
leading to continuous rubbing against posts resulting in wool loss and laceration of the
skin, abnormal gait and posture. Ataxia occurs later and results in the animals being
unable to walk (Brugere-Picoux, 1996).
Scrapie was first shown to be transmissible experimentally in 1936 when sheep were
infected by inoculation from diseased animals (Cuille and Chelle, 1936). The cause of
scrapie is unknown. It has been shown to be transmitted maternally (Foster et al., 1992)
but maternal transmission alone cannot maintain an epidemic. Although not a genetic
disease, polymorphisms in the PrP ORF play a large role in affecting scrapie
susceptibility. Three polymorphisms at codons 136 (Valine or Alanine), 154 (Arginine
or Histidine) and 171 (Arginine, Histidine or Glutamine) in the ovine PrP ORF affect
susceptibility (Figure 1-3). The haplotypes which have been observed are (listed in order
of increasing susceptibility to scrapie) ARR AHR ARQ ARH VRQ. No ARR
homozygote has ever been observed to have scrapie, with the exception of one sheep
from Japan (Ikeda et ah, 1995), and sheep with this genotype are resistant to
experimental infection with scrapie or BSE. In contrast, VRQ homozygotes are highly
susceptible to natural scrapie, with most animals of this genotype developing the disease
if there is an outbreak in a flock. However, the breed of sheep (and therefore genetic
background) also plays a role in scrapie susceptibility as sheep with identical genotypes
but from different breeds can have different susceptibilities. For example, Suffolk ARQ
homozygotes are relatively susceptible to scrapie while Cheviot ARQ homozygotes are
relatively resistant (Hunter, 1997).
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1.1.9 Bovine Spongiform Encephalopathy
The first reported case of BSE occurred in the UK in 1985 (Wells et ah, 1987). Since
then the majority of cases have occurred in the UK although several other European
countries have also reported cases (Table 1-3). Clinical signs include change in
behaviour which develops into ataxia. The pathology is characterised by deposition of
PrP mostly in the basal nuclei and medulla with spongiform degeneration found
predominantly in the brain-stem (Wells et ah, 1992).
Table 1-3 Number of BSE cases by country. Data correct as of January 2001
except UK and Swiss data (December 2000) and Irish data (August 2000) Source:Office
International des Epizooties. www.oie.int
Country Cases
United Kingdom 180501












It is thought that BSE spread through the British herd by the use of spinal tissue and
offal from infected animals in meat and bone meal (MBM) which was fed to cattle as
a food supplement. The epidemic reached a peak in 1992 but has since declined
probably due to the banning ofbovine materials from MBM in 1988.
The original source of the BSE outbreak is unknown; one possibility is a scrapie-
infected sheep that may have been used in MBM preparation and that BSE is therefore
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a form of scrapie. An alternative origin ofBSE is that it arose spontaneously in a cow
as "sporadic" BSE (in an analogous manner to sCJD in humans) and this case was
included in MBM and started the epidemic. The scrapie hypothesis is contradicted by
the lesion profile of BSE infected mice which is different from that of any known
scrapie strain. Although as only a few strains of scrapie have had their lesion profiles
typed, BSE could have originated from a scrapie strain which has not been characterised
or from a strain which changed significantly when crossing the species barrier from
sheep to cattle.
It is unlikely that the question of the origin ofBSE can ever be resolved completely. If
a scrapie strain identical to BSE was isolated in sheep, it would be difficult to determine
if this was a scrapie strain or a case of BSE being transmitted to sheep. The
identification of a sporadic case of BSE in cattle (if such cases occur) would be
extremely difficult, as it would probably resemble BSE contracted orally.
Unlike sheep and humans, the bovine PrP protein has very little variation; the only
polymorphism is in the number of octapeptide repeats. Analysis of common breeds of
cattle in Britain has shown that approximately 95% of bovine Prnp alleles have six
repeats while 5% have five. This contrasts with most other mammalian species where
almost all individuals have 5 octapeptide repeats, neither allele has any discernible effect
on BSE susceptibility (Hunter et al., 1994). Recently a rare breed of Swiss cattle has
been identified with seven octapeptide repeats (Schlapfer et al., 1999) (figure 1-3).
In addition to vCJD in humans, several species of captive or domestic felines (domestic
cats, lions, ocelots, pumas) and ungulates (nyala, kudu, gemsbok, oryk, eland and ankole
cow) also contracted spongiform encephalopathies at the time of the BSE epidemic
(Kirkwood and Cunningham, 1994) (Ministry ofAgriculture, 1996). Incubation periods
and lesion profiles in mice inoculated with brain homogenates from these animals and
vCJD patients show that these TSEs are of the same strain as BSE (Bruce et al., 1994;
Bruce et al., 1997), which strongly indicates that these infections were caused by eating
BSE infected material. Interestingly no TSE has been reported in dogs despite their
similar diet to domestic cats; perhaps the species barrier between dogs and cattle is
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greater than that between cattle and felines. Alternatively, perhaps the rate of replication
of the agent is so slow in dogs that their life span is not long enough to develop clinical
signs of disease.
1.1.10 Transmissible Mink encephalopathy
Transmissible mink encephalopathy (TME) was first observed in farmed mink in the US
in 1947 but has since been observed in Canada and Eastern Europe (McKenzie et al.,
1996). Affected animals changed behaviour, became hyper-excitable and gradually lost
co-ordination. Analysis of TME brains showed the existence of proteinase K resistant
PrP and spongiform degeneration in the cerebral cortex and midbrain regions (Marsh,
1992). Inoculation of Syrian Hamsters with TME brain homogenates led to the
development of a spongiform encephalopathy showing that TME is transmissible. The
source of TME is though to be animal feed, possibly the practice ofUS farmed mink
being fed "downer" cows i.e. cattle unable to stand due to some form of neurological
disease. TME has been experimentally transmitted to cattle orally but not to sheep. After
three passages of a TME case in hamsters two distinct clinical phenotypes emerged,
Hyper (HY) and Drowsy (DY). These two phenotypes are considered strains of TME
as they have different average incubation periods 65 days and 168 days for HY and DY
respectively. End-stage HY animals have a 100-fold higher titre of infectious units than
end-stage DY and the proteinase K resistant PrP proteins produced by the two strains
also have distinct characteristics with HY PrP being more proteinase K resistant than
DY. PK resistant DY PrP protein has a smaller mass than HY due to differing degrees
ofPK sensitivity at the N-terminal of the protein.
1.1.11 Chronic Wasting Disease
Chronic wasting disease (CWD) was first identified in 1967 and occurs in farmed and
wild mule deer, white tailed deer and elk in the US. The pathology is characterised by
spongiform degeneration in the grey matter, astrocytosis and the deposition of amyloid
plaques (Williams and Young, 1993). The mode of transmission is unknown. Oral
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dosing of CWD brain homogenate to mule deer fawns did result in PK resistant PrP
being present in gut associated lymphoid tissue after 80 days, but the experiment did not
continue long enough to determine if CWD would develop or if PK resistant PrP
developed in the central nervous system (CNS) (Sigurdson et al., 1999). CWD
inoculated intra-cerebrally into ferrets caused disease but hamsters are resistant to
infection. If a CWD infected ferret is used to infect a hamster then it does develop
disease. This is an example of a species barrier being by-passed by infecting a third
species.
1.1.12 Experimental TSEs
Although there is no naturally occurring rodent TSE, mice and hamsters have been
infected successfully with most strains of TSE and have acted as the main experimental
animals in TSE research. Experiments using different inbred lines ofmice showed that
a particular mouse line could be classed as a long or short incubating line when infected
with a TSE strain. Analysing the PrP gene in mice shows that there are two alleles, PrP
A and PrP B which are found in short and long incubating lines ofmice respectively.
However some TSE strains, such as 301V (mouse passaged BSE), show the opposite
pattern of incubation periods with allele b mice having shorter incubation periods. Allele
A has a leucine residue at codon 108 and threonine residue at codon 189, allele B has
phenylalanine at codon 108 and valine at codon 189 (Westaway et al., 1987) it also has
a 6kb deletion in the second intron and differences in the upstream putative promoter
region (Westaway et al., 1994).
The difference in incubation periods of the two murine PrP alleles A and B may reflect
different abilities of the two alleles to adopt PrPSc conformation due to the two amino
acids differences. (Moore et al., 1995). Experiments using a transgenic mouse model
where 129/Ola mice (which normally have allele A) had their PrP gene targeted with a
construct which altered codons 108 and 189 to allele B resulted in an incubation period
with mouse adapted BSE strain 301V of 133 days. This is much shorter than the 244
days seen in wild-type 129/Ola mice, but similar to the incubation period of an allele B
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mouse such as the VM/Dk line which has an incubation period of 119 days. There were
also differences in pathology and lesion profile between wild type and transgenic B
alleles. This difference between the TSE incubation periods of transgenic allele B mice
and wild-type allele B mice could be due to the differing genetic backgrounds of the two
lines of mice or the intron deletion and upstream region polymorphisms of the Prnp
gene which were not altered in the transgenic line. Therefore while the amino acid
differences ofmurine allele A and B account for most of the difference in incubation
periods between the two lines, variation in sequence outside of the PrP ORF also affects
TSE incubation periods.
1.2 The PRNP gene and the PrP protein.
1.2.1 Gene structure
The genomic structure of the PrP gene has been determined in rats, mice, cows, sheep,
hamsters and humans. All species except humans have three exons. The first two exons
are short (50-160bp) and form part of the 5' UTR of the processed mRNA. They are
separated by an intron of approximately 2.5Kb. The PrP gene first exon is not well
conserved across species but the second exon is highly conserved (Figure 1-4). The
presence of two non-coding exons may suggest that they play a regulatory role in either
controlling transcription or mRNA stability. In all species, the open reading frame
(ORF) is found in the last exon, which is located 10Kb downstream of the second exon.
The third exon is approximately 2Kb in length and consists of a short (lObp) 5'
untranslated region, the open reading frame and the 3' untranslated region.
The human PRNP gene is found on the short arm of chromosome 20. The genomic
structure of the human PrP gene is similar to that of other species (Lee et al., 1998), it
contains two exons which correspond to the first and third exons in other species with
the open reading frame being found in the last exon. It also contains an exon-like
sequence within the intron which is highly conserved to the second exons of other
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species. The sequence also has consensus splice sites and is found in the same position
within the intron relative to the other two exons as the second exon in other species.
However this exon has not been found in any PrP transcripts or expressed sequence
tagged sequences (EST) and therefore appears to be constituitively spliced out of human
mRNA. The PrP mRNA undergoes alternative splicing in hamsters and cattle (Li and
Bolton, 1997) (Horiuchi et al., 1997). Both these alternative splicing events involve the
first two exons and thus do not affect the open reading frame. In cattle, the first exon can
be 53 or 168 nucleotides long depending on which of the two donor splice sites is used.
The donor site that produces the 53bp exon 1 is homologous to that used in other
species. Both transcripts are found in all tissues except spleen, where only the 53bp exon
1 form is found, and there is no difference in the efficiency of translation of the two
transcripts in vitro.
In hamsters the second exon is only found in a small proportion of mRNAs as the
second exon is usually spliced out of the final mRNA (Li and Bolton, 1997). The level
of alternative splicing is tissue dependent with relatively more exon 2 containing mRNA
in the frontal cortex, than in the hippocampus or superior and inferior colliculi. In
scrapie infected hamsters the levels of exon 2 containing mRNA relative to non-exon
2 mRNA remain constant during the course of an infection in the hippocampus and
frontal cortex but rise in the superior and inferior colliculi. The rise in exon 2 mRNA
expression coincides with a rise in expression of glial fibrillary acidic protein (GLAP)
and a drop in synaptophysin. GLAP is expressed in hamster astrocytes while
synaptophysin is expressed in neuronal cells during the formation of synaptic vesicles.
The changes in expression levels may represent the proliferation of astrocytes and the
death of neuronal cells. Levels of PrP exon 2 containing mRNA are linked to GLAP
levels and may therefore be expressed primarily in astrocytes.
In sheep two mRNAs of 4.6Kb and 2.1Kb in length are produced not by alternative
splicing but by the termination of transcription at different points through the
recognition of different polyadenylation sites (Hunter et al., 1994). The relative ratio of
the two transcripts varies depending on the tissue with the greatest amount of4.6Kb in
brain while the 2.1 Kb mRNA is found at its highest levels in spleen.
23
Figure 1-4 CLUSTALW alignment of the first and second exon sequences of
mammalian PrP genes.
There is relatively little conservation of the first exon sequence across mammalian
genera (A) although it is highly conserved within ruminants and rodents. The bovine
exon lb has been omitted as it contains lOObp downstream of the end of the
conventional bovine exon.
In contrast the second exon (B) is very highly conserved in mammals. Despite the
human exon apparently not being used it does not appear to have accumulated mutations
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Thus three different species use three different means of producing different PrP
mRNAs, cows use different donor splice sites, hamsters use different acceptor splice
sites, while sheep use different polyadenylation sites (Figure 1-5). Untranslated regions
are thought to play a role in mRNA stability, and it is here that all the mRNA variation
occurs. Perhaps differing levels ofPrP protein expression in different tissues is achieved
by alternative splicing between two mRNA variants of differing stability. Therefore, the
putative human second exon may be a regulatory region if it is used in some human
transcripts.
1.2.2 The PrP protein
PrP is a di-glycosylated GPI-anchored protein that is highly expressed in astrocytes and
neurones but also on a wide variety of other cell types. The human PrP protein has
glycosylation sites at amino acids 181 and 197, although both sites are not always
glycosylated, allowing PrP to be separated by PAGE into three bands with molecular
masses between 33 and 35 kDa which are unglycosyated, mono- and di-glycosylated
protein. The amino acid sequence of the PrP protein is highly conserved in mammals.
In humans the PrP protein contains 253 amino acids, with a signal peptide of 22 amino
acids at the N-terminal which is cleaved off in the endoplasmic reticulum and a 23
amino acid signal sequence at the C-terminal which is cleaved to allow attachment of
the glycophosphoinositol anchor (GPI). The N-termini of all PrP proteins have five
imperfect glycine-rich octapeptide repeats between amino acids 51 and 91 (Figurel-1).
PrP has also been found in chickens (Gabriel et al., 1992) and turtles (Simonic et al.,
2000) although in these species the protein has 10 hexa-repeats in its N-terminal rather
than the 5 octa-peptide repeats seen in mammals.
NMR analysis of the structure of human, and bovine recombinant mature PrP protein
expressed in bacteria in H20 (Wuthrich et al., 1999) (Zahn et al., 2000) has shown that
the structure of PrP is highly conserved between in both species.
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Figure 1-6 NMR structure of human PrP protein. Adapted from Zahn
R, et al. 2000. Recombinant PrP consists of an unstructured domain
from the first amino acid to approximately amino acid 120 (not shown)
The rest of the protein forms globular domain of as defined by NMR by
consists of two beta sheets (yellow) and three alpha helices (red). As this
protein is produced in E.coli it is not glycosylated which could affect its
structure, the octapeptides in the N-terminal unstructured region are
though to bind copper which could also affect expression.
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The region between amino acids 23 and 124 is unstructured in solution while the
remainder of the protein (AA125-253) forms a globular domain which contains two (3-
sheets and three a-helices (Figure 1-6). Codon 129 which affects susceptibility to TSEs
in humans is found in the first beta sheet while the five octapeptides are found in the
unstructured region.
Examining the distribution of familial TSE mutations shows that, apart from the
insertion ofoctapeptide repeats, most mutations occur in the C-terminal globular domain
rather than the unstructured N-terminal (Figure 1-1). This may reflect a change in
protein sequence which disrupts the structure of the protein enabling conversion to the
PrPSc conformation which leads to disease.
1.2.3 PrP Knockout transgenic models.
In order to understand the normal role ofPrP, the murine Prnp gene has been inactivated
by gene targeting resulting in five lines of null mice, Zurich I (Bueler et al., 1993),
Edinburgh (Manson et ah, 1994), Nagasaki (Sakaguchi et ah, 1995), RCM (Moore et ah,
1999) and Zurich II (Weissmann and Aguzzi, 1999). Abolishing expression of the PrP
gene does not affect the embryonic development or reproductive ability of the five lines
ofmice (Manson et ah, 1994). The lack of any major phenotype in null mice does not
mean that PrP plays no role in development or adult life but that in its absence other
genes may compensate for its absence by up-regulation. Closer examination of the
Zurich I and Edinburgh null lines have uncovered minor abnormalities in sleep patterns
and circadian activity rhythms (Tobler et ah, 1996) which may be related to the severe
disruptions in sleep patterns seen in FFI. Weakened GABA receptor mediated fast
inhibition and reduction of long term potentiation (LTP) has also been reported in these
two lines ofnull mice (Collinge et ah, 1994) (Manson et ah, 1995) although this effect
has not been replicated in another study (Lledo et ah, 1996). Whether these minor
phenotypes offer any insight into the function ofPrP is unclear.
In order to determine which region of the PrP protein was required to restore
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susceptibility to TSEs, transgenic mice were made which had deletions of the N-terminal
region PrP (Fischer et al., 1996) (Shmerling et al., 1998). Infecting such mice with
scrapie showed that deletion of the region between amino acids (AA) 69 and 84 or
between AA 32 and 80 still resulted in proteins which when expressed on a null mouse
background made the mice susceptible to scrapie infection. However, a further set of
deletions which removed AA 32 to 121 or 32 to 134 resulted in mice which developed
severe ataxia at 3-8 weeks of age depending on the size of the deletion and the level of
expression. A deletion between AA32 and 106 did not result in this phenotype implying
that the region between AA106 and 121 is responsible for this phenotype. However, this
phenotype can be rescued by introducing a wild-type gene or even an AA32-93 deleted
transgene.
The fact that this phenotype is not seen in PrP null mice and can be rescued by a wild-
type gene has led to the proposal of a model where PrP binds to an unknown ligand. In
null mice a protein functionally similar to PrP binds to the ligand and effects signal
transduction, preventing any phenotype from occurring (Figure 1-7) However removal
of the flexible tail (AAA32-121) results in a PrP protein which is proposed to bind to the
ligand but to be unable to effect signal transduction resulting in cell death leading to the
severe ataxic phenotype. It is proposed that the globular domain (as characterised in
vitro byWuthrich (Wuthrich et al., 1999)) ofPrP between amino acids 125-250 contains
a ligand binding site while the flexible domain between AA 32 and 124 effects signal
transduction, although presumably the region between 106 and 121 is sufficient to
induce signal transduction as the truncated proteins have effectively removed the
flexible tail.
1.2.4 Doppel
Three of the null lines (Sakaguchi, RCM and Zurich II lines) develop a syndrome
characterised by ataxia, Purkinje cell degeneration and cerebellar atrophy at 70 weeks
of age (Sakaguchi et al., 1996). This phenotype can be abolished by introducing a PrP
transgene into the line (Nishida et al., 1999). Why these symptoms did not occur in the
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other lines may be due to differences in the construct used to knockout the gene.
Comparing the transgenic constructs used to inactivate the Prnp gene (Figure 1-8) shows
that the two non-ataxic lines (Zurich I, Edinburgh) replaced the central part of the third
exon (Zurich I) or inserted a reporter gene within the third exon (Edinburgh). In contrast
the ataxic lines replaced most of the third exon and some of the 3' end of intron 2
(Nagasaki and RCM lines) or removed the entire third exon, some intronic sequence and
sequence downstream of the third exon (Zurich II line).
Analysing expression patterns in the brains ofRCM and Nagasaki (Moore et ah, 1999)
(Li et ah, 2000) ataxic mice shows that they have high levels of a chimeric transcript that
contains PrP non-coding exons and the coding exon of another gene called Prnd (prion-
like downstream), which produces a protein called Doppel. Prnd is found 16kb
downstream ofPrnp in mice and has a similar genomic structure with two untranslated
exons upstream of a single ORF-containing exon although it also has an untranslated
exon 3' of the coding exon. The gene is normally expressed in testis and heart but not
in the brain or lungs (Moore et ah, 1999). Analysing the chimeric transcripts in the
brains of ataxic mice showed that they contain Prnp exons 1 or 1 and 2 fused to prnd
exon 3. The chimeric doppel transcripts are transcribed from the PrP promoter and
therefore have a PrP-like expression pattern. Transcription runs through the deleted third
exon to the doppel gene. The PrP untranslated exons are spliced to the third exon of
doppel which contains its ORF although some transcripts also have one or two
intergenic non-coding exons. This aberrant splicing is thought to be due to the removal
of the PrP third exon acceptor splice site in the construct used to make the three ataxic
lines (Figure 1-9).
It is proposed that in a wild-type mouse any transcripts which continues through the PrP
third exon into doppel would nonnally not result in a mRNA containing Dpi exons, as
splicing to the third PrP exon would lead to amRNA containing the poly-A signal in the
PrP third exon and the doppel portion of the transcript would be removed. Therefore the
removal of the splice donor site in the ataxic knockouts leads to increased doppel mRNA
in the brain, presumably leading to ectopic expression of doppel in the brain, which
causes the ataxic phenotype.
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The link between aberrant splicing to Doppel and the ataxic phenotype in null mice
could be tested by making a very small deletion of PrP which removes just the
consensus splice site at the end of the second intron. This would also differentiate
between aberrant splicing and the loss of regulatory elements at the 3' end of the second
intron. Doppel is a GPI anchored protein, which contains two consensus glycosylation
sites, however its function and role in the ataxic phenotype are unknown. Analysis of
doppel sequence in humans has shown that there are several polymorphisms in the
protein coding region (Mead et al., 2000), but no doppel allele shows an association with
sCJD or vCJD. The ataxic phenotype seen in three of the five null is probably an artefact
of the particular transgenic strategies used in those lines and as the protein is not
normally expressed in brain it probably plays no role in TSEs.
1.2.5 PrP and copper
The strongest candidate for the function ofPrP is that of a copper binding protein which
may have superoxide dismutase activity. Analysis of the brains of PrP null mice has
shown that they contain less copper in membrane-rich extracts than wild-type (Brown
et al., 1997). The N-terminal region ofmature human PrP protein (amino acids 23-98)
produced in E.coli has been shown to bind copper (Hornshaw et al., 1995). While the
addition of copper to murine neuroblastoma cells stimulates PrP to undergo endocytosis,
this effect is absent in cells expressing mutant proteins lacking the N-terminal (Pauly
and Harris, 1998).
One of the physiological functions of copper is to act as a co-enzyme for Cu/Zn super¬
oxide dismutase (SOD), in PrP null mice there are decreased levels of Cu/Zn SOD
activity and increased levels in transgenic mice over-expressing PrP (Brown and
Besinger, 1998). This effect on activity is post-translational as Northern and Western
analysis shows that Cu/Zn SOD expression and protein levels are not affected, implying
that PrP aids in the functioning of the enzyme, possibly by transporting copper into the
cell. (Brown and Besinger, 1998). Mn SOD activity is increased in null mice probably
to compensate for the decreased levels of Cu/Zn SOD activity. Despite this up-
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regulation ofMn SOD, PrP null cells are more susceptible to oxidative stress in vitro.
The PrP protein itself has shown SOD activity when bound to copper. (Brown et al.,
1999) Thus it may play a dual role in transporting copper to the cytoplasm and also
acting as a SOD in its own right. Analysing PrP binding to other cations has shown if
recombinant PrP protein is denatured in urea and allowed to renature in the presence of
various cations it can bind to Cu, Mn, Ni or Zn but it cannot bind Mg, Fe or Ca. Mn
bound PrP also exhibits SOD activity although at only 50% of the level of activity of Cu
bound PrP. Intriguingly when stored at 4°C for two weeks Mn bound PrP loses its SOD
activity while the copper bound PrP was unaffected. This "aged" Mn bound PrP is
slightly proteinase K resistant and has a higher percentage of beta-sheet secondary
structure (Brown et ah, 2000). The ability to create proteinase resistant PrP with
increased beta-sheet is possibly a pre-cursor ofPrPSc and that the conformation change
may be mediated by metal binding.
Recent studies on recombinant murine PrP (Brown et al., 2000) have shown differences
in SOD activity between the two murine PrP alleles that affect incubation periods. Four
recombinant proteins PrP A (codon 108=L, codon 189=T) PrP B (108=F, 189=V) PrP
A108 (codon 108=F, codon 189=T) and PrP A189 (codon 108=L, codon 189=V) were
compared for SOD activity and copper binding. PrP A had lower levels of SOD activity
than PrP B. PrP A189 had equivalent levels to PrP B while PrP A109 had intermediate
levels of activity. There was no difference in the amount of copper bound (4 atoms)
between any of the proteins. Aged proteins (1 month at 4°C) saw a gradual decrease in
SOD activity which was more pronounced in the two intermediate proteins (PrP A108
and PrP A189) than in the naturally occuring alleles PrP A and PrP B. When the proteins
were aged the two intermediate forms spontaneously formed aggregates and fibrils and
developed proteinase K resistance in solution. This may imply that PrP can
spontaneously aggregate, although these experiments used recombinant proteins at high
concentrations in solution, which may mean they are not applicable to the physiological
behaviour of PrP in vivo.
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1.3 PrP and TSEs
1.3.1 Models: Prion Vs nucleic acid models
There are three competing theories to explain the mechanism of TSEs, the most widely
accepted of which is the Prion theory which states that PrPSc is the sole infectious agent
and that the conversion ofPrPc to PrPSc is catalysed by PrPSc. The viral theory proposes
that TSEs are viral diseases and the formation of PrPSc is a form ofpathological damage
rather than an integral part of the disease process. The virino theory states that a nucleic
acid is the infectious agent which is associated with PrPSc and that this protects the
nucleic acid from mutagens and nucleases.
1.3.2 The prion theory
The prion theory, also known as the protein-only theory states that protein-protein
interactions convert PrPc to PrPSc .The mechanism of conversion from PrPc to PrPSc is
unknown although two models have been proposed. The heterodimer model (Figure 1-
10) (Pruisner, 1991) proposes that a PrPSc molecule interacts directly with a PrPc
molecule changing its conformation to that of a PrPSc protein which in turn can act in
converting more PrPr molecules. In this model, a single PrPSc protein is enough to start
the chain reaction of conversion. The initial PrPSc molecule is proposed to come from
infection (Kuru, Iatrogenic CJD and vCJD) or the very rare misfolding of a normal
protein (sCJD). The mutations in PrP that cause familial prion diseases are thought to
predispose the protein to misfolding and somatic mutations in PrP are also proposed as
another mechanism for the initiation of sCJD.
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The seeded polymerisation model of PrPSc formation (Come et al., 1993) (Figure 1-11)
proposes that the PrP protein is in dynamic equilibrium between the PrPSc and PrPc
conformations with the PrPc conformation pre-dominating. If however a large amount
of PrPSc accumulates, the molecules aggregate together and the PrPSc conformation
becomes favoured, this aggregate also serves as a scaffold that fixes other single
molecules transiently in the PrPSc conformation into the PrPSc conformation
permanently. Portions of the aggregates occasionally break off and initiate seeding in
another part of the brain. This seeding mechanism requires a large aggregate of PrPSc to
start the process. In TSEs this may come from infection or the chance accumulation of
large numbers of PrPSc molecules, PrP proteins carrying familial TSE mutations are
more likely to adopt the PrPSc structure for longer periods of time and thus have more
chance to form aggregates eventually leading to familial prion diseases.
1.3.3 The viral theory
One aspect of TSEs which the prion hypothesis has not satisfactorily addressed is the
existence ofmultiple strains of agent, whose diversity resembles that of a nucleic acid
rather than a single protein. This has led many investigators to retain the original
hypothesis of a novel form of virus which is able to survive processes, such as UV-
irradiation or nuclease treatment (Alper, 1985), which degrade nucleic acids, but which
has not yet been detected. Also not all TSEs exactly fit the prion theory, some diseases
can be highly infectious with very little PrPSc produced e.g. FFI, and not all of the
familial diseases have been successfully transmitted to experimental animals. Under the
viral theory, the conversion ofPrPc to PrPScis part of the disease process rather then the
cause. Evidence supporting the viral theory is a study where BSE inoculated mice
developed TSE symptoms but 50% did not have proteinase K resistant PrP (Lasmezas
et al., 1997). In addition, symmetrical structures have been identified in scrapie-infected
hamsters brains (Diringer, 1996) which resemble virus particles although these
structures are smaller than the smallest known virus.
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1.3.4 The Virino theory
A similar theory to the viral theory is the virino theory, which postulates that the agent
responsible for disease is a nucleic acid, termed a virino, which binds to the PrP protein
(Dickinson and Outram, 1988). The virino is postulated to catalyse the conversion of
PrPc to PrPSc and bind to PrPSc which may protect it from the processes (nuclease
treatment, UV-radiation)(Figure 1-12) which have been used to eliminate any nucleic
acids from a PrPSc preparation. Thus, brain inocula from an infected animal will contain
virino as well as PrPSc. According to the viral and virino theories the mutations in PrP
seen in familial prion diseases do not in themselves cause disease but make carriers
extremely susceptible to particular viral/virino strains which are either ubiquitous in the
environment (Manuelidis and Manuelidis, 1993) or present as a retrovirus in
mammalian genomes (Murdoch et ah, 1990). PrP may possibly act as a receptor for
either the virus or the virino which would explain why null mice are resistant to disease
and over-expression ofPrP decreases incubation periods.
1.3.5 Transgenic models of familial TSEs.
According to the prion theory familial TSEs are caused by mutations in the PrP ORF
that pre-dispose the protein to spontaneously convert to PrPSc. The fact that the
mutations are not always fully penetrant but are transmissible has lead to the proposition
under the viral and virino theories that these mutations do not directly cause disease but
greatly increase an individual's susceptibility to some form of virus or virino to which
most individuals are highly resistant. In order to discriminate between the two
alternatives three familial TSEs have been modelled in transgenic mice.
P102L is the most common form of GSS. In order to model the disease, two different
types of transgenic mice have been made one by microinjection and one by homologous
recombination. In microinjection, the transgenic construct is injected into fertilised eggs
where it integrates randomly into the genome. Varying numbers of copies of the
transgene can be introduced by this method leading to varying levels of PrP expression.
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Homologous recombination in contrast, replaces the endogenous gene with a mutated
transgene. Both the microinjection and the homologous recombination constructs
contained leucine at codon 101 rather than proline (codon 102 in humans is equivalent
to codon 101 in mice). Using the microinjection technique several lines were made
which produced varying levels of P101L (Hsiao et ah, 1990). Mice with the highest
levels of PI OIL expression spontaneously develop a neurodegenerative disease
characterised by spongiform degeneration and deposition of amyloid plaques in the
brain. However the PrP of these animals is not resistant to proteinase K digestion. These
spontaneously sick animals were able to transmit disease to other PIOIL transgenic mice
and hamsters (Hsiao et al., 1994). Another transgenic line which produces lower levels
of 101L (Kaneko et al., 2000) only develop spontaneous disease about 20% of the time
and then only at 400-600 days of age compared with 150-190 days in the high-
expressing line. The possibility exists that the phenotype is due to over-expression
caused by the extra transgene rather than the PIOIL mutation contained within it. This
is similar to what occurs in transgenic mice which over-express the wild-type mouse,
hamster or sheep proteins who spontaneously develop neuromuscular disease and suffer
vacuolation of the grey matter in the absence of any infection. These over-expressing
mice also do not produce proteinase resistant PrP (Westaway et al., 1994). Alternatively,
it may be argued that the over-expressing lines are a more accurate representation of
GSS in humans, which takes 50 years on average for disease to develop. Therefore in
the limited life-span of a mouse over-expression is needed to compensate for the shorter
life-span.
Another line of transgenic mice replaced the endogenous gene with a PIOIL mutant by
homologous recombination (Moore et al., 1995). These mice did not develop
spontaneous disease but 101LL (Homozygous mutant) mice were 100% susceptible to
primary GSS P102L inoculum (i.e. brain homogenate from a GSS P102L patient) in
contrast to wild-type mice where only 14% of wild-type mice developed disease
(Manson et al., 1999). They also had a shorter incubation period (288 days) than wild
type mice (456). Mice heterozygous for the mutation (101PL mice) were less susceptible
to GSS P102L primary inoculum than 101LL mice and had longer incubation periods.
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The 101LL mice infected with GSS had no detectable PrP deposition in the brain and
produced extremely low levels of PrPSc when analysed by Western blot. Heterozygous
mice varied considerably in the amount of deposited PrP and PrPSc produced. However,
on subsequent passage from GSS infected 101LL mice into other 101LL 101PL and
101PP mice all three genotypes were 100% susceptible and had much shorter incubation
periods than primary GSS passage. The pattern of incubation periods was reversed
however when the mouse adapted scrapie strain ME7 was inoculated into the three
genotypes, with wt mice having shorter incubation periods than 101PL or 101LL mice
(although there was no significant difference between 101PL and 101LL mice). This
result implies that a PrP protein containing the 101L mutation is not inherently more
unstable than wild-type (10IP) mouse protein but may suggest that it interacts with
different efficiencies with the infectious agents that cause GSS or ME7 scrapie.
Mice containing nine extra copies of the octapeptide repeat have been made in order to
model the forms of familial CJD and GSS associated with insertion of octapeptide
repeats in the human PrP protein (Chiesa et al., 1998). Of five lines made on a wild-type
background the two lines which expressed low levels of protein did not develop any
abnormal phenotype, while the three that expressed the mutant protein at levels equal
to or above that of the normal protein developed spontaneous neurodegenerative disease
at 100-200 days. When bred to null mice the onset of disease was reduced to 100 days
for mice hemizygous for the transgene array and 60 days for mice homozygous for the
transgene array. The pathology of these mice was characterised by atrophy of the
cerebellum and the production ofPrP that is slightly resistant to proteinase K digestion
but this disease has not been shown to be transmissible so it is difficult to determine
whether or not this syndrome is a model of a TSE or an artefact of over-expression of
a mutant PrP.
The GSS variant Al 17V is unusual in that very little proteinase resistant PrP has been
found in brains and although it is termed a transmissible spongiform encephalopathies
it has not yet been transmitted to experimental animals (Brown et al., 1994). Analysis
ofAl 17V Syrian Hamster proteins expressed in mice has shown that the Al 17V protein
and proteins with mutations near codon 117 adopt an unusual topology with respect to
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the membrane. In vitro studies that digest with cytosolically deposited proteinase K
results in the creation of two partially digested forms of PrP in addition to the extra¬
cellular secreted PrP. These digested forms consist of a C terminal transmembrane (Ctm)
form, which becomes lodged in the membrane and had its N-terminal removed by the
cytosolic PK, and an N-terminal transmembrane (Ntm) form which has had its C-
terminal region digested. All forms ofPrP appear to have a percentage ofproteins in all
three conformations but the A117V mutant and other similar mutations have a high
propensity to adopt the Ctm form. In transgenic mice over-expressing two of these
proteins, spontaneous disease occurs after 60 days. The pathology was characterised by
vacuolation and gliosis in one mutant, and neurodegeneration and gliosis in the other
mutant. Neither deposited any PrP in either plaques or diffuse deposits. This contrasts
with A117V GSS patients who have distinctive PrP plaques. Analysis of brain tissue
from a GSS patient allowed the determination of the topology of its PrP by the fact that
Ctm PrP is very slightly proteinase resistant although much less so than conventional
PrPSc and also has a smaller mass (19kDa) than PrPSc (27-30kDa). Treatment of brain
extracts with mild and harsh proteinase K showed that there was no PrPSc but there was
PrP Ctm implying that GSS A117V may be a different type of disease from other
familial and non-familial PrP diseases. According to the virus/virino hypothesis GSS
A117V may be a genetic disease directly caused by the mutation and thus not infectious
which would explain why GSS A117V has not been successfully transmitted to
experimental animals. (Mallucci et ah, 1999) and others although it is then not clear why
A117V resembles other forms of GSS in clinical signs and brain pathology.
Of the three familial TSEs modelled in mice only PIOIL has produced spontaneous
disease and then only when the protein is over-expressed. However, this mouse line did
not produce proteinase K resistant PrP. The other PI OIL GSS model did not develop a
spontaneous TSE but its susceptibility to GSS was increased while susceptibility to one
strain of mouse-adapted scrapie was decreased. This could reflect either differing
incubation periods to differing TSE strains under the virino hypothesis or that the single
amino acid change at codon 101 has a large effect on the interactions between PrPc and
PrPSc molecules in different conformations according to the prion theory.
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1.3.6 The 129 Polymorphism and PrP theory
The increased susceptibility of codon 129 homozygotes to CJD may reflect the protein-
protein interactions between PrPc and PrPSc which are required for conversion from PrPc
to PrPSc under the prion hypothesis. The differences between proteins in heterozygotes
at codon 129 or 219 may hinder effective conversion thus preventing the onset of the
disease. The presence of 50% ofPrP with a different amino acid structure may be similar
to the species barrier which is controlled by the number of amino acid differences
between two species. Under the virino hypothesis, different strains of virino may have
preferences for particular PrP alleles and thus homozygotes may be more susceptible
than heterozygotes (Palmer and Collinge, 1992).
1.3.7 In vitro conversion
The prion theory predicts that PrPc can be converted to the infectious, proteinase K
resistant PrPSc by direct interaction: so far this has only been shown to occur in infected
animals where the possibility of a viral component cannot be excluded. In order to show
that the infectious agent is entirely proteinaceous and lacks nucleic acid PrPc must be
converted to PrPSc in a cell free system (to prevent viral replication) and this PrPSc should
be infectious. Attempts at cell-free conversion has had some success as mixing PrPSc
with labelled PrPc under certain conditions then digesting with proteinase K has shown
some labelled proteinase K resistant PrP (Caughey et ah, 1995), implying that the
interaction with the PrPSc has caused PrP to become proteinase resistant. However, the
conversion process requires an excess of PrPSc and very little labelled PrPSc is produced.
Although infectious PrP molecules have not been created in a cell-free system protein-
protein interactions ofPrP can confer specific levels ofproteinase K resistance on PrPc.
The PrPSc proteins of different strains of transmissible mink encephalopathy (HY and
DY) have different sensitivities to proteinase K digestion. These differences have been
transmitted to PrPc molecules in a cell free system. (Bessen et ah, 1995).
The fact that the proteinase K resistant protein produced in vitro is in a solution of
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infectious PrPSc makes it impossible to determine if the in vitro converted proteinase K
resistant PrP is infectious. In order to discriminate (Hill et al., 1999) between in vitro
converted recombinant PrP and the excess of PrPSc needed to initiate conversion,
transgenic mice were used. Wild-type mice are resistant to hamster-adapted scrapie
strain Sc237 but transgenic MH2M mice which contain part of the hamster protein with
the murine N and C-terminals of the protein are susceptible to hamster-adapted scrapie
and subsequent passages can infect wild-type mice. Hamster scrapie Sc237 PrPSc was
used to in vitro convert recombinant MH2M protein made in a murine cell line.
Proteinase K resistant MH2M PrP was produced but when injected into wild-type mice,
it did not prove to be infectious but this may be due to the low amounts of PrPres created.
In wild-type mice in vivo produced MH2M PrPSc causes disease in 180 days but it is
uncertain if the level of PrPres produced is equivalent to the level used in the positive
control experiments. Therefore the central tenet of the prion theory, that PrPc can be
converted to infectious PrPSc by protein interaction has not yet been demonstrated in a
cell free system. This may be due to deficiencies in the cell-free system or that some
other agent is required to catalyse conversion.
1.3.8 Species barrier
The species barrier, where transmissions from one species to another are less efficient
than transmissions within species, is thought by the prion hypothesis to represent the
difficulty a PrPSc protein from another species has in converting the PrPc of the host due
to structural differences between the two proteins Once conversion has been achieved,
subsequent conversions are easier as they occur between PrP molecules of the same
species which are often identical. Transgenic experiments to investigate the species
barrier have been carried out in mice carrying copies of the hamster PrP gene in addition
to murine PrP. When a transgenic mouse with 30-50 copies of the hamster PrP gene is
infected with hamster scrapie strain Sc237 it develops the disease as quickly as a
hamster, while mice with 4-8 copies of the hamster gene take a longer time but are still
quicker than wild-type controls. The PrPSc proteins formed were from hamster PrPc
proteins rather than the endogenous mouse PrPc proteins. This experiment shows that
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the species barrier can be removed by expressing the PrP protein of the donor species
in the recipient (Scott et al., 1989).
However, when these mice are infected with mouse-adapted scrapie the incubation
period is longer than in a normal mouse and the PrPSc produced consists ofmurine PrP
rather than hamster PrP, implying that the hamster PrP interfered with the interaction
between the mouse PrP and mouse PrPSc. A different construct which contained the
mouse PrP gene with the hamster sequence between codons 94 and 188 (MH2M) was
made in attempt to make a PrP protein which could interact with both mouse and
hamster PrP. The transgenic mice carrying this protein were equally susceptible to
hamster or murine PrPSc and when they developed disease it could infect either hamsters
or mice with similar incubation periods implying that this chimeric protein is unaffected
by the species barrier between hamsters and mice.
However, introducing a human PrP gene into mice which were subsequently infected
with human prions had no effect on susceptibility to inoculation to the human TSE.
Although it is more difficult to infect a mouse with human TSEs than hamster TSE due
to the greater sequence differences between rodents and primates than between rodents.
When transgenic mice carrying human transgenes were crossed onto a PrP null
background they became more susceptible to human TSE infection (Telling et al., 1995).
A chimeric protein that contained human protein flanked by mouse protein (MHuM)
was more susceptible to human TSEs than wild-type mice even on a wild-type
background.
These results led to the development of the "protein X" theory which suggested that
another protein was required to allow the conversion from PrPc to PrPSc to take place by
binding to specific regions in the C or N-terminals of the PrP protein. A mouse which
expresses both murine and human PrP will only express murine protein X, which will
preferentially bind to murine PrP allowing conversion ofmurine PrP by murine PrPSc.
However, human PrP will not be converted by human PrPSc as human PrP has less
affinity for protein X. On a null background human PrP can bind murine protein X and
allow conversion to PrP50. In the chimeric protein, protein X can interact with the murine
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sequence, N-terminal or C-terminal while the human central region can interact with the
human inoculum. However protein X has not yet been identified nor has it been shown
that the molecule responsible for the effect is actually a protein, therefore further
evidence is required to confirm the existence of protein X.
1.3.9 Prion and virino models of TSE disease
According to the prion theory sCJD occurs either by the spontaneous conversion of a
PrPc protein to PrPSc (Prusiner, 1996) or by a mutation of a PrP gene in a single cell to
a familial CJD mutation which is then highly pre-disposed to assume the PrP& structure.
Both of these events produce a PrPSc protein that then propagates, either by the seeding
or heterodimer interaction model resulting in disease. Alternatively, under the viral or
virino hypothesis these individuals have become infected with a strain of virus/virino.
However, there is as yet no evidence indicating that any of these hypotheses of the
initiation of sCJD are correct nor whether host genetic susceptibility factors act by
increasing the frequency of these rare events or by increasing the likelihood of disease
developing once one of these events have occurred.
Familial TSEs are a more difficult disease to reconcile with the either the prion or
virus/virino theory. Under the prion theory it is proposed that the conformation of the
mutant protein makes it more likely to spontaneously convert to PrPSc which eventually
leads to disease. Yet, the age of onset in familial TSEs is similar to sCJD despite a
familial CJD patient producing 50% mutant protein from birth while a sporadic patient
must await a spontaneous conversion event or a mutation. However, this effect is also
seen in Alzheimer's disease where 10% of cases are linked to mutations in P-amyloid
protein (APP), presenilin 1 and 2 (Das and Lai, 1997) while the other 90% of cases are
apparently sporadic. Perhaps an age-dependent factor or many events unrelated to PrP
are required to initiate disease which would explain the similar age-of-onset in sporadic
and familial CJD. Under the virino hypothesis the mutation is not directly responsible
for the disease but makes an individual orders of magnitude more susceptible to the
agent, with GSS, FFI and familial CJD individuals susceptible to different virino strains.
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The long incubation period of a virino infection would explain why the age of onset is
similar in sporadic or familial CJD. Non-penetrance of familial TSE mutations may
simply reflect individuals who are resistant to infection or have avoided infection.
Familial CJD and GSS mutated proteins are thought to be more likely to convert to a
PrPSc conformation than the wild-type protein. Yet, sporadic disease is clinically and
pathologically similar to CJD rather than GSS. Why are no sporadic GSS cases
observed? Familial CJD is as common as GSS, as there are a similar number and type
ofmutations there is no reason why a somatic mutation to a GSS mutation should occur
less frequently than a CJD mutation. Perhaps the spontaneous conversion of a wild-type
protein to PrPSc is only possible to the conformation that results in CJD-like disease.
1.3.10 Yeast Prions
Evidence supporting the prion hypothesis has come from the field of fungal genetics.
Two non-mendelian phenotypes in Saccharomyces cerevisiae whose mode of
inheritance is uncertain are proposed to be transmitted by a prion-like mechanism. The
[URE3] phenotype (Wickner, 1997) (the brackets indicate an apparent cytoplasmic
mode of inheritance the capital letters that it acts dominantly) leads to a relaxation of
repression of nitrogen catabolic enzymes. While the [PSI+] (Patino et al., 1995)
phenotype leads to skipping of translation termination codons. These phenotypes occur
spontaneously at low frequencies (10°) but are then stably inherited although they can
revert to the normal phenotype at low frequencies. The two phenotypes are related to
two chromosomally encoded proteins, Ure2, which inhibits the transcription factor Gln3
and Sup35 which is a transcription termination factor. Mutations in these genes can lead
to phenotypes resembling [PSI+] and [URE3], but such mutations result in Mendelian
segregation of the phenotype in a recessive manner and the phenotype does not revert
to wild type. Although Sup35p and Ure2p proteins are unrelated to each other, the N-
terminal regions of both proteins are asparagine and glutamine rich. The rate of
occurrence of the [PSI+] phenotype can be increased by transient over-expression of
Sup35 or just the N-terminal region of the protein, the phenotype is then stably inherited,
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even after the cessation of over-expression, conversely mutations in the N-terminal
region of sup35 prevent the [PSI+] phenotype from occurring.
Analysis of cell extracts from [PSI+] and [PSf] cells (cells without the PSI phenotype)
shows that the Sup35 protein in [PSI+] cells forms aggregates which pellet when
centrifuged while Sup35 in [PSf] cells do not. The aggregates were also more resistant
to proteinase K digestion, but this was a general resistance to digestion rather than a
resistant part of the protein as seen the 27-33Kda resistant core seen in PrP. A similar
phenomenon is seen in [URE3] cells where the Ure2 protein is more proteinase resistant
and form aggregates (Wickner, 1994). [PSI+] cells can be cured of the phenotype (i.e.
converted to wild type) by being grown in media containing guanidium chloride, which
is a protein de-naturing agent or by transient over-expression of heat-shock protein 104
(Hspl04) Although cells lacking functional Hspl04 cannot become [PSI+] in the first
instance implying that a minimum level of Hspl04 is required to create the [PSI]
phenotype but at higher levels it abolishes the [PSI+] phenotype (Chernoff et al., 1995).
The yeast prion phenotypes therefore appear to be related to a change in the structure of
the proteins involved.
Attempts to prove the prion theory with mammalian PrP have not succeeded as
recombinant PrP has not been shown to be infectious. The high propensity of the N-
terminal and middle regions alone of Sup35 (NMSup35) (AA1-253) to form aggregates
in vitro was used in experiments where recombinant NMSup35 protein was introduced
to a cell through liposome fusion with a yeast cell spheroblast (Sparrer et ah, 2000). A
high proportion (1.5%) of the fused cells adopted the [PSI+] phenotype (compared with
the 10"5 background rate). This may indicate that the NMSup35 which forms fibrils in
vitro catalyses fibril formation in vivo of the endogenous Sup35 proteins.
The existence of prions in fungi appears to be a form of reversible post-translational
modification that allows the cell to adopt two phenotypes, although it has not been
determined what advantage the [URE3] and [PSI] phenotypes confer on cells. This
contrasts with mammalian PrP where aggregation of PrP results in cell death and
precipitation of protein occurs extra-cellularly as well as intra-cellularly. Aggregation
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ofPrP does not appear to be reversible although this may be due to the fact that neurones
are non-mitotic cells therefore any PrPSc remains in the cell and cannot be diluted by cell
division even if the process of aggregation has ceased. The existence of apparent
protein-protein interaction in yeast by a seeded nucleation model provides evidence that
prions can occur but does not necessarily imply that TSEs are caused by prions as there
is no functional or sequence similarities between PrP and yeast prions and infectious
protease resistant PrP has not yet been produced in vitro. Therefore, more work is
needed on mammalian PrP and yeast prions before stronger parallels with can be drawn
between the two.
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1.4 PrP Expression and TSEs
1.4.1 PrP expression patterns
The pattern of PrP expression is similar in all species examined. High levels of
expression are found in the brain and CNS but PrP is also expressed a wide variety of
other tissues. In adult mice the Prnp gene is primarily expressed in neuronal cells in the
CNS and PNS and in astrocytes but it is also expressed in heart and lung and to a lesser
extent in the spleen and liver (Oesch et al., 1985) (Caughey and et al., 1988). It is also
expressed in resting T-lymphocytes where it may play a role in T-lymphocyte
proliferation which is reduced in null mice (Mabbott et al., 1997). In sheep PrP has a
similar expression pattern being highly expressed in neuronal tissue and also expressed
in spleen, lymph node, lung, heart, skeletal muscle and intestine (Horiuchi et al., 1995,).
In cattle PrP is expressed at high levels in brain, moderate levels in adrenal gland and
skeletal muscle and at low levels in kidney and spleen, no expression was found in liver
(Horiuchi et al., 1997). In rats (Saeki et al., 1996) PrP is expressed at high levels in brain
and placenta and at moderate levels in lung, heart and testis, at low levels in spleen and
kidney and no expression is detected in liver.
Levels of expression vary according to tissue and developmental stage. In embryonic
mice (Manson et al., 1992) expression is not detected in 9.5 day embryos, but by day
13.5 it is detected in the CNS and other neuronal tissue and in the enamel forming cells
of the tooth-buds. By day 16.5 the tooth-bud has the highest levels of expression and PrP
is also expressed in the kidney. It is also expressed in extra-embryonic tissues from very
early in development. At birth, levels of expression in all tissues increase until day 20
when adult levels of expression are achieved (Lazarini et al., 1991). Another study has
however, found that the levels ofPrP expression levels were increasing until six weeks
of age (Miele, 1999).
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1.4.2 PrP expression levels and TSEs
Experiments using transgenic mouse models have shown that the level ofPrP expression
play a role in disease. Transgenic 129/Ola mice hemizygous for functional Prnp (one
functional copy ofPrnp) infected with ME7 scrapie have an average incubation period
of293 days compared with 147 days in wild-type mice (Manson et al., 1994) (Manson,
1996) this effect was also seen with other scrapie strains (Table 1-4). (Sakaguchi et al.,
1995) (Bueler et al., 1994) and in other hemizygous lines (Nagasaki and Zurich I).
Table 1-4 Effect of Prnp gene dosage on TSE incubation periods.
Transgenic mice over-expressing or under-expressing PrP were infected intra-
cerebrally with brain homogenate from various TSE strains. Edinburgh, Zurich I and
Nagasaki lines are hemizygous mice carrying one functional copy of Prnp on the
respective null background.





period (mean +/- s.e.m)
Transgenic
incubation period
Edinburgh 0.5 ME7 147+/-2 293+/-4
Edinburgh 0.5 301C 154+/-1 230+/-2
Edinburgh 0.5 301V 227+/-3 320+/-3
Zurich 1 0.5 RML 158+/-11 290+/-33
Nagasaki 0.5 CJD 138+/-12 259+/-27
Tg93L 2-4 Chandler 125+/-3 97+/-3
Tg94 8 Chandler 137+/2 76+/-2
Tgl 17 8 Chandler 130+/-5 19+1-2
This inverse relationship between expression levels and incubation period has also been
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observed in transgenic mice which over-expresses PrP. I/lnJ transgenic mice which over-
express PrP protein 2-4 fold have reduced incubation periods of 87 days when infected
with the RML scrapie isolate compared with 125 days in wild-type animals. Another
line which over-expresses PrP protein 8-fold has an even shorter incubation period of
76 days (Westaway et al., 1991). Any variation in PrP expression levels in humans may
therefore affect incubation periods in human TSEs which could affect the number of
individuals who develop disease if the incubation period is extended beyond the average
human life-span.
1.4.3 PrP expression patterns and disease
While the levels of expression ofPrP affect incubation periods in transgenic mice, the
pattern ofPrP expression in different tissues also affects susceptibility to TSE infection
and the course of TSEs. Although in TSEs the main site of pathological damage and
infectivity is the CNS, other organs can harbour infectivity. As most natural routes of
TSE infection involve peripheral organs, the mechanisms by which infectivity enters the
periphery, replicates and spreads through the body are important aspects of disease.
In TSE infected mice, infectivity can be detected in spleen implying that the infectious
agent can replicate there as well as the CNS. In BSE infected cattle many different
organs including the PNS and lymphoreticular system (LRS) cells contain infectivity,
while in vCJD PrPSc has been found in the appendix and tonsils of patients. Upon intra¬
peritoneal (ip) infection with the 139a strain of scrapie, infectivity (as measured by
bioassay in mice) spreads from the thoracic cord to the lumbar cord and brain as
infectivity is detected in the spleen and as the splanchic nerve innervates the spleen and
joins the spinal cord in the thoracic region, this suggests that infectivity replicates in the
spleen and is then transported to the CNS via the sympathetic nervous system
(Kimberlin and Walker, 1980).
In order to determine what role, if any, PrP expression plays in the spread of infectivity
different strategies have been used to ectopically express PrP in particular tissues. One
approach was to graft ectoderm tissue from an embryonic day 12.5 PrP over-expressing
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transgenic murine embryo into the brains of adult PrP null mice. Upon intra-cerebral (ic)
inoculation, vacuolation and proteinase K resistant PrP developed in the graft but the
vacuolation did not spread to the surrounding null tissue. While some PrPSc was found
in the areas surrounding the graft, it did not induce neurodegeneration or astrocytosis.
This would suggest that extra-cellular deposits of PrPSc are not toxic to cells and may
therefore be a by-product of infection (Brandner et al., 1996). Alternatively, extra¬
cellular PrPSc could be toxic only to PrP expressing cells by interacting with PrPc bound
to the cell surface. Infected grafts also see a breakdown of the blood-brain-barrier, which
could be an important mechanism in spreading the agent to organs outside the CNS
possibly via the circulatory system. However, neurograft mice infected via the ip, intra¬
ocular (io) or sub-cutaneous (sc) routes of infection do not develop vacuolation or PrPSc
in the graft implying that PrP expression is needed in the periphery to allow infectivity
to travel to the CNS via these routes. In contrast, wild-type animals are susceptible to
infectivity by any of the four routes but have a shorter incubation period and are more
susceptible to dilute doses ofTSE when injected ic (Blattler et al., 1997) (Aguzzi et al.,
1997).
A transgenic models where hamster PrP is expressed in wild-type mice under the control
of the rat neurone specific enolase (NSE) promoter has shown that expression ofhamster
PrP solely in neurons is sufficient to make mice highly susceptible to hamster adapted
scrapie strain 263K injected ic or ip implying that with this strain of scrapie expression
of PrP in spleen is not necessary (Race et al., 1995) (Race et al., 2000). A different
model (Raeber et al., 1997) used a transgenic mouse which expressed hamster PrP under
the control of the glial fibrillary acidic protein promoter which resulted in expression in
astrocytes. These mice were susceptible to hamster scrapie strain 263K injected inter-
cerebrally but only if on a null background. On a wild-type background no disease
occurred possibly due a species barrier effect, although passage of brains of both types
of animals to hamsters showed that the wild type background mice did harbour
infectivity. Therefore PrP expression in neurones or astrocytes is sufficient for disease
to occur using strain 263K.
The presence of infectivity in spleens has led to experiments to determine the role of the
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LRS in TSEs. Experiments with SCID mice have been carried out which show that
while both SCID and wild-type mice are susceptible to ic infection with ME7 strain of
scrapie, SCID mice do not develop disease if infected ip unless infected with very high
doses. In contrast BSE agent does not cause disease in SCID mice suggesting that
different strains have different requirements (Brown et ah, 1997). To determine ifPrP
expression in the immune system is required for the transport of infectivity, PrP null
mice who have a neurograft ofwild-type tissue were irradiated to destroy their bone-
marrow and then had their immune systems reconstituted with wild-type bone marrow.
These mice do not develop TSE pathology in the graft when inoculated ip. Although
wild-type mice irradiated and reconstituted with null or wild type bone-marrow do
develop disease. This implies that expression ofPrP in lymphocytes is not necessary for
the spread of disease to the CNS, but that expression is required in an element of the
immune system not destroyed by irradiation.
Severe combined immuno-deficiency (SCID) mice and wild-type mice are susceptible
to disease upon ic infection, but SCID mice do not develop infectivity in their spleens.
If the immune system is reconstituted with bone marrow from wild type or PrP null
mice, ic challenge leads to the development of infectivity in the spleen, implying that
the immune system needs to be functional but does not need to express PrP for
infectivity to replicate in the spleen. However, SCID mice crossed with PrP null mice,
to produce PrP null SCID mice, and whose immune system is then reconstituted with
PrP wild-type bone marrow do not develop infectivity in the spleen when infected intra-
cerebrally with scrapie strain ME7 (Brown et ah, 1999). This implies that while PrP
expression in lymphocytes is not necessary for infectivity to be transported to the spleen
PrP expression is required in the spleen to allow the agent (PrPSc or a virino) to replicate.
One group of cells in the spleen which may be involved in the replication of the agent
are follicular dendritic cells (FDC). FDCs express PrP and PrPSc accumulates in FDCs
ofCJD infected mice (Kitamoto et al., 1991). FDCs require B-cells to mature, therefore
in SCID mice FDCs cannot mature unless B-cells are provided when the immune system
is reconstituted by bone-marrow graft. In order to determine ifPrP expression in FDCs
is required for agent replication in the spleen, PrP null and wild-type mice were
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y-irradiated to destroy lymphocytes but not the long-lived FDCs. Bone marrow grafts
from PrP null or wild type mice then reconstituted the immune system and the mice
were infected ip or ic with mouse-adapted scrapie strain ME7. Regardless of the
genotype of the graft, null mice remained resistant to infection. In wild-type mice the
PrP status of the bone marrow did not affect ip or ic infectivity or spleen titre as all
reconstituted wild-type mice developed disease and had high spleen titres. Peripheral
expression of PrP is therefore necessary for the replication of infection in peripheral
organs with FDCs being implicated in spleen. However as FDCs are only found in the
spleen, other cells must be involved in the transmission of infectivity between the CNS
and the spleen (Brown et al., 1999).
To further determine the role of the LRS in TSEs, three lines ofmice have been made
which express PrP under the control of different tissue specific promoters on a null
background (Raeber et al., 1999). The IRF transgenic line contained a transgenic
construct where PrP was expressed under the control of the interferon regulatory factor
1 promoter and the Ig heavy-chain enhancer expressed PrP in B and T lymphocytes and
also in the spleen, although in the spleen PrP was expressed at 1000-fold higher levels
than normal in one transgenic line and 100 times in another transgenic line. The
transgenic construct was also "leaky" with PrP mRNA detected in the brain and PrP
protein expression detected in FDCs. The alb transgenic line expressed PrP in the liver
under the control of the albumin promoter, while the lck transgenic line expressed PrP
in t-lymphocytes under the control of the lck promoter. Upon ip infection with the RML
scrapie isolate, the lck and alb lines did not develop disease while the IRF line did,
although with a prolonged incubation period relative to wild-type mice. Bioassay of
spleens from IRF mice hemizygous for the transgene array showed that spleen was
infectious at 14 days after inoculation while the brain did not became infectious until
365 days after inoculation. These experiments show that expression in T-lymphocytes
alone or in hepatocytes does not replicate infectivity while the findings with the IRF
promoter show that PrP expression in spleen and brain are sufficient to make null
animals susceptible to infection although the delay in infectivity developing in the brain
may be due to the low levels of expression in nervous tissue.
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The mechanism by which the agent moves from the periphery to the CNS could be a
physical transport system of the injected infectious molecules which move to the CNS,
or it could be a domino effect where PrPSc converts the PrPc in peripheral tissue and this
conversion spreads to the CNS. The fact that lack of PrP expression in the PNS can
prevent the passage of infectivity may suggest the latter theory is the mechanism. It
could be that the immune system is necessary in the uptake of PrPSc (possibly at Peyer's
patches in the gut or the spleen) and in replication but that infectivity reaches the CNS
via the PNS. Although the replication in the spleen is not obligate depending on the
strain of agent and amount of infectivity used.
These experiments show that any variation in an individual's PrP expression levels in
particular organs could increase or decrease the probability of infectivity replicating in
the periphery and reaching the CNS where disease develops. If a regulatory region
mutation is discovered which affects susceptibility to diseases analysing the expression
pattern of the mutant allele could implicate certain cell types involved in PrP transport
to the CNS.
1.4.4 Expression level variation in other human diseases
The aim of this project is to identify regulatory regions of the human PRNP gene and
identify mutations or polymorphisms within them which affect susceptibility to TSEs.
No polymorphisms have been identified outside of the ORF which alter expression
levels of the human PRNP gene. Although a G-A polymorphism has been identified at
the 3' end of the human intron (intron 2 in other species) (Palmer et al., 1996). There is
no known association between this mutation and disease, the effect of this
polymorphism on expression levels in vitro has not been examined.
Mutations in transcription regulatory regions of other genes have been shown to either
directly cause disease or increase susceptibility to disease. Mutations in regulatory
regions which cause disease have been reported in p-Thalassemia, and X-linked
Charcot-Marie-Tooth disease (Kazazian, 1990) (Ionasescu, 1998). However, these
mutations result in a drastic reduction in expression of the gene in question resulting in
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a null phenotype which is not a model for TSEs. A recent study of the promoter of the
Apolipoprotein E (APOE) gene, which affects susceptibility to Alzheimer's disease
(AD), illustrates how an increase in expression levels of a protein can increase the
incidence of a sporadic disease.
There are many similarities between human TSEs and Alzheimer's disease (AD): both
are neurological diseases with a late age of onset characterised by deposition of amyloid
plaques in the brain. These plaques are composed of P-amyloid protein in AD and of
PrP protein in TSE, although not all human TSEs have plaques. The majority of cases
ofboth diseases are sporadic, but approximately 10% of cases ofboth CJD and AD are
familial, liked to autosomal dominant mutations in PrP in TSEs and in AD mutations
in any of three different proteins (P-amyloid protein (APP), presenilin 1 and 2) (Das and
Lai, 1997).
Polymorphisms in the coding region of proteins have an effect on susceptibility to both
sporadic TSE (the PrP protein) and sporadic AD (Apolipoprotein E) (Rubinsztein,
1997). Apolipoprotein E, which affects lipid uptake in the liver has three alleles, s2, s3
and s4. In European populations 80% of alleles are s3 with the s2 and s4 alleles found
at a frequency of 10% each. Individuals heterozygous or homozygous for allele s4 are
eight times more likely to develop AD than non-carriers (Corder et ah, 1993).
In order to determine if different levels of expression caused by promoter sequence
variation affect susceptibility to late-onset Alzheimer's disease the regions shown to
affect APOE expression (between -1017 and +406) have been sequenced in a case-
control study. Six polymorphisms were identified in the transcription regulatory region,
5 Single Nucleotide Polymorphism point mutations in the APOE upstream region and
one point mutation in the intronic region at +113 (APOE like PrP has two short
untranslated exons). Two of these polymorphisms (-557, -456) were very rare but the
other four (-491A-T, -427T-C, -219G-T and +113G-C) were quite common with the
rarer allele being found at a frequency of 5% to 47%.
Due to the relatively short distance between the promoter and coding regions
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considerable linkage disequilibrium could exist between the regulatory region
polymorphisms and coding region polymorphisms which are known to affect
susceptibility. Such linkage could mask a true association with disease or give an
erroneous association. Analysing the frequency of each allele in individuals with each
of the three genotypes at the other polymorphic positions shows that the -427C allele
is closely linked to the s2 allele in the coding region while the -219G allele is tightly
linked to +113G. The +113G was also linked to the s4 allele.
To determine if these mutations have any functional significance in regulating
transcription, hepatoma and astrocytoma cell lines were transiently transfected with
reporter gene constructs driven by the APOE gene upstream region. Constructs carrying
the rare T allele at position -491 had 60% of the activity of the commoner A allele. A
case-control study of the frequencies of alleles A and T in American and Spanish
populations showed that the A allele was more common in affected individuals than
controls in the Spanish group. Analysing genotypes showed that the AA genotype was
more common in cases (80%) than controls (55%) but again this was only seen in the
Spanish population as the American control group had a higher frequency of the A
allele. The effect of the A allele was stronger if individuals carrying one or two copies
of the s4 allele were excluded.
A similar effect was seen in the -427 polymorphism where the genotype TC was more
common in AD cases than in controls. Dividing the group into e4 carriers and non-
carriers showed that the TC genotype was had no effect on carriers but was three times
more common among AD non-carriers than control non-carriers. The rare C allele also
gave higher expression levels in astrocytoma cells then the T allele thus agreeing with
the -491 result that increased APOE expression increases susceptibility to AD in
individuals with no s4 alleles.
Analysis of the haplotype which considers the effect of the -491-427 polymorphisms
on the same allele shows that the TT (T at -491, T at -427) allele has lower
transcriptional activity then AT while AC has higher levels. Therefore the effects of the
two polymorphisms on expression are additive. Analysing the effect of the -491-427
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haplotype on disease show that it has no effect on individuals who have one or two
copies of the s4 allele ofAPOE but there is a correlation between expression levels in
vitro and susceptibility of s4 non-carriers. Spanish individuals who have no s4 alleles
are at a 4.2-fold increased risk of developing AD if their genotype is AC/AT (high
expressing and normal allele) compared with AT/AT individuals but a 4.3-fold lower
risk if they are TT/AT (low expressing and normal allele) thus expression level affects
susceptibility. In American individuals there is a similar effect but this it much weaker
with AC/AT individuals being 1.3 more at risk than AT/AT while AT/TT individuals
are 1.5 times less likely to develop AD.
This study shows that levels of expression can affect susceptibility to complex diseases
such as AD. Thus while in sporadic AD the s4 allele of APOE is an important
susceptibility factor it is not the sole determinant and levels of expression of other alleles
can affect an individual's susceptibility. The 16-fold difference in risk between AT/TT
and AT/AC individuals in the Spanish population is caused by an expression difference
of approximately 50%, when assayed in astrocytoma cells, which shows that the
increase in risk is much larger than the rise in expression would suggest although there
could be much larger expression variation in other tissues.
One problem with this study is that the effect of expression levels was much larger in
Spanish individuals than American individuals. This difference was due to different
allele frequencies in the two control groups as the affected groups had similar allele
frequencies. The geographical difference in the allele frequencies of healthy individuals
is possibly due to the different ethnic make-up of the two populations resulting in there
being a more significant difference in the Spanish study. This shows the problem of
ethnic background in detecting alleles with weak effects. Other studies have attempted
to duplicate these findings in other Alzheimer's disease patients and not found any
association in Chinese or American Alzheimer's case-control study (Chen et ah, 1999)
(Robeck et ah, 1999), although they did replicate the linkage between the promoter
alleles and the protein s2 and 4 alleles.
The APOE promoter polymorphisms analysis has a lot of parallels with this study of the
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PrP promoter, both diseases are complex but with genetic influences on susceptibility.
The APOE study has shown that expression levels of a particular protein affects disease
susceptibility. This study also showed that the effect of known susceptibility factors
(protein polymorphisms) must be accounted for to detect the smaller effects ofpromoter
polymorphisms. It also demonstrates that two or more promoter polymorphisms can act
co-operatively in affecting expression levels.
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1.5 Aims
The aim of this project is to characterise regulatory regions of the human PRNP gene
and to determine if any polymorphisms affect an individual's susceptibility to sCJD or
vCJD. An individual's susceptibility to sCJD and vCJD is affected by the codon 129
polymorphism in the amino acid sequence of PrP. However, this polymorphism is of
little value in predicting which individual will develop sCJD as individuals carrying the
most susceptible genotype (methionine homozygotes) are only 8-fold more likely to
develop the disease than individuals of the most resistant genotype (heterozygotes)
which is of little predictive value in a disease that affects only 1 in a million each year.
Similarly, although all vCJD patients to date have been methionine homozygotes, this
genotype is shared with 40% of the population. Therefore there may be other genetic or
environmental factors which affect an individual's susceptibility to vCJD or sCJD.
Genetic susceptibility factors may be genes at different loci which may interact with PrP
or variation in regulatory elements which affect the level ofPrP expression. Differences
in expression could be caused by mutations in the PrP promoter or mutations in the 5'
or 3' untranslated region, which affect mRNA stability. Analysing the promoters of
sCJD and vCJD patients might detect mutations which increase their expression levels
and predispose them to develop the disease. As TSEs have very long incubation periods
in humans, differences in expression which increase or decrease incubation periods,
possibly extending them beyond the average human life-span, would be very important
in disease.
Differences in expression levels of particular genes have been shown to directly cause
some human genetic diseases (Ionasescu, 1998; Kazazian, 1990) and has been shown
to influence susceptibility to Alzheimer's disease. Differences in expression levels have
been shown to have a large effect on TSE incubation periods of transgenic mice which
over or under-express PrP. Any variation in PrP expression levels could be confined to
a particular tissue and still have an affect on susceptibility to CJD, as PrP gene
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expression in peripheral organs is necessary for disease to occur through peripheral
infection.
To determine if variation in PrP expression levels or patterns affects susceptibility to
disease, the aim of this project is to identify sequences that control the expression of the
human PRNP gene (Chapter 3). These regions will then be used to control expression
of a reporter gene in transgenic mice (Chapter 4) to determine if the regulatory regions
act in controlling expression in a tissue specific manner. In humans, the regulatory
regions will then be sequenced in controls and CJD patients to determine if any
polymorphisms exist which pre-dispose individuals to sCJD or vCJD (Chapter 5).
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2 Chapter Two: Materials and Methods
2.1 General Materials and methods
All techniques described here are adapted from Sambrook et al. 1989 (Sambrook et al.,
1989) unless otherwise stated
Bacterial strain used for cloning was XL-1 Blue
Strains used in lambda propagation were XL-1 Blue and XL-1 MRA
XL-1 Blue Genotype: recAl endAl gyrA96 thi-1 hsdR17 supE44 relAl lac [P proAB
lacld ZAM15 TnlO(Tetr)]
XL-1 MRA Genotype: A(mcrA) 183. A(mcrCB-hsdSMR-mrr) 173 endAl supE44 thi-1
gyrA96 relAl lac.
2.2 DNA manipulation techniques
2.2.1 Electrophoresis
DNA was separated by electrophoresis in a 0.8-2.5% agarose in IX TAE buffer gel and
electrophoresed at 100V in 1XTAE buffer.
2.2.2 50X TAE
242g Tris, 57.1ml Glacial acetic acid, 100ml 0.5M EDTA pH 8, H20 to 1 litre
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2.2.3 Restriction endonuclease digests
All restriction enzymes used were from Promega. A typical digest composed:
1-2 pg of plasmid DNA
2 pi of 10X reaction buffer
5-10U of the restriction enzyme or enzymes
H20 to 20 pi
The reaction was incubated at the appropriate temperature for 1 -3 hours.
2.2.4 Ligation
Ligations were carried out using the Boehringer Mannheim Rapid ligation kit.
50ng of vector DNA
3X the molar amount of insert DNA
H20 to 8 pi
2pl ofDNA dilution buffer
10 pi of reaction buffer
1 pi of T4 DNA ligase
This was incubated at room temperature for 5 minutes for a "sticky-ended" ligation or
30 minutes for a "Blunt-end" ligation reaction. The reaction could then be used directly
to transform E.coli.
2.2.5 Filling-in DNA Overhangs with Klenow fragment.
Klenow reactions were carried out using reagents in the Erase-a-base kit (Promega)
3pl of Klenow mix (5 units of Klenow fragment in 30pl of 20mM Tris.Cl pH8.0,
1OOmM MgCl2) from the Erase-A-base kit (Promega) was added to
27pl of DNA in TE
Incubated for 3 minutes at 37°C
3pl of dNTP mix (0.125mM of dATP, dCTP, dGTP and dTTP) was added
Incubated for 5 minutes at 37°C.
Heat inactivated at 65°C for 10 minutes.
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2.2.6 TE buffer
10mM Tris.HCl, ImM EDTA pH 8.0
2.2.7 Making competent cells
One colony ofE.coli strain XI-1 Blue was added to 2mls ofLB, and incubated overnight
at 37°C. The next morning 0.5ml of the overnight culture was added to 50mls ofLB and
grown at 37°C until the OD600 reaches 0.6. The cells were centrifuged at 3500g for ten
minutes. The pellet of cells was resuspended in 25mls of ice-cold 100mM CaCl2 then
centrifuged again at 3500g for 10 minutes and the pellet resuspended in 3 mis of ice-cold
lOOmM CaCl2 .The cells were then ready to be transformed.




H20 to 1 litre
pH to 7.0
Autoclave at 121°C for 15 minutes.
2.2.9 X-Gal/Ampicillin plates
Autoclave 500mls ofAgar broth at 121°C for 15 minutes, when it has cooled, add 250pl
of 0.1M IPTG , 1ml 2% X-Gal, 500pl Ampicillin lOOmg/ml. Mix and pour into 80mm
petri dishes. To make an LB amp plate into an X-Gal amp plate spread 30pl of IPTG and
50pl of 2% X-Gal onto the surface of the plate. Allow to dry before use
2.2.10 Transforming E.coli using the Heat-shock method
100pl of competent cells were added to a 10pl ligation reaction (section 2.2.4). The
reaction was placed on ice for 10 minutes then placed in a 42°C water-bath for 45
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seconds. The cells were then placed on ice for a further two minutes then 500pl ofLB
broth was added and the cells incubated at 37°C with shaking for 1 hour. 200pl of cells
were spread on an agar plate containing ampicillin, allowed to dry then incubated at
37°C overnight.
2.2.11 Small scale preparation of plasmid DNA using
alkaline lysis
One bacterial colony was placed in 2.5ml of LB containing lOng/ml of ampicillin and
grown overnight shaking at 37°C. Two ml of culture were placed in an Eppendorf tube
and centrifuged in a micro-centrifuge for 2 minutes at 13000g at room temperature. The
pellet was resuspended in lOOpl ofDNA prep Solution 1. 200pf ofDNA prep solution
2 was added and the cells vortexed briefly then placed on ice for five minutes. 150pl of
DNA prep Solution 3 was then added and the cells centrifuged for five minutes at
13000g at room temperature. The supernatant was then transferred to a fresh Eppendorf
tube and 2.5 volumes of 100% ethanol and 0.1 volumes of 3M Sodium Acetate added.
The mixture was then place on ice for ten minutes then centrifuged at 13000g at room
temperature for 10 minutes. The pellet was washed in 70% ethanol, air-dried then
resuspended in 100pl ofH20 with lpl of lOmg/ml RNase. The DNA was then stored
at -20°C.
DNA Prep Solution 1
0.9% Glucose, 0.01M EDTA pH 8
DNA prep Solution 2
1% SDS, 0.2N NaOEl
DNA Prep Solution 3
3M Potassium Acetate, 11.5% (v/v) Glacial acetic acid
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2.2.12 Large scale preparation of plasmid DNA
200ml of LB containing lOng/ml of ampicillin was inoculated with lOOpl of an
overnight culture or a single colony and incubated overnight at 37°C in a 1 litre flask.
The culture was then centrifuged at 2500g for 10 minutes at 4°C. The pellet was
resuspended in 9ml of ice-cold DNA prep solution I and split into two 50ml tubes and
0.5ml of freshly prepared lysozyme solution (lOmg/ml in lOmM tris.Cl pH8) added to
each tube. The tubes were mixed thoroughly then 9mls of solution II was added to each
tube. The tubes were placed on ice for 5 minutes then 7mls of ice-cold solution III added
to each tube, the tubes were mixed then placed on ice for 10 minutes. The tubes were
then centrifuged at 2500g for 15 minutes at 4°C in a Beckmann GS-6R centrifuge. The
supernatant was removed and 0.6 volumes of isopropanol added and left at room
temperature for 10 minutes. The tubes were then centrifuged at 4000g for 15 minutes at
4°C the supernatant discarded and the DNA pellet washed in 10ml of 70% ethanol. The
pellet was air-dried for 1 hour then resuspended in 4.8ml of H20. 4.5g of CsCl
(Boehringer Mannheim) was then added and the DNA solution vortexed briefly then
20pl of a lOmg/ml solution of Ethidium Bromide added and vortexed again. The
solution was then transferred to a Beckman quick seal tube and centrifuged at 80000g
for 16-18 hours at 20°C in a Beckmann TL100 centrifuge using a TL100.4 rotor.
The lower band ofEtBr containing the closed circular plasmid DNA was then removed
with a hypodermic needle and transferred to a 15 ml tube. An equal volume of water
saturated n-butanol was added to the tube which was then vortexed. The upper butanol
layer which contained most of the ethidium bromide was removed and more water-
saturated butanol added to the aqueous layer mixed and vortexed, the extraction
procedure was repeated until no EtBr was visible. H20 (4mls) and lOmls of 100%
Ethanol was then added to the tube and the DNA was precipitated for 1 hour on ice. The
tubes were then centrifuged at 4500g for 15 minutes in a Beckmann J2-21 centrifuge,
washed with 5ml of 70% ethanol then air-dried for 10 minutes. The pellet was
resuspended in 500pl of H20 which was split into 4 aliquots and stored at -20°C.
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2.2.13 Phenol/Chloroform extraction ethanol precipitation.
One volume of phenol and one volume of chloroform was added to the solution and
centrifuged at 13000g for 15 minutes. The upper aqueous layer was taken and one
volume of chloroform added to it. The mixture was then centrifuged at 13000g for 15
minutes at room temperature. The upper aqueous layer was taken and two volumes of
100% ethanol and 0.2 volumes of 3M Ammonium acetate pH 5.2 added. Incubated on
ice for 10 minutes then centrifuged at lOOOOg for 15 minutes at room temperature. The
pellet was washed in 70% ethanol, then centrifuged at 13000g for 2 minutes at room
temperature, air-dried and the pellet resuspended in 0.5 ml TE.
2.3 Lambda techniques
2.3.1 Lambda strains
The lambda strain used was lambda dash (Sambrook et al., 1989) and
genomic lambda library prepared from DNA prepared from the blood of an
human donor (P.Estibeiro personal communications).
2.3.2 Growing lambda phage
E.coli strain XL-1 blue was grown to an OD600 of 0.5 and 100 pi mixed with 50 pi of a
phage suspension and incubated at 37°C for 30 minutes. The mixture was then added to
2.5mls ofmelted 0.7% top agarose (agarose in LB) and poured onto a 90mm agar plate.
The agar plates had been pre-warmed at 37°C to allow the top agarose to be spread on
the plate before it set. For the initial screens of the Estibeiro genomic lambda library 12
large agar plates were used with 300pl ofbacteria 0.5 pi of the library and 6.5 mis of top
agarose for each plate this equals 3 genomic equivalents. When the agarose has set the




2.3.3 Lambda DNA preperation: Plate method (Promega)
Four to five 90mm agar plates were prepared as described in section 2.3.2 with top
agarose containing enough lambda suspension sufficient to lyse all bacteria after over¬
night incubation. 3mls ofSM buffer was added to each plate and the top agarose scraped
of the agar and transferred to a COREX tube. The agarose was broken up with a spatula
and the then left to stand at room temperature for 30 minutes to allow the phage to
diffuse into the buffer. The tube was then centrifuged at lOOOOg for lOminutes at 4°C
in a JA-21 rotor. The supernatant was taken and 0.3% volumes of chloroform added to
kill any remaining bacteria. The reagents and protocol (from step IV) in the Promega
wizard lambda prep DNA purification system were then used as follows 40pl of
nuclease mixture added to lOmls of lambda lysate and incubated at 37°C for 15 minutes
4mls of phage precipitate was added mixed and placed on ice for 30 minutes, the
mixture was then centrifuged at 10 OOOg for 10 minutes. The supernatant was removed
and the pellet resuspended in 500pl ofphage buffer and transferred to a 1,5ml centrifuge
tube and centrifuged at 10 OOOg for 10 seconds at room temperature to pellet any
remaining insoluble matter. 1ml ofpurification resin was added to the tube and mixed
by inverting the tube. The lysate was pipetted into a Luer-Lok 3ml syringe which was
attached to a wizard minicolumn. The lysate was injected through the column and the
flow-through discarded. The column was then washed by injecting 2mls of 80%
isopropanol through the column. The column was then centrifuged for 2 minutes at 10
OOOg at room temperature to dry the column. Then lOOpl of pre-heated H20 added to
the column and the DNA eluted by centrifugation at 10 OOOg for 10 seconds at room
temperature.
2.3.4 SM Buffer
2.9g NaCl, lg MgS04 25ml 1M Tris pH 7.5, 2.5ml 2%Gelatin, H20 to 500ml. The




2.3.6 Lambda DNA Preparation:Qiagen midi method.
E.coli XL-1 Blue were grown to an optical density of 2.5 OD600 units in 10 mis LB
supplemented with 0.01M MgS04 and 0.01% Maltose which is approximately equal to
2xl010 cells. The cells were centrifuged at 4000g for 10 minutes at room temperature
then resuspended in 600pl of Sm buffer. Approximately 200pl ofphage suspension was
added to the cells and incubated at 37°C for 20 minutes the mixture was then added to
lOOmls of LB supplemented with 0.01M MgS04 and 0.01% Maltose. The cells were
incubated over-night during which time the cells lysed and the culture became
translucent. The Qiagen lambda midi kit protocol was then followed according to the
manufacturer's instructions. The DNA was precipitated by centrifugation at 15,000g at
room temperature.
2.3.7 Lambda DNA prep. Phage buffer
150mM NaCl, 40mM Tris-HCl pH7.4, lOmM MgS04
2.3.8 Lambda DNA prep. Phage precipitant
3% polyethylene glycol (PEG-8000) 3.3M NaCl
2.3.9 Lambda DNA prep. Nuclease mixture
0.25mg/ml RNase A, 0.25mg/ml DNase I, 150mM NaCl, 50% Glycerol
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2.3.10 Lambda library Filter lift
To transfer phage from plaques on an agar plate to a membrane for hybridisation, an
Amersham Hybond-N nylon membrane was placed on a petri dish containing the
lambda plaques that were to be screened. The filter was orientated by stabbing through
the filter and agarose 2-3 times in three places with a needle dipped in ink. Two filters
were lifted from each petri dish. The first filter was left on the plate for 1 minute the
second filter for two minutes. The filter was placed onto 3mm paper wetted with
denaturing solution (1.5M NaCl 0.5 M NaOH) for 1 minute then transferred to 3mm
paper wetted with neutralising solution (1.5M NaCl, 0.5 M Tris HC1 pH 7.5) for 1
minute. Washed in 2X SSC then air-dried (DNA side up) at room temperature on paper
towels for 10-20 minutes. The DNA was UV cross-linked to the filter using a UV cross-
linker (Hybaid) at 0.60 J/cm2 under saran-wrap. The filters were stored under saran-wrap
at room temperature until ready to be hybridise
2.3.11 20XSSC
175.3g NaCl, 88.2g Sodium Citrate, 800 mis H20, pH to 7.0 make to llitre with H20
The solution was autoclaved at 121°C for 15 minutes.
2.3.12 De-naturing solution for plaque lifts using Hybond-N
filters.
1.5M NaCl, 0.5 M NaOH
2.3.13 Neutralising solution for plaque lifts using Hybond-N
filters.
1,5M NaCl, 0.5M Tris-Cl pH 7.5
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2.3.14 Pre-Hybridisation buffer when using labelled
oligonucleotides
5X SSC, 0.5% SDS, 1mm EDTA pH 8.0, 5X Denhart's solution.
2.3.15 Hybridisation buffer when using Labelled
oligonucleotides.
6X SSC, 0.5% SDS, 100pg/ml Herring sperm DNA, 5X Denhart's
2.3.16 Denhart's Solution 50X
5g Ficoll, 5g Polyvinylpyrolidone, 5g Bovine serum albumin Fraction V, H20 to
500ml. Filter-sterilise. Do not autoclave
2.3.17 Labeling reaction.
(Adapted from Pharmacia's T7 quickprime kit protocol)
10-20ng ofDNA in TE buffer was denatured at 94°C for 3 minutes then spun briefly
in a benchtop centrifuge
lOpl of quickprime reagent mix (aqueous solution of dATP, dGTP and dTTP with
random 9-mer oligonucleotides)
5pi of (3000 Ci/mmol) ot-32p dCTP= 50mCi
lpl of T7 DNA polymerase
H20 to a total of 50pl.
The reaction was mixed and centrifuged briefly then incubated at 37°C for 20 minutes.
2.3.18 Separating Incorporated label from unincorporated
label.
A sephadex column was made by adding 3mls of 10% (w/v in H20) G-50 sephadex
(Amersham Pharmacia) to a 5ml pipette tip which had some glass wool blocking the
bottom. The column was placed in a retort stand and 20 opened 1.5ml Eppendorf tubes
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were placed in a rack underneath the column. A few mis of TE buffer was run through
the column. When the TE had passed through the 50pl of the labelling reaction was
added to the column then more TE was added. Twenty 6-drop fractions were placed into
a scintillation counter rack counted with LKB 1219 Rackbeta scintillation counter. Two
peaks appeared when the amount of radioactivity was plotted the first was the
incorporated nucleotide which migrates quickly through the column the second peak is
the unincorporated nucleotides. The 3-4 tubes containing the first peak were added
together, denatured at 94°C for 3 minutes, then placed on ice before being added to the
hybridisation cylinder(s).
2.3.19 Hybridisation washing solutions PCR probes
attached to Hybond-N filters.
First wash, IX SSC, 0.1% SDS
Second wash 0.1X SSC, 0.1% SDS
2.3.20 Hybridisation buffer for PCR probe labelling
5X SSC, 0.5% SDS, lOOpg/ml Herring sperm DNA, 5X Denharts
2.3.21 Hybridisation of lambda libraries.
The UV cross-linked filters were wetted in 5X SSC then placed in a hybridisation
cylinder containing 50mls of hybridisation solution (0.5% SDS, 5X SSC, 5X Denharts
solution, 100 pg/ml of herring sperm DNA) and incubated on a rotisserie at 65°C for
30 minutes.
The labelled DNA probes were then added to the tubes and the cylinders were incubated
at 65°C overnight.
The Filters were washed in pre-heated (65°C) IX SSC, 0.1% SDS at 65°C for 15
minutes, then washed in pre-heated (65°C) 0.1X SSC, 0.1% SDS at 65°C for 15 minutes.
The damp filters were taped to 3mm paper with address labels dotted with radioactive
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ink. Covered in saran wrap and exposed to XOMAT film overnight. The films were
developed and any positive spots on the two duplicate filters compared. Where two spots
overlapped perfectly, the radioactive ink marks on the address labels and the ink marks
made with the needle when the filters were lifted from the plate were used to orientate
the agar plate from which the filters were lifted. The plaque or group ofplaques which
aligned with the positive spot on the film was removed from the plate with a yellow
Gilson tip, and placed into an Eppendorf tube which contained 1ml of Sm buffer and 1
drop of 100% chloroform was added to kill bacteria. The phage were allowed to diffuse
into the buffer for 1 hour at room temperature then stored at 4°C. If necessary the phage
in the buffer were then used to inoculate more bacteria at increasing dilutions in a
subsequent round of screening until a single plaque corresponded to a positive spot.
2.4 PCR
2.4.1 PCR Oligonucleotides for exon 1 region
Oligonucleotides were designed using the GCG9 program Prime. Sequence positions
are taken from genbank entry X83415 (Puckett et al., 1991) ".f' signifies that the oligo
is on the forward strand ".r" signifies that the oligo is on the reverse strand
All oligonucleotides were manufactured by MWG (Milton Keynes UK).
HuPrPf GGCACAGAGTGTGCGCCGGC Position 21-40
HuPrP2f AATTGGTCCCCGCCGCGACCT Position 50-70
HuPrPr TTACCTGCCTCGGTCGTGGAG Position 210-188
HuPrP2r TCGTGAGGAGAGGAGAAGCT Position 197-178
Primers designed from the mammalian consensus sequences of PrP specific motifs




2.4.2 PCR Oligonucleotides and conditions for the open
reading frame
Oligonucleotides were designed using the GCG9 program Prime. Sequence positions
are taken from genbank entry U29185 (Lee et al., 1998) ".f' signifies that the oligo is
on the forward strand.
3'huprp CCTCCCTCATCCCACTATCAGGAAGATGAGGAA Position 26217-






DNTPs 0.2mM each nucleotide
3'huprp primer 100pm













2.4.3 PCR Oligonucleotides and conditions for upstream
and intron probes for the lambda library
Oligonucleotides were designed using the GCG9 program Prime. Sequence positions
are taken from genbank entry U29185 (Lee et al., 1998) ".f' signifies that the oligo is
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.f CCTCCCTCTAAATCCTGTCCTTCTATC Position 11953-11979











































a=Humproml.f and l.r oligonucleotides, b=Humprom2.f and 2.r oligonucleotides,
c=Humprom3.f and 3.r oligonucleotides
2.5 Manual Sequencing of plasmid DNA
2.5.1 Sequencing reaction
Adapted from Pharmacia T7 Sequenase 2.0 kit.
The DNA to be sequenced was denatured as follows
10 pi of sequencing denaturing solution (2mM EDTA , 2N NaOH)
5pg of plasmid DNA
H20 to 1 OOpl
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Incubate at 37°C for 30 minutes
Sequencing denaturing solution
4pl of 500mM EDTA, 200pl of ION NaOH 769 pi H,0
Then lOpl of 3M NaAc and 300 pi of 100% ethanol was added to the mixture and the
DNA precipitated at -70°C for 15 minutes. The mixture was then centrifuged at 13000g
for 10 minutes in a benchtop centrifuge at room temperature, the pellet was washed in
70% ethanol, then resuspended in 7pi ofH20. 2pl of sequenase buffer (200mM Tris.HCl
pH 7.5, lOOmM MgCl2, 250mM NaCl) and 1 pi of sequencing primer (lpmol/pNlpmol)
was added and the mixture was incubated at 37°C for 30 minutes to allow the primer to
anneal. The reaction was then cooled on ice.
In a separate tube the sequencing reaction was set up as follows
lpl ofDTT (0.1M),
2pl of sequenase dilution buffer (lOmM Tris.hCl pH 7.5 5mM DTT),
0.5pl ofdGTP,
2pl ofH20,
0.2 pi ofT7 polymerase (13U/pl),
0.4 pi of S35 dATP (lOMCi/ml) was added.
This solution was added to the DNA/primer mix and incubated at room temperature for
3 minutes, then 3.5pl of this sequencing reaction was added to each of 4 tubes
containing 2.5pl of dideoxy ATP, CTP,GTP or TTP. The tubes were incubated at 37°C
for 5 minutes then 4pl of stop solution was then added to each tube. The samples were
then stored at -20°C.
2.5.2 Sequencing denaturing solution
4pl of 500mM EDTA, 200pl of 10N NaOH 769 pi H20 (2mM EDTA , 2N NaOH)
2.5.3 Running a sequencing gel.
Glass sequencing plates were washed with water and detergent then with industrial
methylated spirits and one side of one plate was washed with dimethyldichlorosilane
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(Pharmacia). The plates were separated by 0.5mm spacers and taped at the sides and
bottom. The gel solution contained 6% (w/v) acrylamide diluted from the 40%
acrylogel-5 mixture (BDH) 8M urea and IX TBE. To 75mls of this solution 300pls of
10% w/v APS and 50p,l of TEMED were added to catalyse polymerisation, mixed
thoroughly and poured quickly between the plates the gel was allowed to set for two
hours. When the gel had set it was put into a sequencing rig and IX TBE added to the
upper and lower reservoirs, the gel was mn at 60 watts, 1800 volts and 100mA for 30-60
minutes to warm the gel. Sequencing reactions were heated to 80°C and 2.5pl loaded
onto the gel. When the gel had finished running it was transferred to a sheet of 3mm
paper then covered in Saran wrap (Dow Chemicals) and dried for 1 hour on a gel dryer
at 80°C for two hours. When dried the Saran wrap was removed and the gel exposed to
Biomax film (Kodak) overnight or longer ifnecessary.
2.5.4 Plasmid Sequencing Oligonucleotides
Designed using GCG9 program Prime. Sequence positions are taken from genbank entry
U29185 (Lee et al., 1998) ".f' signifies the oligo is on the forward strand ".r" signifies




































6a.r CAGAGTGAGCAACATAGTGAG Position 11716-11696
8.r AGTGAAATGGGCGTAAACCAT Position 11913-11893
13.r GAATGAGGAAGCAATTTCTG Position 12337-12318
16.r ACTGGCTCGGAGGACAGG Position 12716-12699
17.r GGGCGTTTACCTGCCTCG Position 12777-12760
19.r AACGGGCGGGGAGCGCGAGC Position 13221-13202
24.r TTCTCCAGGCGGTGGCAAC Position 13469-13451
26.r GAGGCTGGTTGTTCCTTG Position 13695-13678
28.r AATTCCTACAGCCACCTC Position 13838-13821
30.r CCTAAGGAAACGGGAAAC Position 14069-14052
31.r TTTATCCAATTCCCTGTTCC Position 14147-14128
32.r AATCACATCCTACCCCTC Position 14314-14297
34.r GATAACCCAAACATGCTC Position 14225-14442
35.r AACCATCTTTGTGACCCC Position 14569-14552
36.r CGAAATGCCCCCAATAAC Position 14696-14679
37a.r GCAGGTAAGTTCTCAGGAGTG Position 14789-14769
37b.r GTTTCTGGGTCACAGCTTC Position 14766-14748
39.r CACATATCACAGGCTCCA Position 14973-14956
41.r GCCCTTAGTGAGAGCAAT Position 15141-15124
43.r CAGGAGTCCTTAAAAACA Position 15397-15380
45.r ATCACAGCCTTTCCTGAC Position 15575-15558
46.r GGCTGCTCCCTTACATAATTC Position 15721-15701
47.r ACAGCCATGTTCAGTGTC Position 15783-15800
Oligos designed from the pCAT3Basic plasmid (Genbank entryU57024)
49.r CTTGATACTTACCTGCCC Position 113-96
Rvprimer3 CTAGCAAAATAGGCTGTCCC Position 3989-4008
2.6 Tissue culture
2.6.1 Cell lines
N2a is a murine neuroblastoma cell line (ATCC CCL-131), SK-N-SH is a human
Neuroblastoma cell line (ATCC HTB 11). Both cell-lines were grown in Dulbecco's
modified Eagle medium (high glucose) with Glutmax I, 4500mg/l d-glucose and sodium
pyruvate (Life technologies) supplemented with 10% foetal calf serum, lOU/ml
penicillin and 10pg/ml streptomycin. The cell lines were grown at 37°C with 5% C02.
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2.6.2 Passaging cells
The media was removed from the flask and washed with 1 Omls ofphosphate buffered
saline (PBS) without calcium or magnesium. For a 75ml flask 5mls of Trypsin (0.1X)
in PBS was added and removed after one minute and the flask incubated at 37°C with
5% CO, for 5 minutes. The flask was then struck several times to dislodge the cells.
20mls of warmed media was then added to the cells and an aliquot was transferred to
another flask and/or 6 well plates. N,a cells were split at a dilution of 1/10. SK-N-SH
cells were split at a dilution of 1 in 5.
2.6.3 Freezing and reviving cells
Cells were trypsinised in the same way as when the cells were being passaged but the
cells were suspended in 5mls ofMEM containing 8% DMSO (Sigma) and aliquoted into
3 cryo-tubes, wrapped in tissue paper and placed in a styrofoam box at -70°C overnight.
The next day the tubes were transferred to liquid nitrogen. Frozen cells were revived by
being placed in a 37°C water-bath to thaw the cells before being adding to 25mls of
warm media. The next day the media was changed to remove the DMSO.
2.6.4 Calcium Phosphate Transient Transfection
Cells in six-well plates were grown to approximately 50% confluence in 2mls ofmedia.
For each well the transfection mix contained 2pg of the plasmid being tested, lpg of
control plasmid to normalise transfection efficiency (either pGL3-Control vector which
encodes luciferase or pSV (3-galactosidase control vector: both contain SV40 early
promoter and enhancer sequences both are supplied by Promega) 12.4pl of 2M CaCl2
and H,0 to 89.25 pi. To this lOOpl ofHepes buffered saline (HBS) was added drop-wise
while gently vortexing the tube. The tubes were left at room temperature for 30 minutes
to allow precipitation to occur. The solution was added to the well and incubated at 37°C
with 5% C02. After 24 hours the media was changed. After another 24 hours the cells
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were harvested by removing the media and washing the cells in 3mls ofPBS then 0.5mls
ofPBS was added and the cells scraped into an Eppendorf using a cell scraper. The cells
were centrifuged at lOOOOrpm for 10 seconds in a benchtop centrifuge at room
temperature and the supernatant removed. The pelleted cells can then be stored at -20°C.
A cell extract was prepared by two different methods depending on the control plasmid
co-transfected with the plasmid being tested. When p-galactosidase was used, the pellet
was resuspended in lOOpl of 0.25M Tris.Cl pH 7.75, frozen in liquid nitrogen then
melted at 37°C this process was repeated three times to lyse the cells. Alternatively when
luciferase was used as a control plasmid, the cells were resuspended in lOOpl IX
reporter lysis buffer (Promega) and left at room temperature for 15 minutes which lyses
the cells. The lysed cells were spun at 13000rpm for five minutes in a benchtop
centrifuge to pellet cellular debris. The supernatant was then taken and this cell extract
was used in a CAT, luciferase or p-Galactosidase assay or stored at -20°C.
2.6.5 CaCI2 2M for transfections.
10.8g ofCaCl2.6H20 in 20ml H20, filter sterilize through a 22pm filter split into 1ml
aliquot s store at -20°C.
2.6.6 Hepes Buffered saline (HBS)
1.6g NaCl, 0.074g KC1, 0.053g Na2HP04.12H20, 0.2g Dextrose,lg HEPES, H20 to
90ml pH to exactly 7.05 with 0.5N NaOH, H,0 to lOOmls, Filter sterilize through a
,22pm filter. Store in 5ml aliquots at -20°C .
2.6.7 B-Galactosidase assays
The Promega P-Galactosidase kit was used and its standard protocol followed. The
300pl reaction contained 50pl of cell extract lOOpl of IX reporter lysis buffer and 150pl
of2X reaction buffer. The mixture was vortexed then incubated at 37°C for 30 minutes
1M sodium carbonate (500pl) was added to stop the reaction. The OD420 was measured
using a spectrophotometer (Beckmann Du650). The results of this assay allowed
correction of transfection efficiencies so that a subsequent CAT assay using the PrP
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promoter constructs reflects the strength of the promoter rather than any variation in
transfection efficiency.
2.6.8 Luciferase assay
The Luciferase assay kit was used and the manufacturer's instructions followed
(Promega). In a 96 well plate 20 pi of cell extract and 50 pi of luciferase assay reagent
(Promega) were mixed together and immediately assayed for luciferase activity using
a Wallac Victor 2 luminometer the plates were shaken 0.1mm at speed three for 1
second prior to reading.
2.6.9 Normalisation of luciferase and (3-Galactosidase
assays.
In a set of transfections 50pl of cell extract from the transfected cells with the lowest
luciferase or P-galactosidase activity would be used in the CAT assay. Multiplying the
activity of this extract by 50pl gives a constant number. Dividing this number by the
activities of the other cell extracts gives the numbers of pi of those extracts which should
be used.
Example
Cell extract Luciferase activity (units) Constant (units.pl) Volume used (pi)
A 1567 78350 50
B 5623 78350 78350/5623=13.9
C 4690 78350 78350/4690=16.7
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2.6.10 CAT assays
Chloramphenicol Acetyl Transferase activity was assayed by incubating up to 50pl of
cell extract with lpl of 0.025mCi/ml of C14 Chloramphenicol and 2pl of Acetyl Co¬
enzyme A 5mg/ml (Sigma) where less than 50pl of cell extract was used the volume was
made up to 50pl with 0.25M Tris.Cl pH 7.75. As a positive control 0.2pl of CAT
enzyme (Promega) was used. After incubation, 500pl of ethyl acetate was added and the
mixture was vortexed for 30 seconds before being centrifuged for 3 minutes at 13000g
then the upper organic phased was taken and dried in a speed vac for 40 minutes. The
dried chloramphenicol was resuspended in lOpl of ethyl acetate before being spotted
onto a TLC silica gel 60 plate (Merck). The plate was then placed in a chamber
containing 50mls of 97% chloroform and 3% methanol. After 40 minutes the TLC plate
was removed, air-dried for 5 minutes and exposed to film (Kodak X-OMAT) overnight
or longer if necessary.
2.6.11 X-gal staining solution
0.2% X-gal from 2% stock in dimethyl formamide
2mM MgCl2 (0.004g/10mls)
5mM K4Fe(CN)6.H20 (0.021 lg/lOmls)
5mM K3 Fe(CN)5 (0.01645g/10mls)
2.6.12 /7-Galactosidase in situ cell staining
Cells in six well plates were washed twice with 2mls of PBS for five minutes on a gently
shaking platform. The cells were then fixed with 2mls of a -20°C 1:1 mixture of
methanol and acetone which was left on cells for 5 minutes, the cells were washed with
2mls of PBS for five minutes on a gently shaking platform. X-gal Staining solution (1
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ml) was then added and the cells which were incubated overnight at 37°C
2.7 Transgenic techniques
2.7.1 Generation of transgenic mice.
Female C57B6/CBA F1 mice were super-ovulated and mated to males of the same
genotype. The mice were killed and their oviducts dissected out in M2 media. Eggs were
isolated in and transferred to a drop ofM2 media containing hyluronidase (0.4mg/ml
type IV-S Sigma F13884) for ten minutes to remove any cumulus cells attached to the
eggs. The eggs were then washed in M2 media then Ml6 media then stored in a drop of
Ml6 media under mineral oil in an incubator at 37°C at 5% C02 for one hour.
Transgenic plasmid DNA were digested with restriction enzymes to remove the plasmid
backbone and the fragments separated on a 1% agarose gel. The DNA was cut out and
extracted from the agarose using the Qiaquick gel extraction kit (Qiagen). The DNA was
eluted in PBS and diluted to a concentration of lng/pl before being microinjected into
an egg pronucleus in M2 under mineral oil. The egg was injected until the pronucleus
was seen to "swell" due to the injected DNA solution. 10-12 injected eggs were
transferred into each oviduct of pseudo-pregnant (mated to vasectomised males the
previous night) TO mice.
Polar bodies
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Figure 2-1 Microinjection of DNA into mouse eggs
M2 =1X Earls balanced salt solution (Gibco), 2mM NaHC03 (BDH), 0.0036g/100ml
NaPyruvate (BDH), 20U/ml penicillin 20pg/ml streptomycin 0.4% BSA (Sigma A-
9647), 20mM HEPES made to volume with water for injection.
M16 =1X Earls balanced salt solution (Gibco), 25mM NaHC03 (BDH), 0.0036g/100ml
NaPyruvate (BDH). 20U/ml penicillin 20pg/ml streptomycin 0.4% BSA (Sigma A-
9647) made to volume with water for injection
2.7.2 Analysis of embryos
Embryos were harvested in PBS the extra-embryonic membranes were removed before
fixing and digested with proteinase K buffer (lOmM Tris-HCl pH7.5, ImM EDTA, 1%
SDS 0.4mg/ml proteinase K (Boehringer)) overnight at 55°C. Then phenol/chloroform
extracted and the DNA was ethanol precipitated and resuspended in 20pl ofH20. The
DNA was then amplified by PCR .
Conditions were
IX Gibco PCR buffer
1.5mM MgCl2 0.25mM each dNTP
O.lmg/ml BSA,
5ng oligo LacZl and LacZ2
0.05U/pl Gibco Taq
lpl ofDNA
H,0 to 20 pi
PCR program
30 cycles of
95°C for 30 seconds
55°C for 60 seconds
72°C for 60 seconds.
Transgenic embryo diagnostic PCR oligonucleotides. GAPDH oligo positions were











A control PCR reaction was carried out under identical conditions but using oligos
G3PDH5 and G3PDH3 to amplify the murine GAPDH gene to control for variation in
the quantity and quality of the DNA prep.
The embryo was fixed in 4% paraformaldehyde in PBS for an hour (El0.5 embryos) to
7 hours (E12.5 embryos). Then washed in PBS-Tween (0.1% tween-20) then stained in
P-gal staining solution (.05M NaddPCk and .05M NaH2P04, 2mM MgCl2 0.02% NP40,
0.01% sodium deoxycholate, 0.1% X-gal 0.24% DMF, 5mM K3Fe(CN)6, 5mM
K4Fe(CN)6, ImM EGTA pEl 8 (ethylene-glycol-tetra-acetic acid)) overnight at 37°C.
2.8 Automated Sequencing
Genomic DNAs from sCJD, vCJD and control individuals were obtained from the CJD
surveillance unit and were phenol extracted to remove any PrP which may still be in the
DNA. The DNA was ethanol precipitated and resuspended in 20pi ofH20. Two separate
PCR reactions were carried out to amplify the upstream and intronic regulatory regions.
The position of the oligonucleotides is taken from Genbank entry AF315723 (Full
sequence in appendix).
The Qiagen Taq PCR core kit was used for both PCR reactions.
Upstream PCR 50pl reaction:
lOOpM of oligonucleotide up3.f
lOOpM of oligonucleotide up3.r
IX Q buffer,
IX PCR buffer which contains 15mM Mg2+
5u Taq polymerase
200pM each dNTP
oligonucleotide up3.f TGCTTCCTCATTCCTGAGCC Position 1251-1270
oligonucleotide up3.r TTTACCTGCCTCGGTCGTG Position 1698-1680
Program
94°C for 3 minutes
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60°C for 2 minutes
35 cycles of
72°C for 1minute
60 °C for 1minute
72 °C for 1 minute
then 72 °C for 10 minutes.
The PCR reaction product was purified using the Qiaquick gel extraction kit (Qiagen)
and eluted in H20.
Intron PCR
Conditions 50pl reaction:
lOOpM of oligonucleotide Intl.f
lOOpM of oligonucleotide Intl.r
IX Q buffer,
IX PCR buffer Mg concentration 1.5mM,
5u Taq polymerase,
200pM each dNTP,
Oligonucleotide Intl.f TTCTCCTCTCCTCACGACCG Position 1668-1687







72 °C 1 minute
then 72 °C forlO minutes.
The amplified product was purified using microcon filters
The cycle sequencing reaction was carried out using the "Big Dye" Sequencing Kit
(Applied Biosystems). The sequencing oligonucelotides came from Microzone Ltd. The
position of the oligonucleotides is taken from Genbank entry AF315723 (Full sequence
in appendix).
Hup-F 5' CAT TCC TGA GCC TTT CAT TTT C Position 1259-1280
Hint-F 5' TCA CGA CCG AGG CAG GTA AAC Position 1679-1699
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8 pi DNA,
8 ja.1 kit PCR mix
3.2pM of sequencing oligonucleotide
H20 to 20 pi
Program
98°C for 5 minutes,
then 25 cycles of
96°C for 30 seconds,
55°C for 15 seconds,
60 °C for 4 minutes.
To the 20pl sequencing reaction 80pl of 75% isopropanol was added, vortexed briefly
and left at room temperature for 15 minutes then centrifuged at 13000g for 20 minutes
at room temperature. The supernatant was removed and 250pl of 70% isopropanol
added. The solution was vortexed briefly, the supernatant removed and the pellet dried
by heating to 90°C and resuspended in 8pl of loading buffer. The sequencing reactions
were then stored at -20°C. The sequencing gel was made using the Long ranger Singel
packs (Flowgen Instruments ltd.) which were prepared according to the manufactures
instructions and poured between two glass plates separated by a 0.2mm spacer. Before
loading on a sequencing gel the samples were denatured by heating to 94°C for three
minutes then stored on ice until loading. The gel was run at 2.99kV, 40mW at 51°C.
2.9 Statistical analysis
T-tests, ANOVA and x tests were carried out using Microsoft excel spread-sheet




2.10.1 EDTA0.5M pH 8.0
Dissolve 186.1 g ofEDTA in 1L H20, pH withNaOH
2.10.2 Magnesium Chloride 1M
Dissolve 203.3g ofMgC12 in 1 liter ofH20.
2.10.3 Tris 1M pH 7.5/8
Dissolve 121.lg Tris in 800mls of H20. Adjust pH with HC1 Make up to 1 litre with
H20. The solution was autoclaved at 121°C for 15 minutes.
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3 Chapter Three: In vitro characterisation
of the human PrP promoter.
3.1 Introduction
3.1.1 Factors affecting susceptibility to CJD
Although the polymorphism at codon 129 is the only factor currently known to affect
susceptibility to sCJD and vCJD it does not have a very strong effect on susceptibility
to sCJD as most methionine homozygotes (the most susceptible genotype) do not
develop sCJD. Similarly in vCJD although all the patients to date have been methionine
homozygotes, this genotype is shared with 40% of the population therefore there may
be other susceptibility factors which affect susceptibility to these diseases. Such factors
could be environmental or genetic.
Genetic factors which affect susceptibility to CJD could be other genes whose proteins
may interact with PrP, or variation in the level ofPrP expression. Transgenic mice that
over or under express PrP have shorter or longer TSE incubation periods than wild type
mice (Manson et al., 1994) (Westaway et ah, 1991), showing that expression levels can
affect the course of disease. Similar expression level variation in humans, if it occurs,
could affect the incubation period of sCJD or vCJD. The tissue specific pattern ofPrP
expression is also critical in disease, as expression in the periphery is needed to allow
infectivity to replicate and spread to the CNS in mice infected experimentally by
peripheral routes. In vCJD the exact mechanisms by which the BSE agent crosses the
gut barrier following oral infection, replicates in the periphery, then spreads to the brain
are unknown so if regulatory region polymorphisms that affect susceptibility exist,
examining their affect on expression patterns could identify tissues that play a role in
disease. Similarly, the tissues involved in the origin, replication and spread of the sCJD
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agent are unknown. As the pathogenesis, clinical and pathological features of vCJD and
sCJD are quite distinct, different tissues may play different roles in the development of
the two diseases therefore polymorphisms that affect expression and alter susceptibility
to one form of CJD need not necessarily affect the other form.
3.1.2 Regulation of gene expression.
In order to determine which sequences control expression of PrP in humans the
sequences that regulate expression ofPRNP need to be defined. The spatial and temporal
control of gene expression is controlled by transcription factors that bind to particular
DNA motifs (Tjian and Maniatis, 1994); the binding of transcription factors allows RNA
polymerase II to initiate transcription. All genes have several transcription factor binding
sites upstream of the start of transcription. This upstream region is often referred to as
the promoter. The positioning of the transcription factor motifs in a promoter is critical
as moving or reversing particular motifs can inactivate a promoter. Another class of
regulatory elements are enhancers, which also contain transcription factor binding sites
but the sites can be located thousands of bases upstream or downstream of the site of
initiation of transcription and enhancer elements are unaffected by being reversed or
moved (Fiering et al., 2000) (Blackwood and Kadonga, 1998).
The sequences upstream of all PrP genes that have been sequenced (mouse, mow, rat,
human, hamster and sheep (Inoue et al., 1997) (Saeki et al., 1996) (Basler et al., 1986;
Lee et al., 1998)) are similar in that they lacks a TATA box or initiator sequence and
have several SP1 transcription factor binding sites near to the transcription start site.
There are multiple transcription initiation sites in the ovine, murine, rat and hamster PrP
genes, although not in the bovine PrP gene.
The initiation of transcription of the human gene, and hence the start of the first exon,
has been identified by primer extension (Puckett et al., 1991). Examining the first exon
of the ovine, murine and human PRNP genes shows that they are located within CpG
islands (Lee et al., 1998), which is characteristic of genes expressed in several tissues.
Normally in mammalian genomes, the cytosine residue in a cytosine guanine
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dinucleotide is methylated to methyl cytosine, which is unstable and converts to a
thymine. This mechanism results in the proportion of CpG dinucleotides being much
lower than would be expected from the nucleotide frequencies. CpG islands are regions
where the number ofCpG dinucleotides is similar to what would be expected to occur
by chance based on the frequency of each nucleotide. They occur where the cytosine in
a cytosine-guanine dinucleotide is not methylated to the methyl-cytosine. As
methylation ofDNA inhibits transcription, the promoters ofhighly expressed genes are
not methylated resulting in CpG islands near the promoters of genes. Analysis of the
human PRNP sequence shows that in the 1 kb around the first exon the GC content is
60.5% and the proportion of CpG dinucleotides is close to what would be expected from
the nucleotide frequencies (91 expected 89 observed (98%)). This is a very high
frequency as CpG islands are defined as regions over 200bp in length with a GC content
over 50% which contains 60% or more of the expected number of CpG dinucleotides
(Gardiner-Garden and Frommer, 1987). Therefore the presence of a CpG island
surrounding the first exon suggests that the sequence either side of the exon may
influence expression (Antequera and Bird, 1999).
Analysing the published upstream sequences ofPrP genes in other species (Figure 3-1)
shows that all species have two consensus binding sites for the transcription factor SP-1
(CCGCCC) upstream of the PrP gene transcription start site except for humans, who
have only one SP1 site, and sheep, who have none although they do have two sites
which align with the bovine SP1 sites and differ from the consensus by only one base
(CCCCCC and CAGCCC). Rodents and humans have an AP-1 site (GGTGACTCA)
and a reversed CCAAT box (ATTGG) in their upstream regions while ungulates have
an AP-2 (CCCCGGGC) site (Kim et al., 1999) (Faisst and Meyer, 1992).
SP-1, AP-1 and AP-2 are common transcription factors used to transcribe many genes
while the CCAAT box is a motif found upstream ofmany genes and which several
transcription factors such as CP1, CP2 and NF-1 can bind to (Chodosh et al., 1988). The
human first exon (Puckett et al., 1991) is also larger than that of other species.
Comparison of the first exons of published species shows that transcription of PRNP
appears to start further upstream than in other species, this is confirmed by the presence
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of two SP1 sites within the first exon (rather than immediately upstream as in other
species) and a highly conserved region at the end of exon 1 in all species. All species
have four conserved 10-15bp DNA motifs 150-300bp upstream of the transcription start
site, although originally termed PrP specific motifs (Westaway et al., 1994), motif 4 is
similar to the specific enhancer of the skeletal muscle gene (Hidaka et al., 1993) while
motif 2 is identical to the binding site ofE4BP4, a repressor protein related to the bZIP
transcription factor family (Cowell et al., 1992).
To identify sequences which control the expression of a gene, deletion analysis using
a reporter gene is carried out. This is done by cloning a putative promoter region
upstream of the reporter gene (such as chloramphenicol acetyl transferase (CAT), |3-
Galactosidase or luciferase) and transiently transfecting the construct into a cell line
which normally expresses the gene whose promoter is being analysed. Once a region of
DNA is shown to influence transcription, making further deletions in that region will
show what effect a particular stretch ofDNA has on transcription. A drop in reporter
gene levels after deletion implies that the deleted region has a positive effect on
transcription while a rise in reporter gene levels implies it has a negative effect.
Deletion analysis has been used to identify regulatory regions of the murine PrP gene
in murine neuroblastoma cells (Baybutt and Manson, 1997), the rat PrP gene in rat
pheochromocytoma and glioma cell lines (Saeki et al., 1996) and the bovine PrP gene
in two bovine fibroblast cell-lines (Inoue et al., 1997). Analysis of these three promoters
shows that they share a similar structure. The rat, murine and bovine PrP genes all have
a promoter region between 30bp and 90bp upstream of the transcription start-site.
Deletions upstream of this have no effect on transcription, except in the mouse where
deletions have shown that the 300 base-pair region 360bp to 660bp upstream of the start
site contains regions which have small positive and negative effect on transcription.
Deleting the four PrP specific motifs has no effect on expression levels despite being
ideal candidates for PrP specific transcription factor binding sites as they are well
conserved in all PrP upstream regions. Perhaps they are required for transcription ofPrP
in particular conditions or at a developmental stage or a cell type different from those
used in the reporter gene assays.
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Deletions to -60 in cows and rats cause a large drop in activity while further deletions
to -30 or -40 have a smaller additional effect. Further deletions which remove all
upstream sequence to within 30 basepairs of the expression start site, have the same
effect on transcription as deletions to -30 or -40. This may indicate that no transcription
factors bind there or that this region is too small to bind sufficient transcription factors
to allow transcription to occur. Each of the three promoters has two SP1 sites, with the
deletion of the site furthest upstream leading to a drop in activity, but this may be due
to both sites being required for transcription rather than the first site having a larger
effect than the other site. Rat and mouse promoters also have an inverted CCAAT site,
which also leads to a drop in activity when deleted. In deletion assays, the critical
regions contain the API, CCAAT and two SP1 sites in the murine and rat PrP genes and
an AP2 and two SP1 sites in the bovine gene (Figure 3-1).
The murine and bovine PrP genes also have regulatory regions within the first intron
(this region was not examined in the rat PrP gene). In the bovine PrP gene (Inoue et al.,
1997), deletions between +123 and +891 (the bovine exon 1 ends at +53 or +168
depending on alternative splicing see section 1.2.1) abolish all transcription activity even
if the upstream promoter is intact. Conversely, removal of the upstream region abolishes
transcription even if the intronic regulatory region is intact. Within this 768bp intronic
regulatory region the only recognisable transcription factor binding site is an SP1 site.
Whether this site is the crucial region requires further deletion analysis. The intronic
region is not an enhancer element as cloning the reporter gene into the PrP first exon
(effectively moving the intron region downstream of the reporter gene rather than
upstream) abolished activity (Inoue et al., 1997).
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In the murine PrP gene the first intron contains regions which have a positive and
negative effect on transcription (Baybutt and Manson, 1997), the negative region is
located within the first kilobase of the 2Kb intron while the positive region is located in
the last 500bp of the intron. Unlike the bovine PrP gene, high levels of transcription can
be achieved using only this second regulatory region while deletion of just the last
500bp of the intron abolishes almost all transcription even if the first promoter is left
intact. Thus the murine intronic regulatory region is relatively stronger then the bovine
intronic region which requires the first bovine promoter to allow transcription to occur.
One series of experiments which used a "half-genomic" construct which included the
first exon and first intron but the second intron had been removed was used to drive
expression of a PrP transgene which had deletions of the N-terminal (Shmerling et al.,
1998). This construct gave a similar PrP expression pattern to the wild-type but lacked
expression in Purkinje cells, which implies the existence of a Purkinje cell specific
enhancer in the large second intron implying that there may be expression regulatory
elements within the second intron (Fischer et ah, 1996).
3.1.3 Plan
Based on studies ofPrP regulatory regions in other species, the sequence upstream of
the human first exon, the first exon itself and the intron region between the first and
second exon-like untranslated exons may contain regulatory sequences. To determine
if this is the case this region was cloned into the reporter gene construct pCAT3 Basic
(Promega). This construct has no promoter but does contain the chloramphenicol acetyl
transferase (CAT) gene that encodes a bacterial enzyme, which transfers acetyl groups
from acetyl Co-A to chloramphenicol. The CAT gene was chosen as the reporter gene,
rather than any of the other commonly used reporter genes such as luciferase or P-
galactosidase, as the murine Pmp gene deletion study had been carried out in the same
lab as this study using a similar CAT reporter system and therefore expertise in this
technology was available.
The construct was transiently transfected into the human neuroblastoma cell line Sk-N-
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Sh which expresses PrP, therefore if the region surrounding the first exon is a regulatory
region of the PRNP gene, it would drive expression of the CAT gene when transiently
transfected into the cells. The amount ofCAT activity can be determined by incubating
cell extracts with C14 labelled chloramphenicol and measuring the amount of acetylated
chloramphenicol produced, as it migrates faster than un-acetylated chloramphenicol on
a thin-layer chromatography plate. The level of expression is proportional to the amount
of CAT activity, therefore by making a series of deletions within the proposed
regulatory region the regions controlling expression can be defined.
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3.2 Results
3.2.1 Cloning the putative regulatory region
To clone the putative regulatory region into the reporter construct, a human genomic
lambda library (a kind gift from Dr. Peter Estibeiro, Centre for Genome Research,
Edinburgh) was screened for the sequence surrounding the PRNP first exon. In order to
screen the library a probe of human sequence from the first exon/upstream region was
required. Attempts were made to make a probe used the Polymerase Chain Reaction
(PCR) to amplify the first exon sequence published by Puckett and colleagues (Puckett
et ah, 1991)(Section 2.4.1). This published sequence was quite short (220bp) and very
GC-rich (79.5%) (Puckett et ah, 1991), therefore primer design was greatly constrained
and the two forward primers (HuPrPf and HuPrP2f) and the two reverse primers
(HuPrPr and HuPrP2r) that were designed, using less than optimal parameters, failed to
amplify the region using PCR buffers and Taq polymerase from GIBCO and Qiagen and
also failed to amplify using the Stratagene opti-prime PCR kit which contains 12
different PCR buffers of differing pH, MgCl2 and KC1 concentrations and PCR adjuncts
formamide, DMSO, glycerol, BSA, (NH4) 2S04 and Perfect Match™ reagent. The
upstream motifs 2 and 3 which are highly conserved in the cattle sheep mice, rats and
hamsters PrP gene upstream regions (Westaway et ah, 1994) were used to design two
short forward primers (Mot2f and Mot3f) in an attempt to amplify the sequence between
the motifs and the first exon but these oligos also failed to amplify the region.
As the first exon could not be amplified by PCR, the open reading frame (ORF) of the
PRNP gene was amplified by PCR as this exon has a larger published sequence (2.3Kb)
with a lower GC-content (44%) than the first exon, allowing the design of optimal
primers (Figure 3-2) (Puckett et ah, 1991). This sequence would then be used as a probe
to screen the lambda library. As the ORF is 12Kb downstream of the first exon and the
average size of genomic DNA inserts in the lambda library is 15Kb it is unlikely that a
single clone will contain both the ORF and the first exon, therefore once a lambda clone
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containing the ORF was identified its 5' region would be used as a probe in a second
round of screening to "walk" upstream to find a clone which contains the first exon.
3.2.2 Screening of the lambda library
The ORF region was amplified by PCR using oligonucleotides Keorf.f and 3'huprp
(section 2.4.2) which gave a 743bp DNA fragment. This fragment was extracted from
agarose using the Qiaquick gel extraction kit (Qiagen). The DNA was eluted in TE and
used to make a P32 labelled DNA probe by the random primer method. This probe was
then used to screen the human genomic lambda library.
The library was first diluted in 10-fold sequential dilutions fromlO"4 to 10"10 in SM buffer
and plated out to determine the number of plaque forming units (pfu) per ml of the
library. The 10"6 dilution contained 10 pfu therefore there are 107pfu per lOOpl and 108
pfu per ml. To screen a lambda library the total amount of insert DNA screened should
be equal to three times the genome of the organism being screened. Therefore, to screen
a human library 3 X 3X109 base-pairs need to be screened. As the average DNA insert
in lambda libraries is 1.5X104 base-pairs, 6X105 plaques need to be screened to cover the
human genome, equal to 6pi of the lambda library.
In the first round screen twelve 150mm plates each containing 0.5 pi of library were
screened and five plaques hybridised to the probe. Five further rounds of screening
isolated three of these five initial positives; lambda clones 55, 79 and 80. DNA was
prepared by lambda DNA plate prep and mapped. Restriction mapping of these lambda
clones showed that they were identical to each other and the map agreed with the known
restriction map of the PRNP ORF (Puckett et al., 1991), but showed that the ORF was
located towards the 5' end of the clone and therefore there was little sequence 5' of it
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However, at this time the sequence of the entire PRNP gene and 12 Kb of upstream
sequence, was published (Lee et al., 1998) (Genbank Accession number U29185).
Analysis of this sequence showed that there were discrepencies in the original sequence
of the first exon which could have affected PCR efficiency. One of the two forward
oligonucleotides had an error at the most 3' base which probably prevented annealing
of the last base to the target strand and extension by the polymerase. The second forward
oligonucleotide had two incorrect bases in the middle of the oligonucleotide which
would reduce the efficiency of annealing to the target strand (Figure 3-4). The two
reverse oligonucleotides were unaffected.
Figure 3-4 Discrepancies in the original sequence of the PPA/Pfist exon
and flanking regions.
GAP program (GCG) alignment highlighting the differences between the human first
exon sequences ofPuckett et al. 1991, which was used to design PCR primers, and Lee
et al. 1998, which resequenced the same clone. First exon in Bold. The two forward
oligonucleotides affected by the sequence changes are underlined. The sequences of the
two reverse oligonucleotides were identical in the two sequences.
Puckett 1 GGCCGGCCGCCCGCCGCGGGGGCACAGAGTGTGCGCCGGCGCGCCGGCGA 50w11111 ii 1111111 1111111 T 11111111111111 r MI i i
Lee 1 GGCCGGCCGCCCGC..CGGGGGCACAGAGTGTGCGCCGGGCCGCGCGGCA 48
Puckett 51 ATTGGTCCCCGCCGCGACCTCCGCCCGCGAGCGCCGCCCGTTCCCTTCCC 100
M i M 111 ii M 1111 ri 111111111111111111 mi
Lee 49 ATTGGTCCCCGCGCCGACCTCCGCCCGCGAGCGCCGCCGCTTCCCTTCCC 98
Puckett 101 CGCCCCGCGTCCCTCCCCGCCTCGGCCCCGCGCGTCGCCTCCAGTCGCTG 150
I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I
Lee 99 CGCCCCGCGTCCCTCCC..CCTCGGCCCCGCGCGTCGCCTGTCCTCCGAG 146
Puckett 151 CCAGTCGCTGACAGCCGCGGCGCCGCGAGCTTCTCCTCTCCTCACGACCG 200
I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I
Lee 147 CCAGTCGCTGACAGCCGCGGCGCCGCGAGCTTCTCCTCTCCTCACGACCG 196
Puckett 201 AGGCAGGTAAACGCCCGGGG 220
I I I I I I I I I I I I I I I I I I I I
Lee 197 AGGCAGGTAAACGCCCGGGG 216
The publication of the full sequence of the human PRNP gene allowed the design of
primers to amplify probes near the first exon which were not constrained by length or
GC content. Three sets ofPCR primers were designed using the prime program ofGCG
(Figure 3-5), two pairs of primers lay upstream of the first exon (Humproml.f and
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Humproml.r creating a 241bp PCR product, Humprom2.f and Humprom2.r creating a
568bp PCR product) and one pair between the first exon and the second exon-like
sequence (Humprom3.fand Humprom3.r creating a 381bp PCR product)(section 2.4.3).
All three amplified at the recommended annealing temperature under standard PCR
conditions (Figure 3-5). The PCR products were cloned into pGEMT and large scale
plasmid DNA preparations made. These were digested with SacII and NotI to release the
cloned sequence which were then radio-labelled using the random primer method and
used to screen the lambda library. The first probe failed to hybridise to any plaques, the
second hybridised to a very large proportion ofplaques in the first round screen, further
analysis of the sequence of this probe showed that it contained part of an Alu element
ofwhich there are approximately 300,000 in the human genome. This would account for
the very high proportion of hybridisation. The third probe hybridised to two different
clones 311 and 314 (Figure 3-6) which were isolated after three and four rounds of
screening respectively.
Restriction mapping of Clone 311 (Figures 3-7 and 3-8) showed that the third probe
(which is downstream of the first exon) is 14.7Kb long and located at the 3' end of 311
and the clone does not include the putative second untranslated exon. Clone 314 is 15Kb
long and the first exon is located towards the 5' end of the clone. Mapping of this clone
shows that it extends 1.5 Kb upstream of the first exon. As clone 314 contained the
putative second exon and 1.5 Kb of sequence upstream of the first exon which contains
regulatory elements in other species it was decided to sub-clone the upstream, first and
second exons and the first intron from clone 314 into the pCAT3 Basic reporter plasmid.
Lambda clone 314 was digested with EcoRX and BglXI producing a 4.8Kb fragment,
containing 1.5Kb of upstream sequence, the first exon and 3.1Kb of intron which
included the cryptic second exon sequence. This fragment was sub-cloned into the
EcoRX and BamHX sites in pBluescript (Stratagene) creating construct p4.8BS (the
4.8Kb fragment cloned into pBluescript)(Figure 3-9 and 3-11). Construct p4.8BS was
then digested with KpnX and NheX and sub-cloned into the KpnX and SpeX sites of
















Figure3-5PCRprobesfotheutativpromot rregi nfPRNPUsinggenomicseq encf(Lal.\991)th probeswermadbyPCRanus dtsc enhu ngen miclambdali r y.H genomicDNAwasam lifiedPCR usingprimersfrothupstreamsequencefPRNP(PIand2)in rofP( 3).ExpectsizesI241b ,504bp, P3386bp.Afteramplificationthcorrectbandwasextr ctedfrot ga osclintpGEMTdsubsequ ntlyus screenthlambdaibraryfoclonont iningtsequenceurroundthPRNPfir texIdidnhybridis y plaqueswhilrobP2hybridisedthund edsofplaquihfirstounscreenatc nt edp rArepetitivelem nt ofwhichtherear300,000inehumangenom .Pr be3ybridis dtwlambdacl s311a d4.
Figure3-6inalro ndscreenflambdaibr rycl n314usi gthP3p bHybridisationofhuPRNPint opr e withlambdaplaquesinthefi lroundfscre n.Tpet i-diswliftdupli teres l ingi nenticalat rof
—plaques.Thestrengthofhybridisationigre rnthfi tlt rpapliftedfrometri-dish(l f )ths condf lt rpap 5(right).
Lambdaclone311





5Kb 4Kb 3Kb 2Kb 1.5Kb 1Kb 500bp
8Kb 6Kb
Figure3-7Restrictionmappingofla bdaclones11and4A)Digestl mwi hS l(S)aR-Xb ldou l digest(SX)theSalIresultsin10KbandA5bauto leiresults4.6 22doubl .T9K bandislambdarm.Thisrestr ctionpatterg eeswitht atofu lishedhu nqu nce(L l.1997)B)314dig t. wasdigestedithEcoRlandcoRl-Xba .Thi estpatterngreit ublishes qu nce10.2Kbbailam d arm.Thecloneontains5.61 5d4Ec Rlfragments.coR -XbaItsf0 8.92 2KbXb l- Xbalfragment.
Exon123 I
0122436Kb P3probe Xs IClone31114.7Kb Size(Kb)6.22 04 5 EXmu Size(Kb)5.61.51.61.4.82 2.9
Clone31413.8Kb
Figure3-8Mapoflambdaclones11an4.la bdaclones3 ,Cldin tincluthesec dex n whereasclone314did.Clone314asther forus dsub-cl ntr gulatoryr iintpBluescriptde p tclon311hav g longerupstr amsequence.E=EcoRIS=SalIX Xb
Figure 3-9 Cloning putative promoter region
from lambda clone 314 to pBluescript
i
Lambda clone 314 was digested with EcoRl and Bglll giving a 4.8Kb fragment
which contains upstream sequence the first exon and the putative second human
untranslated exon. pBluescript was digested with with EcoRl and BamHl and
the 4.8Kb lambda fragment ligated into pBluescript (Bglll and BamHl have
compatible ends).
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Figure 3-10 Sub-cloning the putative promoter
i
p4.8BS was digested with Kpnl and SpeI, this 4.8Kb fragment was cloned into
pCAT3Basic which had been digested with Kpnl and Nhel, the two fragments
were then ligated together the 5' overhang of Spe I is identical to the 5' over¬
hang of Nhel. The resulting plasmid, p4.8CATBS, has an exonuclease 3
resistant restriction site(A^«I) immediately upstream of an exonuclease 3
sensitive site (EcoRl) allowing unidirectional deletions to be made. This
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The 4.8Kb fragment starts at position -1558 relative to the start of transcription and
extends to position +3250 downstream of the transcription start site. This plasmid was
the basis for all of the deletion constructs used in this Chapter. The pCAT3 Basic
plasmid contains a chimeric intron between the poly-linker and the CAT ORF this
should allow splicing to occur from the first exon or possibly the putative second exon
to the CAT ORF exon.
3.2.3 Sequencing
The 4.8Kb fragment of lambda clone 314 cloned into pCAT3 basic was manually
sequenced (Genbank entry AF315723 full sequence in appendix) and compared with the
sequence published by Lee et al., (Lee et al., 1998) (genbank number U29185) and the
sequence released by the Sanger Centre as part of the human genome sequencing project
(Genbank number dJ1068H6). There are seven sequence differences between the Lee
sequence and the Sanger sequence. The lambda clone 314 sequence is identical to the
Sanger sequence at these seven positions. This difference between the two publicly
available sequences could be due to a lower sequencing error rate in the human genome
project and/or the fact that Lee et al. used the Hela cell line S3 as the source of their
clone and cell lines can accumulate mutations at a higher rate than entire organisms.
There was one position in lambda clone 314 which differed from the Sanger and Lee
sequences, a T to C transition at position +385 relative to the start of transcription,
which creates a BssHll restriction site. Subsequent sequencing of a control population
showed that this difference is a polymorphism (Chapter 5). Therefore the 4.8Kb of
human sequence cloned from lambda clone 314 appears to be correct and has not
undergone any mutations or rearrangements.
3.2.4 Identification of an upstream regulatory region
Construct p4.8CATBS, which contains sequence starting at position -1558 relative to
the start of exon 1 and includes 4.8Kb of putative regulatory sequence, expressed the
CAT reporter gene when transiently transfected into the human neuroblastoma cell-line
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Sk-N-Sh. To determine which regions of the upstream sequence affected expression
levels in this cell-line, a set of unidirectional deletions were created using the Erase-A-
Base system (Promega). Plasmid -1558 (p4.8CATBS) was digested with Kpnl and
EcoRl then incubated with Exonuclease III for varying periods of time. This allows the
amount ofDNA digested to be controlled as Exonuclease III digests DNA at a regular
rate which is temperature-dependent (Figures 3-12 and 3-13). Exonuclease III digests
5' overhangs and blunt-ended DNA, but not certain 3' overhangs such as that generated
by Kpnl. Thus a series of unidirectional deletions was produced. Incubating with SI
nuclease then removes the single stranded DNA. The resulting fragment was treated
with Klenow fragment to fill in any over-hangs then ligated and transformed into
Escherichia coli. These constmcts were sequenced to determine the amount of digestion
that occurred.
Analysing the rate of digestion of exonuclease III shows that it is influenced by GC
content. The amount ofDNA digested in 60-second intervals in the upstream region at
30°C declines with increasing GC content. As the first exon is found in a region of high
GC content the rate of deletion slowed in the immediate upstream region creating
several deletions in this region. Thus the -43 and -9 constructs were made by digesting
for an extra minute which only removed 34 basepairs in contrast to the manufacturer's
stated rate of 125bp/minute, this resulted in much closer deletions in the GC rich
upstream region which is a regulatory region in other species. In contrast to the first set
ofErase-A-Base deletions there was no correlation between the rate ofdigestion and GC
content in the intron deletions although the digestion was carried out at a lower
temperature (25°C) than the upstream deletions (30°C) (Figure 3-14).
Constructs -730, -364, -133, -43, -9 and +289 (the number indicates the start point of the
human sequence relative to the start of exon 1) were made using the Erase-A-Base
system and transiently transfected into Sk-N-Sh cells. Their level of CAT activity
relative to construct -1558 is shown in Figure 3-15 and table 3-1. In each experiment
construct -1558 was transfected in parallel to the other constructs being examined to
allow the comparison ofCAT expression levels. All constructs were co-transfected with
either the pGL3-Control vector (Promega) which encodes luciferase or pSV 0-
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galactosidase (Promega) control vector both ofwhich contain SV40 early promoter and
enhancer sequences to control for variation in transfection efficiency. Early transfection
experiments used the pSV p-galactosidase plasmid but when a luminometer capable of
reading lucifcrasc became available the pGL3-Control plasmid was used.
Removing the upstream sequence between -1558 and -43 had no effect on expression;
statistical analysis showed no significant difference in CAT activity between the five
constructs (One-way ANOVA p=0.51)(Figures 3-15 Table 3-1). This sequence includes
the highly conserved region containing the four PrP specific motifs 150-300bp upstream
of the transcription start site. A lack of transcriptional activity of this region has also
been noted in reporter gene deletion studies in the mouse, cow and rat PrP genes
(Baybutt and Manson, 1997) (Saeki et al., 1996) (Inoue et al., 1997). The functional
significance of the four PrP specific motifs is therefore uncertain. Perhaps this conserved
region regulates expression in different tissues or at particular stages of development.
Deletion studies on mammalian PrP regulatory region have been carried out in only a
limited number of cell types, (human and murine neuroblastoma cell-lines, two bovine
fibroblast cell-lines and rat pheochromocytoma and glioma lines) so it is possible that
using a wider variety of cell types would detect cell types where deletion of this region
affects expression.
Deleting from ^43 to -9 resulted in a significant drop in expression to 32% of construct
-1558 (p=10 5 t-test between -43 and -9 table 3-1). This implies that this region contains
promoter activity. The location (relative to the start of transcription) of this upstream
regulatory region in humans contrasts with that of rat, mouse and cow where removing
sequence between -90 and -30 results in a drop in expression. However the human first
exon is considerably larger than that of other species (Human=134bp Bovine = 53bp
rat= 19-47bp). If the sequences of each species from the conserved motifs to the end of
the first exon are aligned using the CLUSTALW program then the transcription factor
binding sites, including the exonic SP1 sites in humans, and the critical regions in
deletion assays align (Figure 3-16).
Therefore, the region between -43 and -9 in the human upstream region is approximately
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equivalent to the -90 to -60 region in other species, implying that mammalian PrP
promoters have a conserved structure. However, the alignment shows that the regulatory
regions defined by deletion assay are not as well conserved as region further upstream
which contains the PrP specific motifs. The only conserved transcription factor binding
site in the regulatory regions is a reversed CCAAT motif in rodents and humans. This
is therefore a good candidate for further studies, such as in vitro mutagenesis of the site
and gel shift assays to determine if this sequence is bound by proteins in Sk-N-Sh cells
and if the sites removal affects expression.
A further deletion which removes all upstream sequence, the first exon and part of the
intron (construct +289) reduced expression to background levels (p=0.96 t-test between
pCAT3basic and +289). This reduction may be due to the loss of transcription factor
binding sites within the first exon which affect expression or that the first exon is
required to initiate transcription or the first exon could be required to allow correct
splicing to either the second exon or the reporter ORF exon. The most likely explanation
is that there are transcription factor binding sites immediately downstream of the
transcription initiation site with the most likely candidates being the SP1 sites. In the
rodent and bovine analyses, removal of one of the SP1 sites resulted in a drop in
expression. However, this deletion was not made in the human gene as disrupting the
transcription initiation site could affect interpretation of such a construct.
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Figure 3-12 Creation of deletions using the
Erase-A-Base system
Digest plasmid -1558 with Kpnl and EcoRl (restriction sites underlined)
ATAGGTAC AATTCATCTCCCAGTGAGCCA
TATC GTAGAGGGTCACTCGGT






Remove single-stranded DNA with S1 Nuclease
ATAGGTAOS1 7 AGCCA
TATC L S KGTAGAGGGTCACTCGGT
Treat with Klenow polymerase to fill-in any remaining over-hangs then ligate
ATAGAGCCA
TATCTCGGT
Transform and screen by mini-prep
Erase-A-Base protocol plasmid p4.8CATBS was digested with EcoRl and Kpnl
exonuclease III (E3). At one minute intervals the exonuclease digestion was ended
and single-stranded DNA removed using SI nuclease (SI). Any remaining over¬
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Figure 3-13 Creation of unidirectional deletions of construct -1558 Plasmid
-1558 was digested with exonuclease 3 for 1 minute increments then treated
with eSl nuclease which removed the single-stranded DNA. An aliquot was
then ran on a 0.8% agarose gel. On the left are the set of deletions used to make
the upstream deletions, while the inton deletions are on the right. Due to an
excess of ethidium bromide in the upstream deletion gel it is difficult to
visualise the DNA bands .The intron deletions have two bands in the longer
deletion times. The lower band may be due to partial digestion of the Nsil site
by exonuclease III. But all clones recovered were mapped and had their
junctions sequenced to ensure that only unidirectional fragments were used in
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CAT CAT CAT CAT CAT CAT CAT CAT
100 105+/-6 105+/-3 85+/- 93+/- 32+/-6 2+/-1 1+/-1
Constructsweretransientlyt nsfect din ohumanSk-N-SHneuroblas omac ll ,hreg obet -43nd9(Bl r)v largeeffectonxpressionwhileemovalfthfi stx naboli h sex r ib ckg ou dlevel .
Table 3-1 CAT activity levels of PRNP regulatory regions constructs
transfected into human Sk-N-Sh neuroblastoma cells. Constructs were
transiently transfected in Sk-N-Sh cells between 2 and 30 times. Cells were co-
transfected with either P-galactosidase or luciferase reporter genes under the control of
an SV40 promoter to act as a control for variation in transfection efficiency. Construct
-1558 was always transfected alongside the other construct and its expression level taken
as 100. n=number of transfections
Construct Mean CAT activity Standard error n
-1558 100 - 30
-730 105.5 5.5 4
-364 105.3 3.2 3
-133 84.8 8.4 9
-43 93.4 8.8 11
-9 32.3 6.1 12
+289 1.5 0.8 6
A+145:+3259 51.7 4.7 19
A+1925:+2106 103 0.1 2
A+1558:+2106 105.5 0.5 2
A+847:+2106 102.5 3.0 4
A+695:+2106 102.0 14.0 2
A+622:+2106 81.1 7.7 10
A+292:+2106 16.4 4.5 14
A+296:+1084 11.3 2.9 15
A+257:+2106 11.3 4.0 4
A+296:+380 56.6 9.0 9
A+2067:+3267 102.1 15.5 12
+292:+1082Rev. 50.3 5.5 22
+292:+1088@+2068 8.0 1.5 16
+292:+1088 Rev.@+2068 16.1 2.6 16
pCAT3 Basic 1.5 0.4 15
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Figure 3-16 Alignment of mammalian PrP gene exon 1 and upstream
sequences
CLUSTAL W alignment of human bovine murine, ovine and rat PrP
upstream regions and exon 1. Key red=exon blue=regulatory region by
deletion assay green=intron. *=conserved position in all species.
Where exons have multiple start sites the most 5' start site is
used.
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rat TGGGGAGGGGAGTACGGGGGGAGGGGGTTAAACAGATAACAA-GCATTTAAGCCAG T
mouse -G GCGGTTTAAACAGATA-CAA-GCATTTAAGCCAG T



































































3.2.5 Identification of an intronic regulatory region
The relatively high level of expression of construct -9 (32%) suggests that the region
downstream of the transcription start site may contain sequences that regulate gene
expression. To examine this possibility the intron and putative second human
untranslated exon (Lee et ah, 1998) were removed by digesting construct -1558 with
Xmal and ligating the largest fragment to itself. The resulting construct (A+145:+3259)
had only 52% of the expression levels of the full construct implying that the intron
contains sequences that regulate transcription (Figure 3-17). To determine which
sequences within the intron affected transcription a further set ofunidirectional deletions
was made using the Erase-A-Base system by digesting construct -1558 with Nsil and
Csp45l. (Figure 3-14) Digesting the plasmid back-bone with Exonuclease III removed
the 5' overhang created by Csp45l, but not the 3'overhang created by the Nsil site, thus
creating a set of unidirectional deletions in the opposite direction to the upstream
sequence of deletions (Constructs A+1925:+2106, A+1558:+2106, A+846:+2106,
A+693:+2106 and A+254:+2106). The existence of anMM site allowed the creation of
construct A+292:+2106 by digesting construct -1558 withMM and AM, removing 5'
and 3' over-hangs with SI nuclease and ligating.
Transiently transfecting Sk-N-Sh cells with constructs which have deletions of the intron
showed that removal of sequences between +622 and +2106 had no significant effect on
expression (One-way ANOVA p=0.17 table 3-1). However a further deletion to +292
resulted in a drop in expression to 16% of the level of the full construct, implying that
this region contains an intronic regulatory sequence (Yellow region Figure 3-17 and 3-
18). To confirm that the sequence between +292 and +622 is the critical regulatory
region of the intron, a deletion was made (A+292:+1082) by digesting construct -1558
with Mlul and AgeI, treating with Klenow fragment to fill in any remaining over-hangs
and ligating the two ends of the plasmid together. This construct removed the critical
region and gave equally low levels of expression as A+292:+2106 (t-test p=0.24),
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confirming that the drop in expression was due to removal of specific sequences rather
than shortening of the intron. To determine if the 330bp intronic regulatory region can
be further defined by deletions 84 bases of the 330bp critical region were removed
(A+296:+380) by digesting construct -1558 with Mlul and RssHll treating with Klenow
fragment to fill in any remaining over-hangs and ligating the two ends of the plasmid
together. Upon transient transfection this construct resulted in CAT activity of 52% of
construct -1558 implying that this region within the intronic region may contain
important regulatory regions.
One puzzling aspect of the intron deletion constructs is that expression levels are
significantly higher when the whole intron is deleted (A+143:+3253; 52% of construct
-1558) then when only the critical region is deleted. (A+292:+1082 and A+292:+2106
average expression level: 16%)(t-test p=4X10"8 Table 3-1). This may be due to a
repressor element near the second exon (between +2106 and +3253) or between +143
and +292. However, removing the region surrounding the second exon, by digesting
construct -1558 with Csp45l and Bglll (construct A+2067:+3253) filling in with Klenow
fragment and ligating the two ends of the plasmid together, while leaving the intronic
promoter region untouched had no effect on expression this implies that there is no
repressor element in this region. It also implies that the second exon has no apparent
function in transcriptional regulation in this experimental system, in contrasts with the
murine deletion analysis where there was a second promoter region upstream of the
second exon. The possibility remains that there is a repressor element between +143 and
+292 i.e. between the first exon and the intronic regulatory region. However further
deletion analysis within this region is needed to determine if this is correct.
To determine if the intronic region is an enhancer, i.e. can affect expression regardless
of its position and orientation, the intronic region was reversed. This was achieved by
digesting construct -1558 with Mini and Agel, filling in both fragments with Klenow
fragment and religating the Mlul-Agel fragment in the opposite orientation (Figures 3-19
and 3-20). This construct (+292:+1082R, R stands for reversed) both reversed and
moved the critical region which should have no effect on the functioning of an enhancer,
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yet abolish the effect of any position dependent non-enhancer elements in this region.
However, this construct had only 50% ofCAT expression levels relative to construct -
1558 implying that this region is not a true enhancer as being reversed and moved
affects its expression level. To further determine the effect of position on the intronic
element, the Mlul-Agel fragment was ligated into the Csp45\ site of construct
A+292:+1082 in both the forward and reverse orientations (constructs
+292:+1082@+2068 and +292:+1082rev @+2068). These two constructs drove
expression at levels as low as when the intronic region was deleted. Therefore, the
intronic region does not appear to contain an enhancer element. The intronic region must
therefore act by regulating expression in a positional dependent manner, this may imply
that it acts with the upstream regulatory region in driving expression from the first exon
possibly in conjunction with regulatory elements within the exon.
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3.3 Discussion
Examining the upstream and intronic regulatory regions of the human PRNP gene
defined in this deletion study shows that the upstream regulatory region is quite short
at 34 bases (between -43 and -9) compared with that of other species. A reversed
CCAAT site is the only consensus transcription factor binding site in this region. This
site is also found in the critical upstream regions of the mouse and rat PrP genes, but not
the bovine PrP gene. The human gene also has a regulatory region within the intron.
This is also found in the first introns of the murine and bovine genes. The presence of
regulatory elements in the intron which affect expression is not unprecedented as many
genes have sequences within their introns which affect transcription, such as rat fatty
acid synthase, human epidermal growth factor receptor, human myotonic dystrophy
protein kinase gene, human fibroblast growth factor receptor, human smooth muscle
(aortic type) alpha-actin gene, human noreprinephrine transporter gene and human tissue
inhibitor ofmetalloproteinasel (TIMP-1) (Storbeck et al., 1998) (Nakano et al., 1991)
(McEwan and Ornitz, 1998) (Oskouian et al., 1997) (Gebhardt et al., 1999) (Kim et al.,
1999) (Clark et al., 1997). Such elements are often found in introns between untranslated
exons as is also seen in PRNP. The human intronic regulatory region ofPRNP appears
to be more similar to the bovine PrP gene intronic regulatory region then the murine
intronic regulatory region, with a positive regulatory region in the 5' half of the intron.
Unlike the bovine gene, which requires both upstream and intronic regions in order to
drive expression of the reporter gene, in humans either region can function alone,
although each drives expression at a significantly lower level than the full construct. The
first exon is however essential for expression as its removal reduces expression to
background levels.
The 330bp critical region of the human intron appears to contain at least two distinct
elements as a small deletion (construct A+296:+380) within the intronic region reduced
expression 49% but this is not as much as deleting the entire region (construct
A+292:+1082) which reduces expression 88%. Analysing the sequence of the human
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intronic region and the bovine intronic regulatory region identified by Inoue et al (Inoue
et al., 1997) for transcription factor or enhancer consensus binding sites shows that the
human intronic region contains a CCAAT/Enhancer binding protein beta (C/EBPP)
which is absent in the bovine intronic regulatory region. There is also an SP1 site in both
intronic regulatory regions. The SP1 and C/EBP transcription factor binding sites may
explain the expression levels seen in deletions A+292:+1082, A+296:+380 and
+292:+1082R. In A+292:+1082 both the SP1 and C/EBP sites are removed, leading to
a drop in expression while in A+296:+380 the C/EBP site was removed, but the SP1 site
was left untouched. This resulted in levels of expression less than that of the full
construct but greater than those where the intronic regulatory region was deleted.
Reversal of the intronic regulatory region sequence (+292:+1082R) may have affected
one of the two sites leading to the intermediate levels of expression seen. While moving
both sites 1Kb downstream may prevent any transcription factors that bind to these sites
from influencing expression (Constructs +292:+1082@+2068 and +292:+1082rev
@+2068).
CCAAT enhancer binding proteins (C/EBP) are a family of leucine zipper transcription
factors with six members a,p,x,5,s and C,. Despite its name, the consensus binding
sequence for C/EBP P does not contain CCAAT; the consensus sequence is actually
RNRTKNNGMAAK (R=A or G, N=A, C, G or T, K=G or T, M=A or C). Conversely
the CCAAT reversed motif (ATTGG), which affects expression when deleted from the
human and rodent upstream regions, can be bound to by several different transcription
factors, the C/EBP family, CBF/NF-Y CTF andNF-I (Maity and Crombrugghe, 1998).
Which protein actually binds to this region can only be determined by band-shift assays
by adding competitive binding sequences. Another method of determining if the
transcription factor binding sites found in the upstream and intronic regulatory regions
are functional in vivo is to use in vitro mutagenesis to alter the transcription factor
consensus binding sites, such as the two SP1 within the first exon the reversed CCAAT
site in the upstream regulatory region and the C/EBP site and SP1 sites in the intronic
regulatory region. Any alterations in expression levels when the mutated constructs are
transiently transfected into Sk-N-Sh neuroblastoma cells would imply that these
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transcription sites are important in regulating expression ofPRNP.
The possible presence of a repressor region between the exon and the start of the intronic
region suggests that the control of expression may be very complex. Rather than two
distinct positive regulatory regions, one upstream and one in the intron, PRNP may be
controlled by a single regulatory region stretching from -43 to +622, consisting of the
positive elements upstream and between +292 and +622 in the intron, a possible
negative element between +143 and +292 and potential regulatory elements within the
exon (+1 to +134). Further deletion analysis is necessary in this region to test this
hypothesis.
This study only examined 1.5Kb of upstream sequence and 3.1Kb of intron. It is
therefore possible that there are other regions that regulate PRNP expression but were
not included in this construct. One possible such element is the putative Purkinje cell
specific element thought to be located at the 3' end of the murine second intron (Fischer
et al., 1996). There may also be regulatory elements in the construct which have no
effect on expression in neuroblastoma cells, but may regulate PRNP expression in other
tissues; such elements would not be identified in this study. However, this study has
identified the first regulatory regions of the PRNP gene. These regions can now be used
to create transgenic constructs to see the effect of the regions on expression in vivo
(Chapter 4) the regions can also be sequenced in vCJD patients, sCJD patients and
controls to determine if any polymorphisms exist in these regions and if such
polymorphisms have any effect on susceptibility to disease (Chapter 5).
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The results of the transient transfection experiments identified two regions of the human
PRNP gene which regulate expression. However, these regions have been only shown
to control expression in human neuroblastoma cells. If the level of PrP expression
influences disease and polymorphisms in these regions affect susceptibility to CJD then
the effect each region has on expression in an entire organism needs to be examined. To
determine if the upstream and intronic regulatory elements of the PRNP gene can
regulate expression of a reporter gene in the PNS, CNS and other tissues where PrP is
known to be expressed, transgenic mice were created which express the LacZ reporter
gene under the control of the human PRNP upstream and intronic regulatory regions to
determine if the regions identified as regulating expression in vitro control the
expression levels, tissue specificity or temporal expression patterns in vivo. The
upstream and intronic regions may have different effects on expression in different
tissues if they contain tissue specific transcription factor sites.
Other studies have shown that human upstream promoter regions can replicate their
expression patterns when introduced into mice, implying that mammalian transcription
factors and promoters are interchangeable. Intronic regulatory regions of human genes
have also been shown to affect expression patterns of a reporter gene in murine embryos.
One example of this is the serotonin transporter gene. This gene has a variable number
of tandem repeats (VNTR) polymorphism in the second intron, with alleles having 9,
10 or 12 copies of a 17bp repetitive element. Association studies of these alleles with
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bipolar disorder (Manic-Depression) and other affective disorders have shown an
association of these alleles with disease. Other studies however, have failed to replicate
these findings; affective disorder association studies are notoriously difficult to replicate
due to difficulties in diagnosing patients and the complex genetic aetiology of the
diseases (Sher, 2000). In order to determine if the VNTR polymorphism has an effect
on expression, in vitro and in vivo studies have been carried out. In vitro studies used a
reporter gene construct where the 10 copy (Stin 2.10) and 12 copy (Stin2.12) alleles of
the intronic polymorphism were inserted upstream of a LacZ gene driven by a minimal
promoter and transiently transfected into murine embryonic stem cells have shown
differences in expression between the two alleles (Finkerstrand et al., 1999). To examine
the effect in vivo the constructs were injected into fertilised mouse eggs and the
expression patterns of the resulting transgenic embryos were examined (MacKenzie and
Quinn, 1999). While both alleles drove expression of the reporter gene in developing
embryos the Stin2.12 allele construct expressed higher levels of the LacZ reporter gene
in the rostral hind-brain ofmurine at day El 0.5. Although there was no difference at E
12.5, this suggests that the two alleles have functional differences in embryonic
development which could alter an individual's susceptibility to bipolar disorder in later
life. This study also shows that relatively small differences in human regulatory regions
can be detected in transgenic murine embryos.
To analyse the effect of the human PRNP gene regulatory regions in vivo, the upstream
and intronic PRNP regulatory regions were cloned into a construct containing the P-
galactosidase reporter gene. These constructs were then micro-injected into fertilised
mouse eggs which were implanted into pseudo-pregnant mice. The 3.4Kb murine Pmp
gene regulatory sequence identified by Baybutt and Manson (Baybutt and Manson,
1997) was used as a control to determine if expression of a reporter gene driven by the
upstream and intronic regulatory regions of the murine Pmp gene can reproduce the
known expression patterns ofPrP. This was compared with the expression pattern of the
construct containing the human upstream and intronic elements to determine if the
differences between murine and human transcription factors affect the expression of a
reporter gene controlled by the human PRNP regulatory regions in a murine
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environment. Finally, constructs containing either the human upstream or intron
regulatory region were injected to determine the effect of each of these elements
individually. This was carried out to determine if the upstream and intronic elements act
individually or co-operatively in particular tissues. Embryos and adult mice were
analysed for the presence of the transgene by PCR of the extra-embryonic tissues or tail-
snip DNA respectively. Temporal and tissue specific expression ofPrP was examined
by staining transgenic adults and embryos at different stages of development for p-
galactosidase activity.
If this study shows that a particular regulatory region is identified as controlling
expression in a particular tissue this can be used to predict the possible effect of any
polymorphisms or mutations found in these regions in the sequencing study in Chapter
5. If these polymorphisms are associated with disease, then tissues whose expression is
controlled by the regulatory region may be implicated in the initiation or progression of
disease. Any regulatory region alleles pre-disposing individuals to disease would then
be used to create new transgenic constructs so that a direct comparison of the two alleles
can be made to determine in which tissue expression is altered.
Due to random integration of micro-injected constructs into the murine genome,
inactivation of transgenes or ectopic activation by neighbouring enhancer elements is
a potential problem in altering expression patterns. Therefore an expression pattern from
a given transgenic construct needs to be observed in several embryos or transgenic lines.
The micro-injection work and analysis of transgenic mice described in this Chapter was
carried out jointly by myself and Dr. David Stott at the Department ofBiology, Warwick
University, UK; all the implantation of injected eggs was carried out by Dr.Stott.
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4.2 Results
4.2.1 Creation of transgenic constructs.
The reporter gene plasmid used to make the transgenic constructs was placF which
contains a LacZ reporter gene. It also contains sequences from the mouse protamine
gene which provide an intron, 3'UTR and poly-adenylation signal; although coding
sequences from the protamine gene are included they are not translated. The human
regulatory region CAT assay deletion constructs -1558, -9, and A+143:+3259 from
Chapter 3 were digested with Seal and Bst98l to remove the pCAT3 basic plasmid
backbone, filled in with Klenow fragment and ligated into the Sail site of the polylinker
of placF, which had also been filled in with Klenow fragment. This resulted in
constructs full-lacF, downstream-lacF and upstream-lacF (Figures 4-1, 4-2, 4-3, 4-5).
These constructs all contained the chimeric intron from the pCAT3 basic plasmid which
serves to provide a splice acceptor site for the first exon, thereby avoiding splicing from
the PRNP first exon to the protamine exon in LacF. A 3.5Kb BamHl-Kpnl murine
fragment from construct PrP-7 (Baybutt and Manson, 1997) equivalent to the full human
promoter was sub-cloned from the pCAT basic plasmid (Promega) into the Smal site of
the pLacF polylinker (Figure 4-4) by Dr. Herbert Baybutt (NPU). This construct was
termed Murine-lacF. The exon-intron structure of the Murine-lacf construct differed
from the human constructs as the murine sequence ended in the second exon and did not
contain the chimeric intron (which is present in the human constructs) as it was
originally cloned into the pCAT basic plasmid rather than the pCAT3 basic plasmid. In
contrast the human placF constructs all contained a chimeric intron from pCAT3 basic


















Figure 4-1 Cloning of pFull-LacF: The full human promoter construct
p4.8BCAT (construct -1558 in deletion series) was digested with Seal and Bst98\.
This 5.2Kb Scal-Bst98l fragment contains the human sequence plus flanking
regions from pCAT3 basic. This fragment was cloned into the Sail site of pLacF
resulting in plasmid pFull-LacF. The entire plasmid was transiently transfected
into N2a cells but for the creation of transgenic mice the pFull-LacF plasmid
backbone was removed by digesting with Seal and Xbal.
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Figure 4-2 Cloning of pUpstream-LacF The human regulatory region
construct A+l43:3259 was digested with Seal and Bst98\. This 2.1Kb Scal-Bst98l
fragment contains the human sequence plus flanking regions from pCAT3 basic.
This fragment was cloned into the Sail site of pLacF resulting in plasmid
pUpstream-LacF. The entire plasmid was transiently transfected into N2A cells but
for the creation of transgenic mice the pLacF plasmid backbone was removed by





















Figure 4-3 Cloning of pDownstream-LacF: The human regulatory region
construct -9 was digested with .Seal and Bst98\. This 3.7Kb Scal-Bst98l fragment
contains the human sequence plus flanking regions from pCAT3 basic. This
fragment was cloned into the Sail site of pLacF resulting in plasmid pUpstream-
LacF. The entire plasmid was transiently transfected into N2A cells but for the
creation of transgenic mice the pLacF plasmid backbone was removed by
digesting with Seal and Xbal.
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Figure 4-4 Cloning of pMurine-LacF: The murine regulatory region construct
PrP-7 (Baybutt and Manson 1997) was digested with BamHl and Kpnl. BamWl
cuts upstream of the regulatory region while BamHl cuts within the murine second
exon. This 3.4Kb BamHl-Kpnl fragment therefore contains the human sequence
plus flanking regions from pCAT3 basic. This fragment was treated with Klenow
fragment to fill in any over-hangs and cloned into the Smal site of pLacF resulting
in plasmid pFull-LacF. The entire plasmid was transiently transfected into N2A
cells but for the creation of transgenic mice the LacF plasmid backbone was
removed by digesting with Kpnl and Seal.
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Full-lacF: EcoRW digest of
putative full-lacF clones,
lanes 2 and 4 show 5.2Kb,
5.3Kb and 1Kb pattern of the
full human sequence sub-













Upstream-lacF: Kpnl and Smal
digest of a putative clone of
upstream-lacF. Kpnl digest gave
a 8.3Kb and 0.1Kb band (0.1Kb
band not visible). Smal gave a











Downstream-lacF: Bglll digest of
three putative clone of downstream-
lacF (lanes 1-3) show a 6.1Kb and
3.9Kb bands consistent with cloning of
the downstream region of human DNA
into placf in the forward orientation.
Smal digest of the same three
clones(lanes 4-6) shows that only the
first colony (lane 4) contains the 6.6Kb
2.5Kb, 0.5Kb and 0.25Kb bands
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4.2.2 LacF constructs in vitro.
To determine if the human PRNP regulatory would function in mice and if the sub-
cloning of the regulatory regions from the CAT constructs into lacF affected expression,
the four lacF constructs were transiently transfected into murine N2a neuroblastoma
cells. As a control, a P-galactosidase gene under the control of an SV40 promoter was
also transfected. Cells were transiently transfected using the same calcium phosphate
protocol as the transient transfections in Chapter 3. The constructs were co-transfected
with the pGL3 luciferase construct to normalise transfection efficiency. All four LacF
constructs produced P-galactosidase activity in N2a cells as measured by cell extract
assay and by in situ staining (Table 4-1). As the murine regulatory regions had driven
a CAT reporter gene in the same murine neuroblastoma cell-line (Baybutt and Manson,
1997), the sub-cloning of the regulatory region has not affected its efficiency or the
ability of the LacZ reporter gene to produce the correct transcript. The full human
construct had higher activity than the upstream or downstream constructs, which was
similar to the results in the Sk-N-Sh cells with CAT reporter gene. Flowever, the
downstream construct expressed at higher levels than the upstream construct, a reversal
of their relative strengths in Sk-N-Sh cells. The full human construct gave higher levels
of expression than both the murine-lacF and an SV40 promoter control plasmid.
Table 4-1 p-galactosidase activity of lacF constructs transiently
transfected into murine N2a neuroblastoma cells.
n=number of transfections
Construct Average P-galactosidase activity relative to Full-lacF. n






The results from the transient transfection studies show that the sub-cloning of the
human regulatory regions into the pLacf reporter construct did not disrupt the regulatory
ability of the human regions. The relative differences between the full human construct
and the upstream and downstream constructs may be due to different interactions with
murine transcription factors. The low level of expression of the murine-lacF construct
relative to the human construct could be due to differences in the exon intron structure
between the two constructs as the murine construct does not contain any of the murine
second intron and does not have a chimeric intron. Splicing therefore occurs from the
first exon to the second exon which is fused to the LacF ORF containing exon. Whereas
in the human constructs the first exon splices to the chimeric intron acceptor site,
possibly including the second exon-like sequence, which includes the ORF.
4.2.3 Expression of lacF constructs in vivo
Having shown that the regulatory regions of the human PRNP gene can regulate
expression of a reporter gene in murine cells, the human regulatory region lacF
constructs were digested with Xbal and Seal to remove the plasmid back-bone, while
murine-lacfwas digested with Kpnl and Seal. The digested plasmids were run out on
agarose and the fragment containing the regulatory regions and LacZ gene purified from
the agarose using the Qiaquick gel extraction kit (Qiagen) eluted in PBS and micro-
injected into the pro-nucleus of fertilised eggs. The results of the injections are shown
in table 4-2.
Full-lacF: Two of five embryos recovered at E10.5 (Day 10.5 of development i.e. 10.5
days post coitus) carried the full-lacF transgene (as determined by PCR Figure 4-6). The
normal pattern of PrP expression at El0.5 as previously reported (Miele, 1999) show
that PrP is expressed in the telencephalon, mesencephalon and metencephalon the
epithelia of the neural tube and the otic pits. However, no P-galactosidase staining was
observed in any of the embryos (Table 4-2).
144
At developmental stage El2.5 eight embryos were recovered, including one which had
not developed fully and appeared similar in size and level of development to an El 0.5
embryo, four of the eight were transgenic (including the underdeveloped embryo) as
determined by PCR. At this stage of development PrP expression has previously been
detected (Manson et al., 1992) by in situ hybridisation in the developing brain and spinal
cord and also in some non-neuronal tissues but no staining was observed after 24 hours
incubation in X-gal staining solution. After staining for 48 hours weak P-galactosidase
staining was seen in the tissue surrounding the 4th ventricle, and between the
telencephalic ventricles (Figure 4-7). This staining was seen in all 7 fully developed
El 2.5 embryos however as only 3 of the 7 were transgenic, as determined by PCR, the
staining may be due to endogenous P-galactosidase activity. Mammalian P-galactosidase
is active at slightly acidic pH while bacterial P-galactosidase works best at neutral pH
but is still active at slightly alkaline pH which inactivates mammalian p-galactosidase.
The pH of the X-gal buffer was 7.0 this might therefore allow some endogenous p-
galactosidase activity to be detected after prolonged staining. The fact that the staining
was weak and there was no difference between transgenic and non-transgenic embryos
suggests that the transgene was not functional in these embryos.
Upstream-lacF and Downstream-IacF: Two upstream LacF and one downstream LacF
El2.5 embryo were produced. All three embryos were positive for the transgene by PCR
but no staining was observed after 24 hours. After 48 hours of staining a similar pattern
of staining to the background staining of the full-construct were observed. Again
suggesting that there was no transgene expression.
Mouse-lacF: Three of six E12.5 embryos injected with the mouse construct contained
the transgene but none stained for p-galactosidase. Although background X-Gal staining
was again seen in both transgenic and non-transgenic embryos after 48 hours.
Expression in adults:
As the murine regulatory region construct failed to express the reporter gene in
embryonic mice, some implanted eggs injected with the murine construct were allowed
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to develop to term and expression in adult mice was examined. Seven transgenic adult
mice were produced but no X-Gal staining was detected in paraformaldehyde fixed
brain, heart, lung, kidney, spleen, muscle or liver in these animals. Therefore, these
constructs do not appear to be able to express the reporter gene in embryonic or adult
mice. The analysis of the adult mice was carried out by Dr.David Stott.
Table 4-2 Results of transgenic experiments
Construct Eggs Developmental Number of Number of P-Gal.
injected Stage embryos/adults transgenics Staining
Full-lacF 32 E10.5 5 3 0
Full-lacF 39 E12.5 8 4 0
Up-lacF 31 E12.5 2 2 0
Down-lacF 22 E12.5 1 1 0
Mouse-lacF 44 E12.5 6 3 0
Mouse-lacF 88 Adult 11 7 0
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Figure 4-6 PCR analysis of Extra-embryonic





Figure 4-6 PCR analysis of Extra-embryonic tissues from E12.5 embryos
injected with the full-LacF construct. The extra-embryonic membranes from
the 8 embryos were used to prepare DNA which was used in PCR reactions to
detect the lacZ open reading frame of the pLacf construct (Upper lanes) and
GAPDH as a control (Lower lanes). Embryos 1, 5, 6 and 8 were positive. The
positive control is DNA from a different line of transgenic mice which contain a
pLacF construct, it gave a very weak signal in the Lacf PCR which is not visible
in this picture but is just visible in the original photograph. The level of the
GAPDH PCR product is also smaller in the control than most of the other
embryos possibly due to a lower DNA concentration or degradation of the DNA
147
B
Figure 4-7 Background P-galactosidase in E12.5 embryos. Embryos which
contained (A) or didn't contain (B) the transgene when analysed by PCR were
stained for LacZ activity for 48hours. Weak staining was observed in the tissue
surrounding the 4th ventricle (arrow in A), the non-transgenic embryo was
dissected as shown by the dashed line and the P-galactosidase staining was seen
in a thin ridge or tissue either side of the 4th ventricle (Arrows in B)
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4.3 Discussion
4.3.1 Expression of PrP
PrP is expressed at high levels in the brain, spinal cord and PNS and at lower levels in
many other non-neuronal tissues. The expression ofPrP during murine development has
been analysed by in situ hybridisation (Manson et ah, 1992). At E9.5 no PrP was
detected but at El3.5 and El6.5 abundant transcripts are found in the developing CNS,
PNS and in non-neuronal tissues. Recent analysis (Miele, 1999) has detected PrP
transcripts at E9 using RT-PCR. The level of PrP expression in the brain increases
during development relative to a P-actin control until post-natal day 20 when it reaches
its adult level (Lazarini et al., 1991). Attempts to determine the temporal and spatial
pattern ofPrP expression using wholemount in situ hybridisation using DIG labelled PrP
riboprobes shows that PrP is undetectable at E8.5 but is detectable at E9.5 in the
telencephalic, mesencephalic and metencephalic vesicles of the developing brain (Miele,
1999). Therefore a reporter gene should be detectable in the transgenic mice if the
regulatory regions are sufficient to drive expression.
4.3.2 Possible reasons for the lack of expression of the
constructs
Transgenic mouse embryos containing the full human promoter did not express the P-
galactosidase transgene at E10.5 or E12.5, while the equivalent murine region similarly
did not drive expression at El 2.5 or in adult mice. Given this failure of the murine and
full human constructs to express LacZ, it is unsurprising that the upstream-lacF and
downstream-lacF constructs also failed to drive LacZ expression as they contain less
regulatory sequence than the full human lacf construct.
Although in this study the human and murine sequences failed to promote expression
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of a reporter gene in murine embryos or adult mice, a similar study which used 6.7Kb
ofbovine PrP sequence consisting of4.3Kb ofupstream sequence, the first exon the first
intron and second exon, expressed a Green fluorescent protein (GFP) reporter gene in
adult mice (Lemaire-Vieille et al., 2000). Implying that the upstream and intron
regulatory regions of the bovine PrP gene can express a reporter gene although it is
possible that the expression pattern from the bovine sequence could be due to vital
regulatory elements in the 4.3 Kb ofbovine upstream sequence which are missing from
the 1.2 Kb ofupstream sequence in the murine-lacF construct, or the 1.5Kb ofupstream
sequence in the human constructs. The bovine construct also had a different 3'UTR
(SV40) than the lacF constructs which could also affect expression in vivo.
Another transgenic model has used the 3.5Kb ofupstream and intronic murine sequence
in construct Murine-lacF to drive expression of the murine PrP gene in transgenic mice
made by micro-injection (G. Telling, personal communication). These mice show a
similar pattern of PrP expression to that of normal PrP, suggesting that this region
contains sufficient regulatory regions to reproduce the expression pattern ofPrP in mice.
One difference between the Murine-lacF construct used in this study and the PrP ORF
construct driven by the upstream and intron region is that the PrP ORF construct has the
3' UTR ofPrP rather than the mouse protamine gene 3' UTR that was used in the LacF
constructs. As 3'UTRs play a role in mRNA stability its alteration could affect the levels
of translation produced. This could account for the differences in expression between
the two types of transgenic mouse.
There are several possible reasons for the failure of the human and murine lacF
constructs to drive expression in murine embryos. There may be elements required for
expression in the entire organism which have not been included in the murine and full
human constructs. These elements may be further upstream or downstream i.e. within
the second intron. Such a region in the second intron in mice immediately upstream of
the third exon is believed to direct expression of PrP in Purkinje cells (Fischer et al.,
1996). However, the bovine PrP regulatory region reporter construct expressed GFP in
Purkinje cells in mice (despite lacking the second intron) suggesting that there is no
Purkinje expression element in the second intron or that a Purkinje tissue specific
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expression element is located in a different region of the bovine PrP gene and this was
included in the construct.
Using larger constructs with more upstream elements or the intron might lead to
expression which would identify further regulatory elements. Perhaps the neuroblastoma
cells used in the testing of the constructs have unusually high levels of expression with
a minimal promoter, and other regulatory elements either further upstream or within the
second intron are required for expression in normal cells. It has been shown that
sequences within the 3'UTR of the ovine PrP gene affect expression levels of a reporter
gene in transient transfections in murine neuroblastoma cells so the human 3'UTR may
also play a role in expression (Goldmann et ah, 1999).
Depending on the location of their insertion into the genome, transgenes can be
inactivated if they insert into euchromatic DNA which is transcriptionally inactive or if
it inserts near a repressor element. It is therefore possible that the limited number of
transgenic embryos and adults created all had the transgene silenced by its position of
insertion. The production of further transgenic animals may result in the insertion of the
transgene in a region of the genome which allows expression.
The lack ofLacZ expression is unlikely to be due to a problem caused by the cloning of
the regulatory regions from the CAT reporter constructs to the LacF constructs, such as
interference with correct splicing or a mutation of the LacZ gene, as the constructs
functioned in murine neuroblastoma cells. Another less likely scenario is that over-
expression of the transgene could be toxic for the embryo resulting in selection in ntero
for embryos which do not express the transgene, although the LacZ protein is not toxic
to mammals. Alternatively the insertion of large copy numbers of the transgene may
have disrupted global gene regulation, perhaps by titrated out an essential transcription
factor, which is incompatible with survival. Although it is difficult to then explain the
existence of embryos that contained the transgene unless again their genomic position's
chromatin structure prevented binding of transcription factors.
Expression may be occurring, but at a level below the limits of detection of this system
although if levels of expression are below the level of detection of (3-galactosidase then
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expression would be so low that it is unlikely that it would represent faithful
recapitulation of PrP expression. However the expression levels in transiently
transfected murine neuroblastoma was high enough for P-galactosidase staining to be
observed in situ. Although this could be an artefact of using that particular cell line.
4.3.3 Future work
As the most likely reason for the failure of reporter gene expression is due either to the
low numbers of transgenic mice or absence of transcription elements, any future
continuation of this work should initially make more transgenic embryos and adults to
determine if the regulatory regions are indeed incapable of driving expression. If this
fails to lead to expression, new PRNP reporter constructs could be made which contain
more upstream sequence. Initially 4Kb of sequence should be used, as this amount of
the bovine upstream region resulted in expression of a reporter gene in murine embryos.
If the transgenic approach is unsuccessful, transient transfection studies in a range of
murine and human cell types may determine the effect different regions have on levels
of expression. The possibility remains that the mouse protamine 3' UTR may affect
expression or mRNA stability in vivo but not in neuroblastoma cells, therefore using a
different LacZ construct or a different reporter gene system such as luciferase or Green
fluorescent protein may lead to a PrP-like expression pattern of the reporter gene.
If a future study shows that the upstream and/or intronic regulatory regions can drive
expression of a reporter gene in mice, but not fully reproduce the tissue specific
expression pattern ofPrP, this regulatory region could be used to create constructs where
the PrP protein is driven by the regulatory regions. These constructs could then be used
to create transgenic mice by homologous recombination with an NPU PrP hemizygous
embryonic cell line and used to create transgenic mice which could then be crossed with
null mice to remove the endogenous PrP gene. Such a line ofmice with limited PrP
expression could be useful in experiments that examine the role of PrP expression in
other tissues plays in disease, by showing which tissues require PrP expression to allow
disease to develop by infection by different routes.
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5 Chapter Five: Sequencing and analysis
of PRNP regulatory regions.
5.1 Introduction
5.1.1 Association study of the PRNP regulatory region.
Work in transgenic mice has shown that the level of PrP expression affects the
incubation of TSEs (section 1.4.2). Variation in human PrP expression levels may
therefore affect susceptibility or incubation period to CJD. This Chapter describes an
association study where the 34bp upstream regulatory region and 330bp intronic
regulatory region of the PRNP gene, identified as regulating expression in Sk-N-Sh
human neuroblastoma cells, were sequenced in sCJD, vCJD patients and in control
individuals. If any polymorphisms in these regions modulate PrP expression levels or
patterns and affect susceptibility to sCJD or vCJD they will be more frequent in CJD
patients than controls. Polymorphisms or mutations could affect expression by
increasing the binding of transcription factors or abolishing a repressor-binding site.
Variation in expression could alter susceptibility to vCJD by affecting the uptake of
infectivity in the gut, the replication of infectivity, or the transport of infectivity from
the periphery to the CNS.
The age of onset of disease and the duration of disease was also examined to determine
if regulatory regions polymorphisms affect disease through altered expression levels. In
sCJD, the age of onset of disease could be lower in high expressing individuals
according to the spontaneous misfolding hypothesis of sCJD as more PrP is produced
the likelihood ofmis-folding increases. In vCJD, variation in expression levels could
shorten the incubation period by increasing the replication rate of the agent.
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5.1.2 Association study theory
Association studies are used to detect susceptibility alleles in complex genetic diseases
with multiple genetic and environmental influences, such as schizophrenia and bipolar
disorder (Hodge, 1994). An association study is a non-parametric method of genetic
analysis that does not specify any model of inheritance. Polymorphic loci close to
candidate genes are analysed for any difference in allele frequency between affected and
control individuals. If a polymorphic marker is tightly linked to a disease-causing
mutation or a susceptibility allele then it will be more common in affected individuals
than in controls. In this study, the polymorphism itself is proposed to affect disease. The
effect of a susceptibility allele is described by the odds ratio, which measures the
increased or decreased likelihood of someone carrying a particular allele developing the
disease relative to someone who does not.
The ethnic origin of both affected and control individuals must be the same in an
association study to ensure that any differences detected are due to disease rather than
differing allele frequencies in different ethnic groups. Differences in allele frequencies
in different ethnic groups is termed ethnic stratification and can lead to erroneous
associations between alleles and disease(Hamer and Sirota, 2000). For example if the
affected individuals in a study come from ethnic group A but the controls from groups
A and B, then any allele found exclusively in group A would be more common in
affected individuals than controls leading to an erroneous association. Therefore, care
must be taken in selecting a control population to ensure no ethnic stratification exists.
In a case-control association study, a mutation that is found at the same frequency in
affected individuals and control individuals is probably a polymorphism with no effect
on susceptibility. If it is found in both groups but at a significantly higher level in
affected individuals it is a susceptibility allele, while if found at significantly low levels
in the affected population it may confer resistance to the disease. If it is only found in
affected individuals, it may be directly causing the disease. It is unlikely that regulatory
region mutations are causing vCJD, as epidemiological and transmission studies in mice
suggest that BSE is the cause of vCJD. Regulatory region polymorphisms could
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however affect susceptibility to vCJD. In sCJD, it is possible that some cases are
familial but caused by a mutation outside of the ORF, familial CJD is diagnosed on the
basis of amutation in the ORF and then family history is examined for evidence ofCJD-
like diseases. A hypothetical mutation outside of the ORF that causes CJD could
therefore be classified as sCJD if there was no strong family history of CJD-like
neurological disease.
This study aims to detect polymorphisms that affect susceptibility to vCJD, sCJD, or
unique mutations that may cause sCJD. In order to discriminate between a rare
susceptibility allele and a disease causing mutation, a large number of control
individuals must be sequenced to determine if the allele is found in the general
population at low levels. The size of the control sample in this study was large enough
to be 95% confident of detecting an allele present in the population at 1% (the definition
of a polymorphism by convention) This is calculated by the formula:
Log(l -P)/Log(l -F)=n
Where P is the desired probability of finding a variant allele, F is the frequency of the
variant allele in the control population, n is the number of alleles that need to be
sequenced (n/2 individuals). Therefore, to be 95% certain of finding at least one copy
of an allele this is present at 1% in the general population, 300 alleles (150 individuals)
must be sequenced.
5.1.3 The study population.
The individuals sequenced in this study consisted of 22 vCJD patients, 29 sCJD and 149
control individuals. In this study sCJD and vCJD are considered as separate diseases as
they have different aetiologies. Therefore, any alterations in expression may have
different effects on susceptibility to the two diseases. The regulatory regions were also
sequenced in control individuals to determine the presence and frequency of
polymorphisms in the general population. The control population consisted of 28
individuals who were suspected of having some form of CJD but were later shown to
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have a different neurological disease. As these individuals came from hospitals across
the UK as did the CJD patients there is no danger of ethnic stratification. As there were
only 28 such "Hospital" controls the rest of the control group came from random blood
samples donated to the Blood Transfusion Service, 62 from Belfast, Northern Ireland
and 59 from Edinburgh, Scotland. The PRNP ORF of all individuals in the study was
sequenced in the CJD Surveillance Unit to ensure there were no mutations and to
determine the status at codon 129.
There is a potential risk of ethnic stratification between the Edinburgh and Belfast
bloods, which come from specific regions of the UK, and the Hospital controls and the
vCJD and sCJD cases, which come from across the UK and there can be genetic
variation between individuals from different regions of the UK (Mastana and Sokol,
1998). There is also the possibility that variation in susceptibility to CJD could have an
ethnic basis. This is more than a theoretical risk as there is evidence of a difference in
the incidence of vCJD in different regions of the UK. Analysis of the 51 vCJD cases in
Great Britain up to 1999 has shown the incidence of vCJD in Northern Britain is
significantly higher that of Southern Britain (CJD Surveillance unit 1999 Annual
Report). In Northern Britain (Scotland, Yorkshire and Humberside, Northwest and the
Northern region.) there were 2.57 cases per million people aged 16-54 in the 1991
census compared with 1.30 per million in Southern Britain (East and West Midlands,
Southeast, Southwest, East Anglia and Wales). The reason for this difference is
unknown, but it could reflect regional differences in genetic susceptibility to vCJD
caused by differing ethnic composition of differing regions, such as the proportion of
Celtic ancestry in inhabitants of different regions. Alternatively, differing regional
dietary habits, such as increased consumption of sausages and meat pies in Northern
Britain could affect exposure to BSE although both the total number of cases of BSE
and its relative incidence were significantly higher in Southern Britain than in Northern
Britain (Stevenson et ah, 2000). The level of sCJD is lower in Northern Ireland than in
the rest of the UK, but this is not statistically significant.
The three sub-groups of the control group will therefore have to be compared with each
other to determine if there are any significant differences in polymorphism frequencies
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between them. Such differences might have no effect on CJD susceptibility but simply
reflect the Celtic origin of the Edinburgh and Belfast control groups that make up the
majority of the controls. Alternatively any differences could reflect differing regional
genetic susceptibility to vCJD and may account for the increased vCJD levels in
Northern Britain. Comparing allele frequencies between the hospital controls and the
Edinburgh and Belfast controls should determine whether any differences in
polymorphic allele frequencies have a regional basis.
The regulatory region examined in this study is c.l2Kb upstream of the open reading
frame that contains the codon 129 Methionine/Valine polymorphism. This
polymorphism affects susceptibility to sCJD with methionine homozygotes (MM) being
more likely to develop CJD than valine homozygotes (VV) and heterozygotes (MV) are
less likely to develop sCJD. In vCJD, all individuals to date have been methionine
homozygotes. Due to the relatively short distance between the regulatory region and the
ORF, significant linkage dis-equilibrium may occur between a promoter polymorphism
and codon 129, which could give an erroneous association. For example, if a
polymorphism occurred which has no effect on disease, but was linked to the methionine
allele, then a higher frequency would be observed in vCJD patients (100% methionine
allele frequency) than in a control population (c.60%). Similarly among sCJD patients,
there is a higher frequency of methionine alleles than in the normal population. Such
linkage disequilibrium would have a similar effect to ethnic stratification discussed
previously, as the affected group has been effectively selected for one polymorphism
while the control group has not. This could affect the frequencies of linked
polymorphisms. Linkage disequilibrium can be estimated by examining the genotypes
to determine if the alleles segregated independently. If alleles do not segregate
independently, the frequency of regulatory region polymorphisms in control and affected
individuals can be compared within individuals of genotypes MM, MV and VV to





Based on the results of the deletion assays (Chapter 3) the sequences surrounding the
regulatory regions between -43 and -9 and between +292 and +622 were chosen to be
sequenced as potential regulatory regions. In order to prevent bias in reading sequencing
gels all individuals were coded before sequencing and the code broken when sequencing
was completed.
Two PCR reactions were performed on genomic DNA (Figure 5-1 and 5-2). The first
amplified a 448bp region between -310 and +139 using oligos Up3.f and Up3.r (Figure
5-1) this region included the upstream regulatory region between —43 and -9, the PCR
product was excised from an agarose gel and purified using a Qiaquick gel extraction
kit (Qiagen) (Figure 5-1). The second PCR reaction amplified the 577bp region between
+109 and +684 using oligos Intl.f and Intl.r (Figure 5-1), this region includes the 330bp
intronic regulatory region between +292 and +622. The PCR product was purified using
Microcon filtration columns. The purified PCR products were sequenced using
oligonucleotides UpSeq.f or IntSeq.fwhich overlapped the forward primer of each PCR
reaction and fluorescent oligonucleotides and TAQ from the "Big Dye" Sequencing Kit
(Applied Biosystems) in a cycle sequencing reaction. The fluorescent labelled sequence
was then isopropanol precipitated, resuspended in loading buffer and run on an ABI377
automated sequencer. No PCR product was obtained from some individuals while
sequence data was obtained in one region but not another in other individuals (Table 5-
1). Of the five different groups the efficiency of the PCR reactions was poorest in
Belfast controls, with just over half of the individuals (32/62) being sequenced in both
upstream and downstream regions and almost a quarter (15/62) of the DNA samples
failed to amplify. This reduced efficiency of the PCR reactions could be due to poor
quality DNA from the Belfast controls although the ORF of all Belfast controls was




























Figure 5-1 PCR primers and sequencing oligonucleotides. First exon in blue,
regulatory regions defined by deletions in green, Polymorphisms in red
underlined: S=G or C. Y=C or T PCR oligos =black arrows. Sequencing oligos =
red arrows. See chapter 2 for details of the PCR reactions.
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Figure5-2PCRamplificationofenomicDNAf automat dseq encing.Sa plplific tionthwr actio s
—whicheresequen ed.A=448bpUp tr amuenceB=577bpDownstr anc , o
Table 5-1 Efficiency of sequencing
Sporadic CJD vCJD Hospital Edinburgh Belfast
Fully sequenced 25 16 23 45 32
Partially sequenced 3 3 1 10 15
Not sequenced 1 3 4 4 15
Total 29 22 28 59 62
5.2.2 Polymorphisms
Three single nucleotide polymorphisms (SNP) were identified (Figure 5-3): in the
upstream region a C to G transversion occurred at position -101 (Figure 5-4), in the
intronic regulatory region a G to C transversion occurred at position +310 (Figure 5-5)
and a T to C transition at position +385 (Figure 5-6)(Full data in appendix).
Differences in allele and genotype frequencies of the different polymorphisms, between
controls and CJD patients were tested for significance using x tests or Fisher's exact
test. These tests analyse differences in the distribution ofnumbers in a contingency table
from what that expected assuming there is no relationship between the different
2 •
categories in the table. Chi-squared (x ) tests are used on most tables, but this test
become inaccurate when the expected values in a table become small and the more
computationally demanding Fisher's exact test is then used. The criteria for using
Fisher's exact test rather than a x2 test is when one of the expected values of a
contingency table with four expected values is less than five or two expected values in
a larger table are less than five. (Agresti, 1992).
Initially the three sub-groups that that make up the control population were analysed for
possible ethnic stratification, which could distort the association study. Statistical
analysis using 3X2 contingency table x2 tests (Table 5-2) showed no significant
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differences between the allele frequencies of the three control groups at codon 129
(p=0.31), position -101 (p=0.36), position +310 (p=0.65) or position +385 (p=0.93).
t herefore the three control sub-groups show no evidence of ethnic stratification and can
be combined into a single control group.
Table 5-3 Number and frequencies of the four PRNP polymorphisms in the
three control groups.
Polymorphism Hospital Edinburgh Belfast
Allele
(Common/rare)
Common Rare Common Rare Common Rare
Codon
129(M/V)
34(0.63) 20(0.37) 85(0.72) 33(0.28) 79(0.64) 45(0.36)
-101(C/G) 44(0.91) 4(0.09) 82(0.84) 16(0.16) 76(0.88) 10(0.12)
+310(G/C) 42(0.92) 4(0.08) 97(0.95) 5(0.05) 68(0.94) 4(0.06)
+385(T/C) 43(0.93) 3(0.07) 95(0.95 5(0.05) 70(0.95) 4(0.05)
Figure 5-3 Polymorphisms of the PRNP regulatory region.
C Common allele G T
G Rare allele C C
-101 |gg +31 0 ■ ■385
-309 -43 -9 +292 +622
Three Single Nucleotide Polymorphisms were identified. In the control population at
position -101, 5' of the upstream regulatory region (green) identified by deletion assay,
a G to C transversion occurred. In the intronic region (yellow) two polymorphisms were
identified, a G to C transversion at position +310 and a C to T transition at +385
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Fig5-4PolymorphismC-101G:ABI377traceofheGtransition( r w).Upp rleftanel























Fig5-6PolymorphismT+384C:ABI377tracefheCransition(Arr w).Left panelwild-typeTThomozygot .CentrCeRight heterozygous(CT)individual.
5.2.3 Analysis of polymorphisms and disease
At position-101, 162 individuals were sequenced: 27 sCJD patients, 19 vCJD patients
and 116 controls (49 from Edinburgh, 43 from Belfast and 24 hospital controls). Table
5-3 shows the genotypes and allele frequencies in affected individuals and controls.
Analysing the frequency ofG alleles between vCJD patients and the combined controls
showed no significant difference (p=0.63 x2-test). There was a higher allele frequency
of the rare G allele in sCJD patients than in controls, but this did not reach statistical
significance (p=0.08 x2_test)- To determine the effect of a polymorphism on an
individual's susceptibility to disease, the genotypes of control and affected individuals
were compared rather than the allele frequency. There was no significant difference in
the distribution of genotypes between vCJD and controls (p=0.56 Fisher's exact test) or
between sCJD and the control population (p=0.13 Fisher's exact test). Comparing the
effect of carrying at least one -101G allele (i.e. treating CG heterozygotes and GG
homozygotes the same) showed that there was a larger proportion of carriers in sCJD
patients than in controls (10 of 27 sCJD, 28 of 116 controls). This is not a significant
difference (Fisher exact test p=0.131), but there is a trend towards G allele carriers being
more likely to develop sCJD with an odds ratio of 1.85.
The G to C polymorphism at +310 was sequenced in 26 sCJD, 16 vCJD and 110
controls (23 hospital controls, 51 Edinburgh and 36 Belfast controls). Despite the high
frequency of the C allele in sCJD patients and its absence in vCJD patients (Table 5-4)
neither of these differences were statistically significant (x2-test p=0.11 and 0.131
respectively). Analysing the difference in the number of carriers versus non-carriers in
patients and controls was also non-significant in sCJD and vCJD (Fisher's exact test
p=0.122 and 0.155 respectively).
The T to C polymorphism at +385 was sequenced in 26 sCJD 16 vCJD and 110 controls
(23 hospital controls, 50 Edinburgh controls and 37 Belfast controls.). There was no
significant difference in allele frequency between the control and sCJD groups (p=0.86)
(Table 5-5). The frequency of the C allele in vCJD patients (0.156) was almost 3 times
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that of the control group (0.054) and this difference just reaches statistical significance
(p=0.049 Fisher's exact test). The effect of carrying a +385C allele on susceptibility to
vCJD was examined by comparing the proportion of vCJD patients who were carriers
with control (4 of 16 vCJD, 11 of 110 controls).This gives an odds ratio of 3.0 but the
numbers are not large enough to reach significance (p=0.099).
Preliminary analysis of the three polymorphisms therefore shows that all are found in
both disease and control groups suggesting that the polymorphisms do not act as the sole
determinants of disease. The +310C allele is not found in vCJD patients possibly
suggesting that it may decrease an individual's susceptibility to vCJD but the absence
of this allele is not significant.
Table 5-3 C-101G allele. Genotype and allele numbers and frequencies in
sCJD, vCJD and controls.
The numbers of alleles and genotypes in sCJD and vCJD patients were compared with
those of the control population and deviations from what would be expected from
random distribution analysed using Fisher's exact test of a chi-squared test.
sCJD vCJD All Controls
cc 17(0.63) 13(0.68) 88(0.76)
CG 8(0.30) 6(0.32) 26(0.22)
GG 2(0.07) 0 2(0.02)
Fisher's exact test p=0.13 p=0.56
C 42(0.78) 32(0.84) 202(0.87)
G 12(0.22) 6(0.16) 30(0.13)
X2 test p=0.08 p=0.63
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Table 5-4 G+310C allele. Genotype and allele numbers and frequencies
in sCJD and vCJD and controls.
sCJD vCJD All Controls
GG 20(0.77) 16 97(0.88)
CG 6(0.23) 0 13(0.12)
CC 0 0 0
Fisher's exact test p=0.12 p=0.16
G 46(0.88) 32 207(0.94)
C 6(0.12) 0 13(0.06)
X2 test p=0.11 p=0.13
Table 5-5 T+385C Genotype and allele numbers and frequencies in
affecteds and controls.
sCJD vCJD All Controls
TT 23(0.88) 12(0.75) 99(0.90)
TC 3(0.12) 3(0.19) 10(0.09)
CC 0 1(0.06) 1(0.01)
Fisher's exact test p=0.83 p=0.13
T 47(0.94) 27(0.84) 208(0.95)
C 3(0.06) 5(0.16) 12(0.05)
Fisher's exact test p=0.86 p=0.049
5.2.4 Linkage with codon 129
To determine if linkage between the regulatory region polymorphisms and codon 129
exists which would affect the frequencies of the polymorphisms in sCJD, vCJD and the
control population, each polymorphism was examined for linkage disequilibrium.
C-101G: In order to determine if the -101G allele is in linkage dis-equilibrium with
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either methionine or valine at codon 129 in the ORF, the -101/codon 129 haplotype was
inferred from the genotypes of the control population. CJD patients were excluded from
this analysis as they have been selected for methionine homozygosity and may also have
been selected for particular regulatory region alleles and this could lead to an erroneous
assumption of linkage to codon 129 methionine. The haplotype can be inferred in all
individuals except those heterozygous at both positions (Table 5-6). A Fisher's exact test
for independent assortment of haplotypes shows that the distribution is not random
(p=0.005) and all 20 G alleles whose linkage can be inferred are linked to methionine
at codon 129.
This method of analysis ignores double heterozygotes, as their haplotype cannot be
deduced. However, the data from double heterozygotes can be used to estimate the
frequency of the four haplotypes. An Estimation-Maximisation (EM) algorithm has been
devised (Weir, 1990) which uses reiteration to find the haplotype frequencies which best
fit the data. Firstly, an estimate is made of one haplotype frequency (in this example the
frequency of-lOlC codon 129 methionine haplotype=MC) which allows the other three
haplotype frequencies to be calculated.
Step 1. Estimate of MC haplotype frequency = p' MC (p' is an estimated
frequency)
The other haplotypes frequencies can then be calculated from the allele frequencies of
codon 129 Met and -101C in table 5-6
Step 2. p' MG= pM - p'MC (pM is the known frequency of the M allele.)
p' VC= pC - p'MC
p'VG=l- pM- pC + p'MC
The haplotype frequencies can then be used to calculate the proportion of double
heterozygotes who have the two common alleles in cis (on the same chromosome i.e.
MC/VG) rather than in trans (on different chromosomes i.e. MG/VC) assuming random
mating.
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Step 3 Frequency of in cis double heterozygotes = 2 X p'MC X p'VG
Frequency of in trans double heterozygotes = 2 X p'MG X p'VC
Proportion of double hets who are in cis = (2 X p'MC X p'VG)/((2 X p'MC X
p'VG)+ (2 X p'MC X p'VG))=K'
A new estimate of the original estimated haplotype (p"MC) can then be calculated using
the frequencies ofMC haplotypes, which can be calculated from Table 5-6, plus the
estimate of the number of double heterozygotes carrying that haplotype. The frequency
of MC haplotypes is equal to twice the number of MMCC individuals (2 MC
chromosomes) plus the number of MVCC, MMCG and in cis MVCG (double
heterozygotes) who each have one MC haplotype, divided by the total number of
haplotypes.
Step 4 p"MC = ((2 X pMMCC) +pMVCC +pMMCG+(K' X pMVCG ))/total
number of haplotypes.
pMMCC is the frequency of individuals ofgenotypeMM at codon 129 and CC at -101,
which can be calculated from Table 5-6.
The new estimate of the frequency ofMC haplotypes p"MC is then used in step 2 to
calculate the other haplotype frequencies and a new in cis homozygote proportion K"
in step 3 and a new estimate ofMC frequency (p"'MC) in step 4. After several cycles,
the estimates ofMC frequency converge until eventually the new estimate equals the
previous estimate. This gives the haplotype frequencies which are most likely to give
the genotype combinations seen in the original table. The choice of initial MC haplotype
does not affect the final frequency, as the same final haplotype frequencies are found
using several different initial estimates.
Applying this method to -101 and codon 129 gives estimated haplotype frequencies
which support linkage disequilibrium between -101G and 129C (MC haplotype
frequency=0.586, MG=0.129, VC=0.284, VG=0.0000021). A larger study may find
individuals who have VG alleles but this study indicates that this haplotype is absent or
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extremely rare. This could reflect a relatively recent origin of the -101G mutation which
occurred on a codon 129 methionine allele and not enough time has occurred to allow
recombination. Examination of polymorphic markers upstream and downstream of
PRNP could determine if all -101G alleles share a common haplotype, indicating a
single mutation.
To control for the linkage of-lOlG to codon 129M the study population was sub¬
divided by codon 129 genotype. As all vCJD individuals and 22 of29 sCJD patients are
methionine homozygotes, they were compared with the 61 MM controls. Despite the
high proportion ofMM sCJD patients that carry at least one G allele compared withMM
controls (resulting in a relative risk of 2.4), this difference did not reach statistical
significance (p=0.095) (table 5-7). There were no MV and VV sCJD patients who
carried -101G but the numbers were too small for this absence to be significant.
Table 5-6 Linkage disequilibrium between Codon 129 and -101
All individuals sequenced at -101G and codon 129 were classed according to their
genotype combination. The genotypes were inferred in all individuals except the 10
double heterozygotes e.g. the 43 MM CC individuals have 86 M-C chromosomes, the
34 MV CC individuals have 34 M-C and 34 V-C chromosomes etc. All the
chromosomes deduced in this manner were counted and random assortment tested in
a chi-squared test.
n=116 Codon 129 Genotype
-101 Genotype MM MV VV
CC 43 34 rr
CG 16 10 0
GG 2 0 0
Haplotypes M V Total
C 136 56 192"
G 20 0 20
Total 156 56 2l2~
Chi-squared test p=0.005 Linkage disequilibrium between -101Gandl29M
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Table 5-7 Effect of-101G on sCJD and vCJD susceptibility in codon 129
methionine homozygotes
vCJD sCJD Controls
-101G carriers 6 10 18
Non-carriers 13 10 43
Odds ratio and p value relative to OR=l.l p=0.86 OR=2.4 p=0.095
controls.
G+310C: In order to determine if the +310C allele is in linkage disequilibrium with the
codon 129 polymorphism the haplotype was inferred from the genotypes of the control
population. The C allele was found linked to both methionine and valine and although
there was a higher frequency on V alleles there was no significant linkage disequilibrium
(p=0.369) (Table 5-8). The EM Algorithm estimates that the haplotype frequencies are
not what would be expected under independent assortment and show partial linkage
disequilibrium between codon 129 valine and +310C (Table 5-9). If these haplotype
frequencies are applied to the 220 chromosomes in table 5-8 the difference reaches
significance (p=0.02). Therefore partial linkage disequilibrium may exist and has to be
accounted for when analysing the effect of the polymorphism on disease.
Table 5-8 Linkage disequilibrium between Codon 129MV and +310 GC
n=l 10 Codon 129 Genotype
+310 Genotype MM MV VV
GG 53 36 8
CG 4 6 3
CC 0 0 0_
Haplotypes M V Total
G 146 55 201
C 4 3 7
Total 150 58 208
Fisher's exact test. p=0.304
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Table 5-9 Estimated +310/codon 129 haplotype frequencies compared
with the expected values under linkage equilibrium.
Haplotype Expected Algorithm Estimate Difference
MG 0.667 0.686 +0.019
MC 0.042 0.023 -0.019
VG 0.274 0.255 -0.019
VC 0.017 0.036 +0.019
To control for linkage disequilibrium, the presence of +310C alleles was examined in
controls, sCJD and vCJD patients of all three codon 129 genotypes (Table 5-10).
Analysing MM individuals show no significant difference between the controls and
either vCJD or sCJD. The numbers of sCJD patients ofMV and VV genotypes are small
and although statistical significance is not reached, there is a trend towards VV +310C
carriers being more susceptible to sCJD and MV +310C carriers being extremely
susceptible to sCJD.
Table 5-10 The effect of the +310C allele on sCJD and vCJD susceptibility
by codon genotype 129.
Codon 129 MM MV VV
Status vCJD sCJD Controls sCJD Controls sCJD Controls
Carriers 0 2 4 2 6 2 3
Non-carriers 16 17 53 1 36 2 8
OR, p value OR=0 p=0.62 OR=0.64 p=0.62 OR==12.0 p=0.08 OR=2.7 p=0.41
T+385C: Analysing control haplotypes for linkage of the +385C allele to codon 129
shows that all of the 7 +385C alleles for which linkage can be determined in the control
population are linked to Methionine alleles at codon 129 (Table 5-11). This does not
reach significance (p=0.093) but the EM algorithm estimates the VC haplotype
frequency at 3.6 X 10~7 which supports linkage disequilibrium between +385C and
codon 129M. Although the rarity of the +385C allele means that a larger sample is
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needed to confirm that no VC haplotypes exist.
Table 5-11 Linkage disequilibrium between Codon 129 and +385
n=l 10 Codon 129 Genotype
+385 Genotype MM MV VV
TT 51 37 11
TC 5 5 0
CC 1 0 0
Haplotypes M V Total
T 144 59 203
C 7 0 7
Total 151 59 210
Fisher's exact test. p=0.095 +385C approaching linkage disequilibrium to 129 Met.
To control for linkage disequilibrium, the presence of +385C alleles was examined in
controls, sCJD and vCJD of all three codon 129 genotypes (Table 5-12). In sCJD there
were no significant differences between MM sCJD and controls, and while no MV or
VV sCJD patients carried the allele this is not a significant difference. Analysing the
numbers of vCJD patients carrying at least one copy of the +385C allele with MM
controls shows that there is no statistically significant difference, although there is a
trend towards it increasing susceptibility to vCJD (Odds ratio=2.8).
Table 5-12 Effect of +385C allele on sCJD and vCJD susceptibility by
codon 129 genotype.
Codon 129 MM MV VV
Status vCJD sCJD Controls sCJD Controls sCJD Controls
Carriers 4 3 6 0 5 0 0
Non-carriers 12 16 51 3 37 4 11
OR and p value OR=2.8 OR=1.6 OR=0 NA
p=0.218 p=0.54 p=0.52
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Linkage disequilibrium analysis of the three polymorphisms therefore shows that the -
101G allele and the +385C allele are in linkage disequilibrium with codon 129M. The
+3IOC allele is found linked to both V and M at codon 129 but is predominantly linked
to V. Re-analysing the results taking linkage disequilibrium into consideration shows
that -101G increases the risk ofMM individuals to sCJD, +310C increases the risk of
sCJD in codon 129 heterozygotes and that the +385C allele is more common in vCJD
patients than MM controls. However none of these results reach statistical significance
as all three alleles are relatively rare and do not have very large effects on disease
susceptibility to reach highly significant results in a case-control study of this size.
As the three regulatory region polymorphisms are very close to each other, there may
be considerable linkage disequilibrium between them as recombination will occur very
infrequently. Analysing each pair of the three regulatory polymorphism shows that the
haplotype distribution of-101G and +310C (Table 5-13) is not significantly different
from random distribution even if the single double heterozygote is considered as a
CG/GC or as a CC/GG. Similarly, despite both being linked to codon 129M, the -101G
and +385C alleles do not appear to be linked to each other (Table 5-14). However, the
two individuals heterozygous at positions -101 and +385 are also heterozygous at codon
129. This means that either -101G and +385C are linked together on the M allele of
these individuals or that one of the polymorphisms is linked to V at codon 129. These
two alternatives can only be resolved by cloning and sequencing both alleles from both
individuals. There was no linkage disequilibrium between +310 and +385, all the
haplotypes could be deduced as there were no double heterozygous individuals (Table
5-15)
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Table 5-13 linkage disequilibrium between -101 and +310 in control
population
n=99 -101 Genotype
+310 Genotype CC CG GG
GG 65 21 2
GC 10 1 0
CC 0 0 0
Haplotypes C G Total
G 161 25 186
C 10 0 10
Total 171 25 196
Fisher's exact test. p=0.367 No linkage disequilibrium
Table 5-14 Linkage disequilibrium between -101CG and +385TC
n=100 -101 Genotype
+385 Genotype CC CG GG_
TT 68 20 2
TC 8 2 0
CC 0 0 0_
Haplotypes C G Total
T 164 24 188
C 8 0 8
Total 172 24 196
Fisher's exact test. p=0.599 No linkage disequilibrium.
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Table 5-15 Linkage disequilibrium between +310 and +385
n=109 +310 Genotype
+385 Genotype GG CG CC
TT 85 13 0
TC 10 0 0
CC 1 0 0
Haplotypes G C Total
T 193 13 206
C 12 0 12
Total 205 13 218
Fisher's exact test. p=0.369 No linkage disequilibrium.
5.2.5 Could more than one regulatory region
polymorphism have an effect?
The previous analysis of each polymorphism implicitly assumed that the other two
polymorphisms had no effect on susceptibility, as the number of carriers of a given allele
was compared with the number of non-carriers in patients and controls. This method of
analysis excludes the possibility that two or possibly all three polymorphisms could each
have an effect on susceptibility. To determine ifmore than one allele has an effect on
susceptibility, the haplotype (the status of each regulatory region polymorphic site on
each chromosome) of each individual was examined to determine if the regulatory
region polymorphisms may act co-operatively. This can only be done in the 141
individuals who have been sequenced at all three polymorphic positions, (100 controls
25 sCJD and 16 vCJD). The "wild-type" haplotype CGT (-101 :+310:+385) is the most
frequent the others being GGT, CCT and CGC (rare allele in bold) each having one of
the rare alleles. Two individuals are heterozygous at positions -101 and +310 and two
heterozygous at positions -101 and +385. Due to the fact that a PCR product was
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sequenced it is impossible to determine if these individuals have one rare allele on each
chromosome or two rare alleles on one chromosome and a wild-type haplotype on the
other i.e. a genotype of GGT/CCT or CGT/GCT for the two individuals heterozygous
at the first two polymorphic sites.
Analysing the 141 individuals sequenced at all three positions (Table 5-16) showed that
individuals who carried any of the rare alleles -101G, +310C or +385C are significantly
more likely to develop sCJD than those who did not (odds ratio=2.93 p=0.02 x2-test).
As only one sporadic and three control individuals carry rare alleles at two loci this
increased risk is not due to an additive effect of the rare alleles. It may be due to two or
more alleles each independently increasing susceptibility to sCJD. In this model, the
effect of a polymorphism can only be analysed by comparing carriers to individuals who
are homozygous for the common allele at all three positions. This is because comparing
carriers of an allele to individuals who lack that allele but may be carrying susceptibility
alleles at another locus could mask the effect of both alleles. To analyse the effect of
each position, the 141 individuals sequenced at all three positions were sub-divided by
any rare allele they possessed and by codon 129 genotype as this affects the frequency
of all three rare alleles (Tables 5-17, 5-18, 5-19).
Table 5-16 Effect of carrying at least one rare allele on vCJD and sCJD
susceptibility.
vCJD sCJD Control
Carry at least one rare allele 9 17 42
Common allele at all three 7 8 58
Odds ratio and probability OR=1.78 OR=2.93 p=0.02
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Table 5-17 The effect of-101G on susceptibility to vCJD and sCJD.
Individuals homozygous for -101C but carrying other regulatory region polymorphisms
have been excluded, leaving only -101G carriers and wild-type individuals. The vCJD and
sCJD patients were divided by codon 129 genotype and compared with controls of the
same genotype. Differences in the proportions of carriers and non-carriers were used to
calculate the odds ratio and the probability of such different proportions occurring by
chance. a=includes two homozygotes, b=includes one individual heterozygous for +310C,
concludes two individuals heterozygous for +385C. NA=not applicable as no patients or
controls carry a-lOlG allele.
vCJD sCJD Controls
Codon 129 MM All MM MV VV All M MV VV
-101G carrier 5 9 9ab 0 0 24 14a 10bc 0
Wild type 7 8 5 1 2 58 30 21 7
Total 12 17 14 1 2 82 44 31 7
Odds ratio 1.5 2.7 3.86 0 NA
Probability 0.5 0.06 0.03 0.5 1.0
Table 5-18 The effect of the +310C allele on susceptibility to vCJD and sCJD.
Individual of genotype +310GG carrying other regulatory region polymorphisms have
been excluded, b=includes one individual heterozygous for-lOlG
vCJD sCJD Controls
Codon 129 MM All MM MV VV All MM MV VV
+310C carrier 0 6 2b 2 2 11 3 5b 3
Wild type 7 8 5 1 2 58 30 21 7
Total 7 14 7 3 4 69 33 26 10
Odds ratio 0 3.95 4.00 8.40 2.33
Probability 0.41 0.02 0.16 0.07 0.48
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Table 5-19 The effect of +385C on susceptibility to vCJD and sCJD.
Individuals of genotype +385TT carrying other regulatory region polymorphisms have
been excluded, a=Includes one homozygote, c=includes two individuals heterozygous for
-101G. NA=not applicable as no patients or controls carry a I 385C allele.
vCJD sCJD Controls
Codon 129 MM All MM MV VV All M MV VV
+385C carrier 4a 3 3 0 0 10 5 5C 0
Wild type 7 8 5 1 2 58 30 21 7
Total 11 11 8 1 2 68 35 26 7
Odds ratio 3.43 2.18 3.60 0 NA
Probability 0.11 0.30 0.13 0.63 0.99
Comparing the number of carriers of -101G and wild-type individuals in vCJD andMM
controls showed no significant differences. Similarly, there were no significant
differences when the effect of +3IOC was considered in vCJD patients. There was a
trend towards +385C carriers having an increased risk of vCJD but this did not reach
statistical significance.
Comparing sCJD and controls showed an excess of carriers of -101G relative to wild-
type controls which approached statistical significance. When the linkage of -101G to
codon 129 was considered and MM homozygotes were examined the effect of -101G
was statistically significant and had a higher relative risk. No MV or VV sCJD
individuals carried any -101G alleles, but this was not significant. The number of+310C
carriers was significantly higher in sCJD patients than controls when compared with the
number of wild-type individuals. Sub-dividing by codon 129 genotype showed no
statistically significant differences between sCJD patients and controls. However, this
lack of significance is due to the reduction in numbers and is not caused by linkage to
codon 129, as the odds ratio was unchanged inMM individuals, greatly increased inMV
individuals and decreased in VV individuals. The +385C allele was found in more sCJD
patients than controls but this was not significant. Stratifying by codon 129 showed that
there was an increased relative risk inMM sCJD (RR=3.43) but this difference was not
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significant (p=0.1).
To summarise +310C and -101G independently increase an individual's susceptibility
to sCJD. The +3IOC allele significantly increases susceptibility in all individuals but the
effect was greatest in codon 129 heterozygotes while -101G increases susceptibility in
methionine homozygotes. The +385C allele did not reach statistical significance as a
susceptibility factor although there is a trend towards it being a susceptibility factor to
both sCJD and vCJD in methionine homozygotes. One possible problem in this method
of analysis is that the wild-type individuals used to compare with carriers are the same
for each allele, therefore any sampling error of the proportions of healthy or CJD wild-
type individuals will affect all the results.
5.2.6 Effect of polymorphisms on age of onset and
duration of disease
In order to determine if the polymorphisms affect clinical parameters of disease the age
of onset of the disease and the duration of disease was examined in vCJD and sCJD
patients. Alterations in expression patterns or levels could influence an individual's
susceptibility to infection or progression of disease once the disease has become
established.
The age of onset of disease and duration of disease of the 16 vCJD patients sequenced
at all three regulatory region polymorphic loci are shown in Figure 5-7. Neither -101G
nor +385C had any significant effect on disease although the individual with the longest
duration of disease was homozygous for +385C. No vCJD patient carries the +3 IOC
allele.
The age of onset of disease and duration of disease of the 25 sCJD patients sequenced
at all three regulatory region polymorphic loci are plotted in Figure 5-8. Analysing the
age of onset of disease showed a trend towards +385C carriers having a younger age of
onset than non-carriers (58.3 years and 66.4 years respectively) but this is not significant
(t-test p=0.19). Previous studies have that 18% ofVV sCJD cases occur in people under
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the age of 50 compared with 9% ofMV cases and 4% ofMM cases (Alperovitch et ah,
1999). To determine if the regulatory region polymorphisms have an effect on disease
when divided by codon 129 genotype the population was split into the 18 MM, 4 VV
and 3MV individuals. Among MM homozygotes +385C carriers had a younger age of
onset (58.3 years) than non-carriers (67.4) but this was not significant (t-test p=0.16).
There was no effect seen in +310C or -101G carriers.
Three sCJD patients were atypical in being quite young and had very long duration of
illness (The three individuals on the extreme left of figure 5-8). Two of these individuals
were the only sCJD patients who were heterozygous at +310 and codon 129. This may
suggest an interaction between the two polymorphisms, as the other +310C carriers are
unremarkable as is the other codon 129 heterozygote. The other atypical individual was
the youngest sCJD patient who was a methionine homozygote and homozygous for the
common allele at the regulatory region polymorphisms. The patient was suspected of
being a vCJD case on clinical grounds but neuropathological examination showed the
features of sCJD. The re-classification of this individual removed a potential significant
association between +385C and a younger age-of-onset in MM sCJD patients as if that
individual is excluded the average age-of-onset ofMM CJD patients who do not carry
+385C rises to 69.4 years and the p value when the ages are compared to the +385C
carriers is 0.016. However this is based on a very small number of carriers (3) and a
larger study is required to determine if +385C affects the age-of-onset of sCJD.
Despite there being no statistically significant effect on clinical parameters in this study
of sCJD and vCJD cases, the relationship between the three regulatory region
polymorphisms and codon 129 are so complex with a large number of possible
interactions that a very large study of 200 sCJD patients will be needed to detect any
significant effect. Other phenotypic differences among sCJD patients that could be
examined to determine if they are be influenced by the regulatory region
polymorphisms, include neuropathology, PrPres isotypes and specific clinical features
such as the presence or absence of abnormal EEG patterns. These could also be
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The effect of Polymorphisms on disease.
Three polymorphisms were identified within or adjacent to the regulatory regions of the
PRNP as defined by deletion assay. Analysis of the presence ofpolymorphisms in sCJD,
vCJD and control individuals has shown that carrying either of two of the
polymorphisms (-101G and +3IOC) increases an individual's susceptibility to sCJD but
not to vCJD, while there is a trend towards carriers of the +385C polymorphism being
more susceptible to vCJD.
This study has identified methionine homozygous -101G carriers as a sub-group within
methionine homozygotes that is more susceptible to sCJD. Previous studies have shown
that codon 129 methionine homozygotes are more likely to develop sCJD than valine
homozygotes while heterozygotes are least likely to develop sCJD. This results in 70%
of sCJD cases occurring in the 40% of the Caucasian population who are MM
(Alperovitch et al., 1999). The difference in susceptibility between MM and VV
homozygotes is not necessarily due to the differing structures of the codon 129 M and
V PrP proteins as valine homozygotes are more susceptible than methionine
homozygotes to iatrogenic CJD. This study has now shown that MM -101G carriers
(11% of the total Caucasian population) account for half ofMM sCJD cases (35% of
total sCJD cases). In contrast, MM non -101G carriers (29% of the total population, 35%
of sCJD cases) are no more susceptible to sCJD than VV individuals (11% of the
population, 16% of sCJD cases)(Figure 5-9). Therefore, the effect of codon 129 in
affecting susceptibility to sCJD is influenced by linked regulatory polymorphisms.
Perhaps homozygosity at codon 129 is the major susceptibility determinant of sCJD
while -101G plays a minor role. The effect of -101G may not be sufficient to alter the
susceptibility of heterozygotes and as -101G appears to be linked to methionine, its
effect is only apparent in methionine homozygotes. This model would explain why
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The +3IOC allele increases susceptibility to sCJD when the effects of other
polymorphisms are excluded. Its effect is strongest inMV individuals, although this is
based on a very small sample. The +3IOC allele is absent in vCJD patients, but this can
be accounted for by it being predominantly linked to valine at codon 129 as all vCJD
patients are methionine homozygotes.
There is a trend towards +385C MM carriers being more susceptible to both sCJD and
vCJD, but neither reaches significance. sCJD patients heterozygous for +385C also have
a younger age of onset compared with other sCJD patients, but this is not significant
although as there are only three such patients a larger sample size is needed to further
examine the effect of this polymorphism on the age at onset of sCJD.
The different effects of the polymorphisms on susceptibility to sCJD and vCJD may
reflect different effects variation in PrP expression plays in the two diseases. While
vCJD is probably contracted by the oral route, the aetiology of sCJD is unknown; it may
occur spontaneously by somatic mutation of the PrP ORF, or spontaneous mis-folding
of a PrP protein to the pathogenic PrPSc conformation or be caused by an as yet
unrecognised infectious agent. The results presented here suggest that two regulatory
loci, -101 and +310 affect susceptibility to sCJD. These polymorphisms may achieve
this by altering PrP expression patterns which may alter the efficiency with which
infectivity replicates in an individual, resulting in differing susceptibilities to sCJD in
the population. It is possible that increased expression in a particular tissue could
increase susceptibility to spontaneous sCJD but have no effect on the probability of a
vCJD infection developing into disease.
Differences in expression levels could also affect the age at disease onset or duration of
disease (onset of clinical signs to death). However, carrying a rare allele at -101, +310
or +385 had no significant effect on the age distribution or length of disease in sCJD or
vCJD patients in this study. Given the large number ofpotentially interacting factors the
number of sCJD and vCJD patients in this study is too low to definitively rule out an
effect of the regulatory alleles on the incubation period or age at disease onset of either
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form of CJD. If this lack of association is confirmed in a larger study this would suggest
that although susceptibility to sCJD is affected by the polymorphisms the incubation
period is not. This could be reconciled with a model where the transition between the
first step of sCJD (infection, somatic mutation or spontaneous conversion to PrPSc) and
the start of the incubation period is controlled by PrP expression levels or patterns. This
transition stage could be influenced by the polymorphisms, perhaps by localised over-
expression in a tissue involved in the transport or replication of infectivity, but once this
critical point has been passed the incubation periods are similar.
5.3.2 Polymorphisms and transcription factor binding
sites.
The regulatory region polymorphisms may affect susceptibility to disease by altering
binding of transcription factors. To determine if either of the alleles at any of the three
polymorphisms altered a transcription factor consensus binding sites, the sequences were
analysed using transcription factor databases (The GCG9 file tfsites.dat and the
TFSITES search site at http://pdapl.trc.rwcp.or.jp/research/db/TFSEARCH.html).
At the -101 polymorphism neither the G nor C allele created or destroyed any known
transcription factor binding consensus sites. The -101 polymorphism lies upstream of
the transcription regulatory region identified by transient transfection studies in
neuroblastoma cells (-43 to -9). It is possible that this region affects expression in other
tissues which would not be detected using the neuroblastoma transient transfection
system, or that the -101G polymorphism creates a new transcription factor binding site
thus extending the upstream regulatory region.
Sequencing of the lambda clone sequence used in the transfection assays showed that
its haplotype was CGC i.e. it contains the +385C polymorphism. The presence of the
+385C allele creates a BSSHll restriction site which was used to create deletion
A+296:+384. This relatively small deletion had a very large effect, reducing expression
by 50% indicating that this region, which contains +310, is a good candidate region for
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mutations which affect PRNP expression. As the wild-type allele lacks the BssHll
restriction site this deletion cannot be replicated in the more common CGT haplotype.
The G to C polymorphism at +310 gives rise to a GC factor (GCF) consensus site on the
complementary strand. GCGGGGC (GCCCCGC on coding strand). This factor has
been shown to repress expression ofEGFR (Epidermal growth factor receptor) and IGF-
1R (insulin like growth factor 1 receptor), while mutation of the binding site in the
adenylphosphoribosyltransferase gene (APRT) increases expression (She and Taylor,
1995) (Morrione et al., 1995) (Kitadai et al., 1993). The +310C polymorphism could
therefore reduce expression of PrP. However, construct A+292:+382, which removed
this putative GCF site, has only 50% of CAT expression levels relative to the full (-
1558) construct. This result does not support the existence of a repressor element in this
region. The GCF sequence may have no functional significance in PRNP, or that GCF
acts as a positive transcription factor in PRNP in contrast to other genes. Alternatively,
an uncharacterised transcription factor could bind to this sequence. Gel mobility assays
are needed to determine if this sequence binds transcription factors in vivo. The
polymorphism also removes a CpG site but creates one (CGG to CCG) whether this
subtle change would affect methylation of cytosines which inhibits transcription is
unknown.
The T to C polymorphism at +385 was also present in lambda clone 314 from which all
the deletion constructs were made. This polymorphism creates the BssHll (GCGCGC)
restriction site which was used in the creation of construct A+292:+382, which identified
the 90bp region whose removal reduced expression by 50%. Analysing transcription
factor binding consensus sites shows that the polymorphism creates a second AP-2 site
(which overlaps an existing site), a P3A transcription factor site, a metal response
element TGCRCNC consensus binding site (Langmade et al., 2000) and a modulator
binding factor consensus site TGCRCRC (Palla et al., 1994). Clearly not all of these
factors can bind to this site in vivo but binding of one of these transcription factors or
a different factor in the polymorphism could result in higher expression than in wild-
type alleles. As all of these sites are destroyed in construct A+292:+382 they are
candidates for expression modulating factors. Gel-binding assays are needed to
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determine if the transcription factors actually bind to their consensus sites created by the
polymorphisms which could implicate a role in vivo which would correlate the increased
risk ofCJD of carriers of this polymorphism.
5.3.3 Future work
As the three polymorphisms found in this study appear to influence susceptibility to
sCJD their effect in vitro and in vivo should be tested. In vitro mutagenesis can be used
to firstly convert the construct used in the deletion assay (haplotype CGC) to the wild-
type CGT haplotype. A second round of in vitro mutagenesis on that construct will then
create GGT and CCT constructs which can be transfected into a range of cell types to
determine the effects of the various polymorphisms on expression. To determine if any
of the polymorphisms affect transcription factor binding, gel mobility assays can be
performed using cell extracts from different cell lines and oligonucleotides encoding the
three common and rare regulatory region alleles. The creation of a metal response
element by the +385C polymorphism may affect the expression ofPrP in response to
metals. Ifpermanently transfected cells lines were made with this construct they could
be used to determine if expression is affected by copper levels or oxidative stress which
have been proposed as possible functions ofPrP (Brown et ah, 1999).
The effect of the alleles in vivo could be examined by creating transgenic mouse models
that contain reporter genes driven by the different alleles. These models could show in
which tissues PrP expression is affected by the alleles and may therefore play a role in
increasing susceptibility to disease. This might implicate particular tissues in disease
pathogenesis which have not previously been recognised as important. It is also possible
that the apparent effects of these alleles could be due to other polymorphic sites outside
of the region sequenced which are in linkage disequilibrium with those identified in this
study. This could be resolved by sequencing larger regions or carrying out deletion
assays on a larger sequence.
As the number, frequency, effect and linkage disequilibrium of any regulatory region
polymorphisms was unknown at the start of this project, this study was designed to
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detect any rare polymorphism which had a very large effect on susceptibility to sCJD
or vCJD. This study was not designed to achieve very high probability values for several
polymorphisms each with relatively weak effects on disease as now appears to be the
case. Now that the -101G and +310C alleles have shown an association with sCJD, and
the +385C alleles may affect vCJD, further larger studies can be designed to confirm the
effect of these polymorphisms on CJD. To examine the possible effect of+385 on vCJD,
a study which sequences 50 vCJD and 100 codon 129 MM controls would reach a
significance of 0.022 if the proportions found in this study were maintained. A future
study of -101G which examines 50 codon 129 MM sCJD and 100 controls would reach
a significance of 0.0001 if the same proportions of carriers and non-carriers found in this
study is replicated. To determine the effect of+310C sequencing 20 MV sCJD and 40
MV controls would result in a significant result (p=0.002).
The polymorphisms may also have an effect in familial TSEs by increasing expression
of a mutant PrP allele or by influencing disease if it is carried on the non-mutant allele.
This could account for the reduced penetrance and clinical heterogeneity seen in some
familial TSEs. Even if the regulatory region polymorphisms do not affect familial
disease, they may serve as markers to facilitate haplotyping of mutated PrP genes to
determine the relationships between different kindreds with a similar mutation. It would
be interesting to determine if -101G and +310C are present in the Japanese population
and have a similar effect on susceptibility to sCJD.
This result shows that in addition to the codon 129 polymorphism, two polymorphisms
within or adjacent to regulatory regions of the PRNP gene affect sCJD susceptibility.
These polymorphisms could act by increasing the overall levels of PrP expression or
expression levels in particular tissues thereby increasing interactions between PrP
molecules leading to a lower age at onset of disease or a greater susceptibility to disease.
Further in vivo, in vitro and sequencing studies are needed to confirm the effect of these
polymorphisms on susceptibility to variant and sporadic CJD.
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6. Summary and Conclusions
This project is the first characterisation of regulatory regions of the human PRNP gene
and the first to identify genetic loci outside of the PrP ORF which affect susceptibility
to sCJD or vCJD. Based on studies of regulatory regions in other species, 4.8 Kb of
sequence, containing 1.5Kb of upstream sequence, the first exon and 3.1Kb of intron,
was cloned from a human genomic lambda library into a CAT reporter gene. Transient
transfections in human neuroblastoma cells of this construct and of nested deletions of
this construct, identified two regulatory regions, one between -43 and -9 bases upstream
of the transcription initiation site and one within the intron between +292 and +622. The
consensus transcription factor binding sites found in the upstream sequence are similar
to that seen in other species while intronic regulatory regions have been found in the first
introns of the murine and bovine PrP genes.
Having identified two regulatory regions in neuroblastoma cells the effect of the two
regulatory regions in vivo was examined by making three constructs where expression
of a LacZ reporter gene was driven by wither the 4.8Kb human fragment, the upstream
and exon sequence alone or the exon and intron sequence. These constructs were
designed to determine if the 4.8Kb region contained sufficient regulatory elements to
express the reporter gene with the same tissue specificity as PrP and to determine the
effects of the upstream and intronic regulatory region independently. Another construct
which contained 3.4Kb ofmurine sequence containing upstream sequence, first exon
and intron sequence of the Prnp gene was used as a control. Although all four constructs
were successfully injected into fertilised eggs giving rise to transgenic embryos and
adults, no LacZ expression was detected although faint background staining was
observed in all embryos after staining for 48 hours. The failure of the constructs to
express may be due to lack of sufficient regulatory elements to drive expression in entire
organisms as all four constructs expressed LacZ when transiently transfected into murine
neuroblastoma cells.
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The upstream and intronic regions were sequenced in sCJD, vCJD and control
individuals to determine if any polymorphisms or mutations exist in the regulatory
regions which affect susceptibility or directly cause either form of CJD. Three
polymorphisms were identified; a C to G transvcrsion at position -101 relative to the
start of exon one was found at an allele frequency of 13% in control individuals, a G to
C transversion at +310 found at a frequency of 6% in controls and a T to C transition at
position +385 found at a frequency of 5% in controls. While the +310 and +385
polymorphisms lay within the 330bp intronic region which affects expression, the -101G
allele lay outside the upstream regulatory region, but was detected in sequencing as this
position is adjacent to the upstream regulatory region. It is possible that sequence
changes at this position could affect the binding of transcription factors and therefore the
activity of the upstream regulatory region.
Analysis of the frequency of these polymorphisms in sCJD patients and controls showed
that the -101G and +310C alleles each independently significantly increase an
individual's risk of developing sporadic CJD. Both alleles were analysed for linkage
disequilibrium to the polymorphic codon 129 methionine/valine polymorphism, which
is known to affect sCJD and vCJD susceptibility. The -101G allele is linked to the
methionine allele and effect of the -101G allele only reached significance in codon 129
methionine homozygotes. Similarly, the +310C allele is in linkage disequilibrium with
valine at codon 129 and although there was a trend towards codon 129 heterozygotes
who carry the +310C allele being more susceptible to sCJD than non-carriers, the
number of sCJD cases was too small to reach statistical significance when sub-divided
by codon 129 genotype. In vCJD, no allele reached statistical significance, although
there was a non-significant trend for carriers of the +385C being almost three-fold more
likely to develop vCJD. Due to the large number ofpotential interactions between the
regulatory region and codon 129, a larger study is needed to confirm the associations
found in this study.
How these polymorphisms may influence susceptibility to sCJD is not yet known. The
most likely explanation is that the polymorphic alleles affect PrP expression levels.
Reducing PrP expression levels results in a lengthening of TSE incubation periods in
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transgenic mice and it is therefore difficult to envisage how a decrease in expression
levels would increase susceptibility to human TSEs. The effect of the rare alleles is
therefore more likely to be an increase rather than a decrease in expression levels. If the
-101G and +3IOC alleles do increase PrP protein levels this could be due to increased
transcription levels or, in the case of the +3 IOC allele, an increase in mRNA stability
which could result in an increase in PrP protein levels. Analysis of the transcriptional
activity of these alleles in vivo and in vitro is necessary to determine if the
polymorphisms actually affect expression levels.
Relatively small changes in expression levels could conceivably affect the course of
disease (if the expression increase occurs in a tissue critical in the development of
disease) therefore, the relative levels of expression driven by different alleles will have
to be examined in a wide variety of human cell lines and tissues and in transgenic mice
expressing reporter genes to detect differences between different alleles. It is possible
that the apparent effect of the polymorphic alleles of increasing susceptibility to disease
may not be caused by those alleles but by linked polymorphisms or mutations located
outside of the region analysed in this study. In vitro testing of the effect of the
polymorphisms on expression could rule this possibility out if a difference in expression
levels can be detected between the different alleles.
The aetiology of sCJD is unknown. Previous work has identified heterozygosity at
codon 129 as a protective factor and that methionine homozygotes are more likely to
develop disease than valine homozygotes. This study has shown that codon 129
methionine homozygotes who carry -101G are more likely to develop sCJD than those
who do not. This could be reconciled with a model where difficulties in interactions
between the methionine and valine proteins in heterozygotes hinders the disease process
making them less likely to develop sCJD. While an increase in expression levels caused
by -101G leads to a greater likelihood of sCJD developing by increasing the rate of
replication of infectivity perhaps in the spleen, or efficiency of transport of the agent,
if the difference in expression levels is seen in the peripheral nervous systems. The
interactions between the codon 129 proteins appears to be a more important factor than
the levels of expression as codon 129 heterozygotes who carry -101G are at no more risk
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than those who do not carry the allele. Codon 129 may therefore be the main genetic
factor in determining susceptibility to sCJD with -101G as a secondary factor. But its
linkage to methionine means that only methionine homozygotes are at increased risk.
A similar model can be devised for the +3IOC allele, which has shown a trend towards
increasing the susceptibility of codon 129 heterozygotes to sCJD. Again differences at
codon 129 in the protein reduces the likelihood of disease occurring, but the +3IOC
allele may increase expression of one allele perhaps making an individual effectively
homozygous at codon 129 in a particular tissue if the majority of protein produced in
that tissue is either valine or methionine at codon 129. This could then increase the
likelihood of an individual developing sCJD. These two models are speculative and
further epidemiological and molecular analysis is required to determine if the
polymorphisms act in this manner. But these results have extended the spectrum of
susceptibility to human TSEs beyond the open reading frame of the PRNP gene.
Susceptibility to iatrogenic CJD could also be influenced by the regulatory region
polymorphisms and an examination of iCJD cases could show if the polymorphisms
affect susceptibility and the incubation period of iCJD. The interaction of regulatory
region polymorphisms with codon 129 could show a different effect in iCJD as, in
contrast to sCJD, valine homozygotes are more likely to develop iCJD than methionine
homozygotes.
Other forms of TSE such as BSE in cattle or CWD in deer could also be influenced by
variation in PrP expression levels or patterns. The best candidate for regulatory region
analysis may be scrapie in sheep as it has the most polymorphic PrP ORF suggesting
that scrapie has exerted considerable selective pressure in sheep. The identification of
regulatory regions could identify factors which cause scrapie and possibly lead to the
selection of highly resistant animals to breed resistance into affected flocks. It is also
possible that the apparent effect of some of the ovine protein polymorphisms could be
due to linkage disequilibrium with regulatory region polymorphisms.
The existence of regulatory region polymorphisms in the immediate upstream and
intronic regulatory regions that affect susceptibility to disease opens the possibility that
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other regulatory regions of the PRNP gene which lie outside of the region examined in
this study may also contain polymorphisms which alter expression and susceptibility to
CJD. The discovery of such regions could identify factors which determine
susceptibility to sCJD and/or vCJD which might allow a better estimate of the scale of
the vCJD epidemic by determining the variation in susceptibility to vCJD in the
population. A better understanding of sCJD and vCJD susceptibility factors would also
allow the identification ofuniquely susceptible individuals who could be candidates for




Sequence of lambda clone 314
Genbank entry AF315723: Exons in red;
1 gaattcatct cccagtgagc catctctgag gaaaggaggt aaggctctga atgcgatgtc
61 aacctaagca ttacataaca ctgataggtt gtaaaatggc ctcgctgcct agtgctcatt
121 ctaactggcc acaatccagt cctccctgtt gcactgagtc agctccctcc aaaggcggcg
181 ctttccaggc ctcctggttg ccctttccca gcagaccttt caagtgctca cccacactca
241 cataaacatg gcccaggcac tgtttacagc agctctcctc tgtgcattct cctggcttct
301 cctgtctctc gccatttgta cccctcccct gcaacttgag tgacagtgat tggtcctgag
361 atgcaaatat ttgatgcaca tatgtttaca atgcagcctc agcttttttt tttttttttg
421 taaagagaca aagagtgaga cagggtcttg gcctatagcc ctgtggccca ggctggagtg
481 cagtggcaca attaaagctc actgcagcct ctacctcctg ggctcaagca atcctcccat
541 ctcagcctcc ccagtagctg ggactacagg actgtgccac cgttcccagc aatttttttt
601 attttttgta gaaatggggt ctcactatgt tgctcactct ggtctcaaac tcctgagctc
661 aagcaatctt cctgccttgg cctctgaaag tgctgggatt acaggcctga gccactgcac
721 ctggctgtca acattcttaa atctctttcc ttacatgctt cctaaacctc tcacccaaaa
781 ctaggagact agatgtccta ttttccccag ggcatgcctg gtttacgccc atttcacttt
841 aaaagtgccc aatttgggta ataatttata agatccccct ccctctaaat cctgtccttc
901 tatcacttca tccttcgctc tcctttaaaa tgagacagtt gtcagcagga atcctgcgca
961 agaacacacc accctgtttc atagaagata tctcaggtaa tgtgcaaaca cgggttttta
1021 aacggagcgc atttttctca tttgttaata tcaccaccta aatcatctct tgcctaaaac
1081 aaggagtaga aagtgaatga aggaaggaac aggtgatggt cagtgtcctt tctacgcctc
1141 aaaatttaag agtttatgtg aaaattcata aatattaatc tcaatccagg ttaagcaaaa
1201 ttttttgctc tcctctttag aaatttctgg ttgccaaagt tccagaaatt gcttcctcat
1261 tcctgagcct ttcattttct cgatttctcc attatgtaac ggggagctgg agctttgggc
1321 cgaatttcca attaaagatg atttttacag tcaatgagcc acgtcaggga gcgatggcac
1381 ccgcaggcgg tatcaactga tgcaagtgtt caagcgaatc tcaactcgtt ttttccggtg
1441 actcattccc ggccctgctt ggcagcgctg caccctttaa cttaaacctc ggccggccgc
1501 ccgccggggg cacagagtgt gcgccgggcc gcgcggcaat tggtccccgc gccgacctcc
1561 gcccgcgagc gccgccgctt cccttccccg ccccgcgtcc ctccccctcg gccccgcgcg
1621 tcgcctgtcc tccgagccag tcgctgacag ccgcggcgcc gcgagcttct cctctcctca
1681 cgaccgaggc aggtaaacgc ccggggtggg aggaacgcgg gcgggggcag gggagccgcg
1741 ggggccgagt gaggaccccg ggcctcgggt cccaggcgca agggtgcccg gccgggcggg
1801 gtcgggaccc cagtgaggag gggccggggg ctgccccgcg ggcgcgtgac gcgtctcggg
1861 cctgcccggc tgcgctggtc tccgctcggg tgaggcggct tggcttcgct tttcaggtta
1921 ggaaagctcc ctttactgcg cgctgggggg ctgggggagc tggcggagcc ccgttaggga
1981 ggtcggtggc gccggggtgt ctcagcgccc cctgcacccc gcgcgggtcc ggcccagcgg
2041 gcgatcgctg gcgcccaggg aactccggga gggccgccag cgggctccgc agggcgcggg
2101 gcggggaggg gcgcctgggg gccgcggggc tcgcgctccc cgcccgttgg ccgcccctcg
2161 gaggccgaga tcggggccca gaacgcccct tggcaaggcc tggcgcttcc gcgatgccca
2221 gagggtgctt ggggggatgg agagaggggc gcccgccggg ggagttccgg gagcctcggt
2281 gcctcccgcc gcagctgcag cgttcctccc gggaggcggc ccagcccttc atcctcgccg
2341 cctgagcttc tccgaggggg gctgcagcct tgcggccgtt gccaccgcct ggagaagcgg
2401 cccacgcgga ctgacgggcg ggggcggggc ctcgggcctc ggcgggggcg gggtccgggg
2461 aggccccacc ctctgttctc caggggcggg gagagaggag ctgcaggtct gcggcctggc
2521 cccaggtgcg atggcggacc ccagcttggc cagtcacatt cctcccagtc cccctggagg
2581 gagaacgctg gccatggggg gctccaagga acaaccagcc tcggatgacg acccttgggt
2641 caccggtctc cccacctgtg cggcaggcgc cttcacgttt cattattaaa caatggggag
2701 aaatccatgt ttactgtcct ttttaaggaa ttttttgctc ttctctttga ggtggctgta
2761 ggaaatagat ttttttttta acctcgcaat tccaccacgg tcacatccat cctcgccatc
2821 gcagagccac agctctccgt ttttgtttcc tagcctccag attctcacac aacacagtgc






























































































































































































































Results of sequencing CJD patients and controls. Number=randomised i.d. number
for each individual. -101,+310, +385 =Genotype at each of the regulatory region
polymorphisms. Common allele in Capitals.Rare allele in small font. A^=not sequenced.
Class=Origin of control (Hospital, Edinburgh or Belfast) or form of CJD (sporadic or
variant). Codon 129 =Genotype at codon 129 in the ORF (ORFs sequenced at the CJD
unit Edinburgh)
Number -101 +310 +385 Class Codon129
1 CC GG TT Edinburgh MM
2 cc NS NS Edinburgh MM
3 NS GG TT Edinburgh MM
4 NS NS NS Hospital MV
5 CC GG TT Hospital MV
6 NS NS NS Edinburgh MV
7 CC GG TT Edinburgh MM
8 NS NS NS Edinburgh MV
9 NS GG cc Edinburgh MM
10 CC GG TT Edinburgh MV
11 CC GG TT Edinburgh MV
12 NS NS NS Variant MM
13 CC GG Tc Variant MM
14 CC GG TT Edinburgh MM
15 CC Gc TT Hospital MM
16 CC GG TT Sporadic MM
17 eg GG TT Sporadic MM
18 cc Gc TT Belfast VV
19 eg GG TT Sporadic MM
20 CC GG TT Edinburgh MM
21 CC GG Tc Edinburgh MM
22 eg GG TT Edinburgh MM
23 cc GG Tc Sporadic MM
24 cc GG TT Edinburgh VV
25 cc GG Tc Belfast MM
26 cc GG TT Edinburgh VV
27 cc GG TT Belfast MM
28 cc GG TT Sporadic MM
29 cc GG Tc Sporadic MM
30 gg GG TT Sporadic MM
31 NS Gc TT Edinburgh MM
199
32 NS NS NS Edinburgh MV
33 eg GG TT Edinburgh MM
34 CC GG TT Edinburgh MV
35 CC GG TT Edinburgh MV
36 NS GG TT Edinburgh MV
37 CC NS NS Edinburgh MV
38 eg GG TT Edinburgh MM
39 eg GG TT Variant MM
40 Cg GG TT Belfast MM
41 CC GG TT Edinburgh MV
42 eg GG TT Sporadic MM
43 CC GG Tc Hospital MM
44 NS GG TT Sporadic MM
45 CC GG CC Variant MM
46 CC GG TT Edinburgh MM
47 CC GG TT Belfast MM
48 CC GG TT Hospital MM
49 Cg GG TT Edinburgh MM
50 CC GG TT Edinburgh MM
51 NS GG TT Edinburgh MM
52 CC Gc TT Edinburgh MV
53 NS NS NS Edinburgh VV
54 Cg NS NS Hospital MM
55 CC GG TT Belfast MM
56 CC GG TT Edinburgh MM
57 CC GG TT Hospital MM
58 cg GG TT Belfast MM
59 CC GG TT Hospital MM
60 CC Gc TT Sporadic MV
61 CC GG TT Edinburgh MM
62 CC GG TT Hospital MM
63 CC GG TT Variant MM
64 CC GG Tc Edinburgh MM
65 CC GG Tc Variant MM
66 cg GG TT Edinburgh MV
67 CC Gc TT Sporadic MM
68 eg GG TT Variant MM
69 CC GG TT Belfast MM
70 gg GG TT Edinburgh MM
71 CC NS NS Sporadic MM
72 eg GG TT Edinburgh MV











































cc GG TT Edinburgh MM
cc Gc TT Hospital MV
cc GG TT Belfast MV
cc GG TT Sporadic MM
eg GG TT Edinburgh MM
cc GG TT Sporadic VV
cc GG TT Edinburgh VV
cc GG TT Sporadic MV
eg Gc TT Edinburgh MV
cc GG TT Hospital MV
cc NS NS Edinburgh MV
cc GG Tc Edinburgh MV
cc GG TT Edinburgh MV
cc GG TT Edinburgh MM
NS NS NS Variant MM
NS NS NS Sporadic MM
CC GG Tc Belfast MV
eg NS NS Edinburgh MM
cc Gc TT Edinburgh VV
eg GG TT Variant MM
eg GG TT Edinburgh MM
cc GG TT Variant MM
cc GG Tc Sporadic MM
cc GG TT Hospital MV
cc GG TT Edinburgh MM
cc NS NS Variant MM
cc Gc TT Edinburgh MM
cc Gc TT Sporadic MV
cc GG TT Sporadic VV
cc Gc TT Sporadic VV
Cg Gc TT Sporadic MM
cc NS NS Belfast MM
cg GG TT Edinburgh MM
eg GG TT Edinburgh MV
cc NS NS Belfast MM
gg GG TT Edinburgh MM
cc GG TT Variant MM
cc GG TT Edinburgh VV
cc GG TT Edinburgh MM
cc GG TT Sporadic MM
eg NS NS Sporadic MM
eg GG TT Belfast MV
116 eg GG TT Sporadic MM
117 CC NS NS Belfast MV
118 NS GG NS Edinburgh MM
119 CC GG TT Belfast MV
120 NS NS NS Variant MM
121 CC GG TT Edinburgh MV
122 CC GG TT Edinburgh MM
123 CC GG TT Edinburgh MV
124 CC GG TT Belfast MM
125 CC GG TT Hospital MV
126 CC GG TT Edinburgh MV
127 CC NS NS Variant MM
128 eg GG TT Sporadic MM
129 Cg NS NS Variant MM
130 CC NS NS Belfast MV
131 NS NS NS Belfast MM
132 NS NS NS Belfast MV
133 CC NS TT Belfast MM
134 CC GG TT Variant MM
135 NS GG TT Belfast MV
136 CC GG TT Hospital MM
137 Cg GG TT Variant MM
138 CC GG TT Belfast MV
139 CC Gc TT Belfast MV
140 CC GG TT Hospital VV
141 CC GG TT Belfast MV
142 CC GG TT Hospital VV
143 CC Gc TT Belfast MV
144 CC GG TT Hospital MM
145 Cg GG TT Belfast MM
146 Cg GG TT Hospital MV
147 CC GG TT Belfast MV
148 gg GG TT Sporadic MM
149 NS Gc TT Belfast MV
150 CC GG TT Variant MM
151 CC GG TT Variant MM
152 CC GG TT Variant MM
153 CC GG Tc Belfast MM
154 cg GG TT Belfast MM
155 CC Gc TT Hospital MM
156 NS NS NS Belfast VV
157 NS NS NS Hospital NS
158 CC GG TT Belfast MM
159 eg GG TT Sporadic MM
160 eg GG TT Variant MM
161 NS NS NS Belfast MV
162 CC GG TT Belfast MM
163 CC NS NS Belfast MM
164 CC GG TT Sporadic MM
165 CC GG TT Belfast VV
166 CC GG TT Belfast MM
167 CC NS NS Belfast MV
168 CC Gc TT Sporadic VV
169 CC GG TT Belfast MV
170 CC GG Tc Variant MM
171 NS NS NS Belfast VV
172 CC GG Tc Hospital MV
173 eg GG TT Belfast MM
174 CC Gc TT Hospital VV
175 eg GG Tc Hospital MV
176 CC GG TT Hospital MM
177 eg NS NS Belfast MM
178 eg GG TT Hospital MV
179 CC GG TT Belfast MM
180 CC GG TT Belfast MV
181 eg GG Tc Belfast MV
182 NS NS NS Hospital VV
183 NS NS NS Belfast VV
184 NS NS NS Belfast MV
185 CC NS NS Belfast VV
186 NS NS NS Belfast MV
187 NS NS NS Belfast VV
188 NS NS NS Belfast MV
189 NS GG TT Belfast VV
190 NS NS NS Hospital VV
191 CC NS NS Belfast MV
192 Cg NS NS Belfast MM
193 NS NS NS Belfast MV
194 CC GG TT Belfast MV
195 NS NS NS Belfast MV
196 CC GG TT Hospital MM
197 NS NS NS Belfast MV
198 NS NS NS Belfast MM
199 NS NS NS Belfast MM
200 NS GG TT Belfast MV
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